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Abstract 
Wound infections present major health problems worldwide. It has been revealed that 
bacterial biofilm communities frequently colonise chronic wounds.Biofilms with Multidrug-
resistant organisms (MDRO) such as Methicillin ResistantStaphylococcus aureus (MRSA) 
and Pseudomonas aeruginosaare increasingly implicated in chronic wound infections. The 
limited therapeutic options are further compromised by the fact that wound-infecting bacteria 
often co-exist within a polymicrobial biofilm community, which enhances bacterial tolerance 
or resistance to antimicrobials.The polyunsaturated fatty acid (PUFA) compounds including 
Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) offer both 
immunomodulatory and antimicrobial properties that could enhance wound healing. 
 This study evaluated the activity and efficiencyof these compounds against wound 
pathogens and compared them to common antibiotics Linezolid (LZD) and vancomycin 
(VAN).Standard antibiotic sensitivity assays were used to determine the ability of PUFAs to 
inhibit growth and biofilm formation. Most activity was observed against S. aureusstrains. 
The bacteriostatic activity (minimum inhibitory concentration - MIC) of DHA and EPA for S. 
aureusSA3 and P. aeruginosa PA01 was 65 and 117 gml-1respectively. Meanwhile, the 
bacteriocidal activity required higher concentrations (MBC) of 260 and 468gml-
1respectively. The antibiotic LZD was most active against Gram positive bacteria (MIC range 
from 1.9 µg ml-1to 3.9 µg ml-1). However, vancomycin was the most potent biofilm disrupter, 
with MBECs ranging from 5-12.5 µg ml-1. These concentrations were 35-fold lower than the 
MBECs recorded for linezolid (125 -500 µg ml-1). Considerably higher concentrations of 
PUFA compounds were required to disrupt biofilms. The MBECs of DHA ranged between 
750 and 3125 µg ml-1. EPA was found to be more disruptive than DHA (MBECs ranging 
xvi 
between 500 and 2250 µg ml-1), while the MBECs of combination treatment with both 
PUFAs (DHA+EPA) ranged from 750 - 1500 µg ml-1. 
The antimicrobial activity of different concentrations of PUFAs was further 
assessedby monitoring inhibition of growth of a clinical wound isolate of S. aureus(SA3)for 
24 h. PUFAs were shown to differentially affect expression of global gene regulators using 
RT-qPCR.DHA and EPA were found to upregulate agrA and icaA butdownregulate sarAat 
the same concentrations and exposure times. 
Two different infection models were used to assess the activity of PUFAs in 
vivo(Galleria mellonella) and on ex-vivo skin compared to common antibiotics (LZD and 
VAN). PUFAs reduced virulence of SA3 in G.mellonella, protecting the larvae from death. 
Furthermore, prolonged exposure to sub-inhibitory concentrations affected growth 
efficiencyof SA3in vivo.Whole genome sequencing of parent vs PUFA and antibiotics-
adaptedstrains of S. aureusSA3 revealed some common mutations in sarA and clfBgenes, that 
may contribute to altered virulence and susceptibility to treatment. Preliminary studies with 
the ex-vivo skin model suggested that this may be a useful system for testing the efficacy of 
antimicrobial compounds for wound-treatment. Differences in SA3 survival and growth were 
measurable in the presence of PUFAs or absence of PUFAs. 
 In conclusion, PUFAs (DHA and EPA) showed weak antimicrobial activity 
compared to common antibiotics against common wound-associated bacteria. However, this 
study shows evidence that PUFAs have additional desirable properties, including disruption 
of global gene regulation, reduction of virulence and low potential to promote development 
of resistance.  
xvii 
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Introduction  
 
 
 
 
 
 
 
 
1 
Chapter 1 Introduction 
1.1 Pathology of chronic wounds 
1.1.1 Definition and epidemiology of chronic wounds 
Skin is the body’s largest organ and is the first line of the innate immune system. The 
surface of the skin is colonised by complex microbiota that form a dynamic barrier to 
compete with potential pathogens (Rosenthal et al., 2011). Usually, the healthy skin 
microbiota, including potential opportunistic pathogens, do not cause infection or stimulate 
the immune system, unless there is disorder of the skin structure or the immune system 
becomes compromised. When the skin barrier is breached, any of the microorganisms’ 
present can cause a wound or skin infection (Stevens et al., 2014). 
A wound is a type of injury (trauma) that cause an acute disturbance of tissues by an 
external force in which skin is torn, cut, or punctured (open wound), or where strong force 
trauma causes a contusion  (a closed wound). Wounds are usually classified according to the 
etiological agent and anatomical site, whether it is acute or chronic or according to 
presentation of symptoms or appearance of tissue type in the wound location (Seidel et al., 
2013). An acute wound is by definition expected to progress through the stages of normal 
healing, resulting in closure of the wound (Guo & Dipietro, 2010). However, without proper 
dressing and wound care management the acute wound can develop complications, poor 
healing and infection. Any acute wound can progress to a chronic wound if it does not heal 
within the expected period, because of poor blood supply, oxygen, nutrients or hygiene 
(Anderson & Hamm, 2014). Acute wounds should be promptly treated to avoid infection, 
inflammation or progression to a chronic, un-healing wound (Seidel et al., 2013). The most 
common definition that has been used for chronic wounds, is that of any wound that has not 
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healed within 3 months of the initial trauma. Some ulcers have been observed to persist for 
years (Iqbal et al.,  2017). 
There are three main types of chronic wound: venous leg ulcers, diabetic ulcers, and 
pressure ulcers. These ulcers are usually a gradual disturbance of tissues caused by triggers 
such as diabetes or high cholesterol. Slow blood flow in veins (ischemia) leads to secondary 
physiological changes due to lack of nutrients and oxygen supply to the tissue. This can lead 
to tissue damage and impaired healing (Avishai et al., 2017). Classical signs of chronic 
wounds include the development of necrotic tissue, foul odour and a cumulative breakdown 
of the tissue structure (Kane et al., 2014). A deterioration and discoloration of granulation 
tissue and increased fragmentation in the site of infection are also often described (Leaperet 
al., 2015). 
Many risk factors are associated with the development of chronic wounds, such as 
diabetes, arterial diseases, microbial infection, and old age (Frykberg & Banks, 2015). The 
increasing elderly population, growing incidence of diabetes and obesity and cardiovascular 
diseases are significant contributions to the increasing incidence of chronic wounds (Avishai 
et al., 2017). For instance, leg ulceration affects 15–18 per 1000 adults in developed countries 
(Agale, 2013). The estimated annual cost of wound management (Dressing, nursing, 
practicing, and patient visit) to the NHS in the UK is between £4.5 and £5.1 billion (Guest et 
al., 2015).  
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1.1.2 Stages of wound healing 
Normal wound healing is a dynamic process consisting of four continuous, 
overlapping, and programmed phases: (i) haemostasis; (ii) inflammation; (iii) cell 
differentiation and proliferation to the wound site; (iv) maturation and remodelling (Gosain & 
DiPietro, 2004; Mathieu et al., 2006). Briefly, coagulation at the site of injury leads to 
formation of platelet thrombus, followed by haemostasis, with vascular constriction and 
formation of fibrin clot. Bleeding is controlled, and the inflammatory phase is promoted by 
infiltration of polymorphonuclear cells (PMNs), macrophages and lymphocytes (Beldon, 
2010; Campos et al., 2008). A major function of PMNs is as a first defence barrier against 
invasion of microorganisms, although they produce proteases and reactive oxygen species 
(ROS) that cause additional parallel damage (Dunnill et al., 2017). Macrophages are also 
important mediators of wound healing by secreting pro-inflammatory cytokines (Figure 1), 
such as Tumour Necrosis Factor α (TNF-α) and interleukin 1 beta (IL-1β), that stimulate the 
production and release of matrix metalloprotease (MMP) enzymes and enhance the 
production of growth factors such as platelet-derived growth factor (PDGF), transforming 
growth factor (TGF), vascular endothelial growth factor (VEGF), fibroblast growth factor 
(FGF), and epidermal growth factor (EGF). The second function of phagocytic cells is the 
engulfment of the microorganisms and apoptotic cells. Phagocytic cells undergo a transition 
to a reparative state that stimulates keratinocytes, fibroblasts, and angiogenesis to regulate 
tissue regeneration (Meszaros et al., 2000; Mosser & Edwards, 2008). 
The proliferative phase of healing is characterised by synthesising collagen as well as 
glycosaminoglycan and proteoglycan, which are major components of the extracellular 
matrix (ECM) (Teller & White, 2009). This phase, involves modulation of immune response 
and T-lymphocytes migrate to the wound site and reach their peak activation during the late-
proliferative/ early-remodelling phase (Ghatak et al., 2015). The activity of T-lymphocytes 
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within an inflammatory exudate is reflected in the relative proportions of T-lymphocyte 
subsets such as CD4+ T helper cells and CD8+ T suppressor cytotoxic cells. These T 
lymphocytes modulate the wound cytokine environment and regulate keratinocyte, fibroblast 
and endothelial cell function (Dunnill et al., 2017; Toben & Baune, 2015). Three distinctive 
cell types; fibroblasts, endothelial cells, and keratinocytes are supported by new blood vessel 
growth via vascular endothelial cell formation (angiogenesis). These mature cells are 
activated by transformed keratinocytes and produce fibroblast growth factor 7 (FGF-7), 
keratinocyte growth factors (KGF), and insulin-like growth factor-1 (Igf-1), to support 
keratinocyte proliferation and cell survival. The fibroblast cells are under the control of 
cytokines and growth factors that are released from platelets and macrophages. Keratinocytes 
synthesize other growth factors transforming growth (TGF-α -β), and keratinocyte-derived 
anti-fibrogenic factor (KDAF), while endothelial cells synthesize vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor (BFGF). The interaction between these growth 
factors and re-epithelialization of the epidermis over the extracellular matrix contributes to 
the maintenance of normal skin and wound healing. 
The final stage of wound healing is the remodelling phase. The critical feature of this 
phase is ECM rebuilding the architecture of normal tissue (Figure 1.2). This process reduces 
cell migration and allows cell differentiation (Diegelmann & Evans, 2004). Several enzymes 
are produced during the remodelling phase such as hyaluronidase, plasminogen activators, 
collagenase, and elastase. Hyaluronidase plays a role in epidermises-epithelialization and 
synthesis of extracellular matrix (Fronza et al., 2014). Plasmin, formed from plasminogen, 
degrades fibrin and urokinase, produced by fibroblasts, endothelial cells, keratinocytes, and 
leukocytes, activates collagenase and elastase (Clark et al., 2007). Collagenase is secreted by 
macrophages, fibroblasts, epithelial cells, and leukocytes and can break down the collagen 
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triple helix. Collagenase activity has been detected at the tissue recovery site for many 
months (Campos et al., 2008; Gosain & DiPietro, 2004). 
The interruption and failure of wound healing leads to the development of chronic 
wounds (Figure 1.3). The major factors that prevent wound healing are ischemia, bacterial 
colonisation, inflammation and oxidative damage (Guo & Dipietro, 2010). Ischemia is caused 
by narrowing of the blood vessels in tissues and is common in old age or individuals with 
diabetes. This causes tissue to become inflamed and release interleukins, chemokines and 
complement factors that attract PMNs (Iqbal et al., 2017; Turner et al., 2014). Further 
complications can be caused by microbial colonisation of the wound attracting a greater 
number of PMNs (Sorg et al., 2017). The PMNs release inflammatory mediators such as 
degrading proteases, collagenase, and reactive oxygen species (ROS) (Falanga, 2000). ROS 
and enzymes such as peroxidase are part of the immune response important for killing 
invading pathogens. However, they have also been shown to prevent host cell proliferation 
and wound closure (McCarty & Percival, 2013). ROS are also the main cause oxidative stress 
in the skin. Excessive production of ROS leads to sustained stimulation of pro-inflammatory 
cytokines and induction of matrix metalloproteases. This can activate proteolysis, degrading 
extracellular matrix proteins and decreasing the integrity of connective tissue. Other effects 
include interference with growth factors and epithelial cell proliferation, impaired dermal 
fibroblast and keratinocyte function and continuing influx of PMNs (Dunnill et al., 2017). 
During the ischemic period, depletion of oxygen and nutrients results in poor blood 
circulation, causing further damage and wound chronicity (Schultz et al., 2003).
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Figure1.1 Initiation of wound healing: Blood coagulation by thrombosis, 
inflammatory response by release the PMNs mediators degrading proteases. 
Collagenase, and excessive production reactive oxygen species (ROS)leads to sustained 
stimulation of pro-inflammatory cytokines and induction of matrix metalloproteases, 
activate proteolysis, secretion of growth factors such as TGF-b and PDGF and epithelial 
cell proliferation. Neutrophils and Macrophages clean, ingest cellular debris and the 
invading bacteria, Anti-inflammatory macrophages are cleared by migration to 
lymphatic vessels, impaired dermal fibroblast and keratinocyte function and continuing 
influx of PMNs (Singer & Clark, 1999). 
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Figure1.2 Rebuilding normal tissue: maintenance of fibrin clot, restoration of tissue 
architecture by extracellular matrix, rebuilding of new blood vessels, fibroblast and 
keratinocyte migration to start re-epithelialisation and proliferation in wound healing. 
 
Figure1.3 Chronic wound: characterised by persistent inflammation. Macrophage 
response triggers cellular signalling by excessive secretion of ROS, cytokines, growth 
factors, and Matrix metalloproteinases (MMPs). Bacterial colonisation and biofilm 
formation, and or ischemia occur. All these factors contribute to a delay in healing.  
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1.1.3 Microbial burden of wounds 
All chronic wounds are usually colonised by microorganisms from the normal skin 
microbiota (McCarty & Percival, 2013) or from environmental sources such as air, water, 
sand, bullets, medical instruments or staff (Gardner & Frantz, 2008). There is a distinct 
difference between wound contamination and wound colonisation. The term contamination 
refers to microbial attachment but no proliferation. In contrast, colonisation requires 
attachment of microorganisms at the wound surface followed by proliferation, without 
clinical signs of host injury (Leaper et al., 2015; Sibbald, 2011). The wound environment 
provides favourable conditions of warmth, moisture and nutrition for easy colonisation of 
opportunistic pathogens. Therefore non-healing wounds are mostly colonised by 
polymicrobial communities (Bjarnsholt et al.,2011; Leaper et al., 2015; Phillips et al., 2016). 
Some microorganisms have been shown to excrete substances, such as bacteriocins, within 
the wound that will reduce or inhibit the growth of others. For example, Escherichia coli 
secrets colicins that will inhibit growth of closely related strains (Johnson et al.,  2013).  
Following colonisation of a wound, heavy proliferation of pathogens and production 
of virulence factors such as adhesins and surface-associated endotoxins (of Gram negative 
bacteria) or exotoxins can overcome the immune response, causing significant damage to 
host tissue and resulting in infection (Galán, 2005; Wilson et al., 2002). According to Hamed 
et al, (2015) and Agren, (2016) the microbial burden of  > 105 CFU g -1 of tissue is 
considered to indicate infection (Agren, 2016; Hamed et al.,  2015). Several classical signs of 
wound infection have been identified (Table1.1). An infected wound will usually have the 
appearance of abnormal granulation tissue with changes in colour due to inflammatory state 
and increased exudate from abscesses around the infected site (McCarty & Percival, 2013). 
Most practitioners depend on clinical symptoms to confirm wound infections, especially 
increasing pain and wound tissue damage (Iqbal et al., 2017).  
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Table1.1 Development and characterisation of infection in chronic wound (Leaper et al., 
2015). 
 
 
1.1.4 Bacteria commonly isolated from chronic wounds 
Chronic wounds are usually co-infected with multiple bacterial species (Table 1.2) 
and several studies have demonstrated their complex ecology (Wolcott et al., 2013; Zhao et 
al., 2013). Traditional microbial culture techniques have found a mean number of bacterial 
species per wound ranging from 1.6-4.4 (Howell-Jones et al., 2005). Staphylococcus aureus 
and coagulase negative Staphylococci (CoNS) have been the predominant organisms isolated 
from both prospective, purpose-collected samples, and retrospective analysis of clinical 
investigations (Zhao et al., 2013). However, molecular techniques such as 16srRNA profiling 
have revealed a more diverse polymicrobial nature of chronic wounds with approximately 
four times more diversity of species in wounds than isolated by culture (Lavigne et al., 2015). 
The dynamics of polymicrobial communities colonising chronic wounds changes over time. 
Abnormal granulation tissue (excessive ‘vascular’ hyper granulation) 
Bleeding from friable granulation tissue at the wound surface 
Epithelial bridging and pocketing in granulation tissue 
Wound breakdown and enlargement 
Changes in the wound bed colour from red to green/ yellow or black 
Increasing inflammatory signs and abscess formation 
Increasing pain 
Increasing odour 
Increased exudate and maceration of surrounding skin 
Delayed healing (beyond expectation) 
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S. aureus, CoNS, Streptococcus spp, and Corynebacterium spp, are primary colonisers before 
the accumulation of facultative anaerobic Gram-negative bacilli, such as Escherichia coli, 
Enterobacter cloacae, Klebsiella spp, and Proteus spp. P. aeruginosa and anaerobes such as 
Bacteroides fragilis and Propionibacterium acnes have been identified later, usually days to 
weeks later (Bessa et al.,  2013; Martin et al., 2010). 
A major problem with wound species profiles reported so far is the incomplete isolation of 
anaerobes, which is both difficult and time consuming by traditional culture method (Charles 
et al.,  2015). For example, anaerobic bacteria were not thought to be present in 73% of non-
infected wound ulcers (Bowler & Davies, 1999) and 82% of infected leg ulcers. However, 
more thorough studies that focused on the isolation of anaerobic bacteria, have yielded a high 
frequency (Zhao et al., 2017). 16S rRNA profiling and metagenomic approaches are 
increasingly useful for exploring such complex bacterial communities including anaerobic 
bacteria (Salipante et al., 2013; Sprockett et al., 2015). S. aureus and P. aeruginosa are 
frequently found together in chronic wound infections (Trivedi et al., 2014). For example, a 
retrospective study was carried out on 217 infected wounds that were found to have 
polymicrobial infections. S. aureus and P. aeruginosa were found together in 59 (27·1%) of 
the samples (Bessa et al., 2015a). Another study showed that the predominant organisms in 
chronic wounds from both surface swabs and tissue biopsies were Staphylococcus spp. and P. 
aeruginosa present in 71.2% of patients (Davies et al., 2007). Gjødsbøl et al., (2006) found S. 
aureus in 93.5% and P. aeruginosa in 52.2% of chronic venous leg ulcers, making these 
species most common and significant for the nature of bacterial communities in wound 
(Gjødsbøl et al., 2006). 
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Table1.2 The most common pathogens detected in wounds (Bessa et al., 2015; Yali et 
al., 2014). 
Group Organisms 
Gram-positive bacteria  S. aureus 
S. aureus (methicillin resistant) 
Coagulase Negative S. aureus (CoNS) 
Streptococcus pyogenes  
Enterococcus faecalis  
Corynebacterium spp 
Gram-negative bacteria Pseudomonas aeruginosa 
Acinetobacter baumannii 
Escherichia coli  
Klebsiella species  
Proteus species  
Enterobacter spp 
Anaerobic bacteria Clostridium species  
Bacteroides species  
Propionibacterium acnes 
Fungi Candida spp 
 
 
1.2 Defining characteristics of Staphylococcus aureus 
Staphylococci are Gram positive bacteria usually arranged as cluster of coccoid cells. 
These facultative anaerobes are nonmotile, and non-spore forming. They are members of the 
family Micrococcaceae consist of more than 47 species and subspecies (Becker et al., 2014). 
These opportunistic bacteria commonly colonise human skin and mucosal membranes as 
commensal normal flora (Schmidt et al., 2014). The staphylococci produce catalase enzyme, a 
feature differentiating them from Streptococcus spp. and they are oxidase-negative and require 
complex nutrients, e.g., many amino acids and vitamins B, for growth. S. aureus is known to 
be tolerant of high concentrations of sodium chloride (Choi et al., 2014). Another feature of 
the genus Staphylococcus is the cell wall peptidoglycan structure that contains multiple glycine 
residues in the cross bridge, which causes susceptibility to lysostaphin (Bastos et al., 2010). S. 
aureus can be distinguished from CoNS using a coagulase test. S. aureus produces coagulase 
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which interacts with prothrombin in the blood causing plasma to coagulate by converting 
fibrinogen into fibrin. 
Antibiotic resistance is widespread amongst S. aureus. The incidence of methicillin 
resistant S. aureus (MRSA) associated wound infection has been well published (Almeida et 
al., 2014; Bowling et al., 2009). Reports revealed that 25%-50% of all hospital S. aureus 
infections in Europe were resistant to methicillin (Johnson, 2011). MRSA strains express a 
modified penicillin-binding protein encoded by the mec A gene which has lower binding 
affinity forβ-lactam antibiotics (Taitt et al., 2015). Over the past three decades MRSA strains 
have become a major public health concern commonly causing health care (HA-MRSA) and 
community acquired (CA-MRSA) infections (Montgomery et al., 2010). The CA-MRSA are 
distinguished genetically by their ability to produce toxins such as Panton-Valentine 
leucocidin (PVL) which kills the leucocytes, contributing to recurrent infections such as boils 
and abscess (David & Daum, 2010). The mec A gene is a major determinant of methicillin 
resistance in both S. aureus and CoNS (Shrestha et al., 2002). This gene has been used for 
rapid identification of methicillin resistant S. aureus (MRSA) (Appelbaum, 2007). 
Vancomycin resistant S. aureus (VRSA) are also developing as an increasing burden on 
public health (Akhi et al., 2017; Taitt et al., 2015). The S. aureus genome is dynamic and 
includes a number of mobile genetic elements, such as transposons, pathogenicity islands, 
insertion sequences, and a staphylococcal cassette chromosome (Alibayov et al., 2014; 
Lindsay, 2010). These elements of horizontal gene transfer are prevalent amongst 
staphylococci and many carry antibiotic resistance genes and virulence factors. For example, 
study analysing the genotypic pattern for S. aureus isolated from wound infection found the 
typical staphylococcal cassette chromosome mec IV elements in 88% of isolates. Panton-
Valentine leukocidin virulence genes were identified in 88% of isolates (Murray et al., 2010). 
In another study, clinical isolates were investigated for resistance to methicillin encoded by 
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the mecA gene carried on a mobile staphylococcal cassette chromosomal mec element 
(SCCmec). These genes were present in up to 49% of non-device associated infection and all 
biofilm-positive isolates except four harboured ica ADBC genes (Mesrati et al., 2018). The 
icaADBC operon is responsible for the synthesis of PIA, the main component of 
staphylococcal biofilm (Cramton et al., 1999).  
 
1.2.1 Staphylococcus aureus infection 
S. aureus is the most common bacterium isolated from both acute and chronic wounds 
(Bessa et al., 2015; Gjødsbøl et al., 2006), but is also capable of causing a wide range of 
other infections (Das et al., 2016; Tonget al., 2015). This opportunistic pathogen frequently 
colonises the human skin and is present in the nasal cavity of 25-30% of healthy people 
without causing harm to the host or any symptoms (Bhattacharya et al., 2015). However, if 
there is a defect in the human skin from a wound, surgery or indwelling device such as 
intravenous catheters; or if there is a suppression of the immune system, then colonising S. 
aureus can cause an infection (Foster et al., 2014). Transmission of S. aureus can occur 
through close contact from both infected individuals and carriers to other healthy subjects 
through poor hand hygiene or through sharing contaminated objects, such as towels or razors.  
S. aureus can cause localized skin infections, such as folliculitis and impetigo (Dhawan et al., 
2015). It can also cause abscesses and spread into blood stream (bacteraemia or sepsis) 
(Fowler et al., 2006), pneumonia (Gillet et al., 2002), bones (osteomyelitis) (Elasri et al., 
2002), and damage heart valves (endocarditis) (Fernández Guerrero et al., 2009). The ability 
of S. aureus to form a biofilm matrix enables this organism to resist the host immune 
response protecting it from opsonisation or phagocytosis and antimicrobial agents (Snowden, 
2016). 
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1.2.1.1 Pathogenesis of S. aureus 
S. aureus coordinates several mechanisms to colonise and survive in vivo. A wide 
range of cell surface-associated adhesins, secreted cytotoxins and enzymes have been 
described, as well as methods of escape from the host immune system (Das et al., 2016). The 
fact that S. aureus has the ability to cause such arrange of different infections is partly due to 
the expression of different cell wall-associated proteins and extra-cellular virulence factors 
which enable the bacteria to attach to and colonise host tissues (Pietrocola et al., 2017). The 
ability of bacteria to adhere to the host surface is a crucial first step to initiate infection and is 
essential for biofilm formation. S. aureus possess a group of microbial adhesins referred to 
Microbial Surface Components Recognising Adhesive Matrix Molecules (MSCRAMMs) that 
help the bacterium to bind antibodies and extracellular proteins such as fibrinogen, 
fibronectin and collagen (Foster et al., 2014). The MSCRAMMs can coat the bacteria surface 
thereby evading detection by immune defences. A biofilm-associated protein (BAP) has also 
been found to be involved in S. aureus adhesion and biofilm formation (Lister & Horswill, 
2014). Collagen Binding Protein (CAP), is also essential for adherence of S. aureus to 
collagenous tissues and cartilage (Hauck & Ohlsen, 2006). It has been shown that anti-
collagen antibodies block the bacterial attachment to those tissues (Speziale et al., 2018). 
Plasma-sensitive proteins (Pls), on the S. aureus surface are processed by plasmin, and 
contribute to binding to both fibrinogen and fibronectin (Crosby et al., 2016). Surface protein 
A binds to von-Willebrand factor, a blood glycoprotein that contributes to haemostasis at 
sites of endothelial damage, contributing to endovascular diseases by S. aureus (Hartleib et 
al., 2000). S. aureus infections associated with implanted biomedical devices rely on the 
ability of this pathogen to form biofilms on the surface of the biomaterial (Lister & Horswill, 
2014; McAdow et al., 2012). 
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S. aureus produces an array of exotoxins, such as haemolysin, leukocidin, kinases, 
coagulase and hyaluronidase, that damage host tissues, destroy leukocytes or stimulate 
symptoms of disease such as Toxic shock syndrome (TSS) (de Haas et al., 2004; Rooijakkers 
et al., 2005). These enzymes act locally to damage host cells providing nutrients for growth. 
Additional sets of exotoxins produced by S. aureus which include the pyrogenic toxin super-
antigens (PTSAgs) toxic shock syndrome toxin-1 (TSST-1) and staphylococcal enterotoxins 
are able to stimulate proliferation of T-lymphocytes (Janik & Lee, 2015). Staphylococcal 
enterotoxin has been shown to cause symptomatic food poisoning disease even in the absence 
of viable bacteria (Dinges et al., 2000). However, Staphylococcal toxic shock syndrome 
(TSS) is only sufficient to cause symptomatic disease, if the toxin is secreted and 
concentrated at colonised sites (Kulhankova et al., 2014). Staphylococcal Scalded Skin Toxin 
SSS causes a skin disease mainly affecting children and immunocompromised patients 
(Brewer et al., 2008). 
A number of S. aureus virulence factors are important for immune evasion, 
preventing recognition by antibodies and complement, and inhibiting phagocytic activation 
(Bien et al 2011; DeLeo et al., 2009). S. aureus produce capsular polysaccharides, protein A, 
coagulase and extracellular fibrinogen binding proteins (Efb A, B) all of which play a role in 
the inhibition of phagocytic engulfment. Coagulase interacts with fibrinogen to form 
fibrinogen clots through activation of prothrombin. Efb proteins stimulate fibrinogen to the 
bacterial surface and promotes clot formation that protects the bacterium from phagocytic 
clearance. These surface-associated proteins also enhance attachment to extra-cellular matrix 
component (McAdow et al., 2012). Clumping factor, A and B (ClfA and ClfB) mediate 
clumping and adherence of bacterial cells to fibrinogen in the presence of fibronectin. 
Clumping factors are thought to play a significant role in wound infections and it has been 
shown that aclfA mutant was less virulent than the wild type isogenic strain (Foster et al., 
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2014). Moreover, S. aureus possesses a cell wall anchored enzyme known as adenosine 
synthase A (AdsA enzyme), that converts adenosine monophosphate (AMP) to adenosine, 
which has immune suppression properties (Thammavongsa et al., 2011). Protein A, encoded 
by the spa gene is cell wall-associated and binds to the Fc domain of immunoglobin G (IgG) 
in the “wrong orientation” on the surface of S. aureus cells which is thought to disrupt 
opsonisation and phagocytosis (Switalski et al., 1993). 
 
1.2.2 Enterococcus faecalis 
E. faecalis is a Gram-positive cocci, that are common inhabitants of the human 
intestinal. They are opportunistic pathogens that infected urinary tract infections, blood-
stream, surgical sites, and wounds (Yali et al., 2014). Enterococcal infections are 
polymicrobial in nature, often biofilm-associated, and resistant to antibiotics. Several 
virulence factors have associated enterococcal infection such as gelatinase production, 
Enterococcus surface protein (Esp), aggregation substance (AS) and biofilm formation 
(Comerlato et al., 2013). The gelatinase is a metalloprotease, encoded by gelE, that is capable 
of hydrolysing gelatine, collagen, haemoglobin and other peptides (Lindenstrau et al., 2011). 
The Enterococcus surface protein (Esp) protein, encoded by the esp gene, contributed to the 
colonisation and persistence of E. faecalis strains in several infections including wound 
(Rahimi et al., 2018). The protein Esp may mediate the interaction with primary surfaces and 
participate in biofilm formation. The aggregation substance (AS) is plasmid encoded by prgB 
gene that play role in cellular aggregation required for conjugative plasmid transfer and 
facilitates the adherence to contributes to biofilm formation (Wardal et al., 2013). In addition, 
E. faecalis encodes 2 sortase enzymes, SrtC and SrtA, that associated with surface cell wall 
structured and pilli (Mandlik et al., 2007). These components play major role in initial stage 
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of biofilm formation. The expression of the SrtA substrate aggregation substance along with 
biofilm formation, can evade and protect E. faecalis from macrophages and neutrophils. The 
antimicrobial Resistance of E. faecalis such as vancomycin-resistant E. faecalis (VREfs) are 
the most clinically significant in the genus. These resistance genotypes are commonly 
disseminated on the mobile elements Tn1546 like transposon vanA and Tn1549 conjugative 
transposon vanB, which are generally encoded on plasmids and chromosome, respectively 
(Zhong et al., 2017).  
 
1.2.3 Pseudomonas aeruginosa  
An opportunistic human pathogen that causes life-threatening infections in patients 
with cystic fibrosis (CF), endocarditis, wounds or artificial implants. In addition, P. 
aeruginosa is one of the most common pathogens in chronic wounds due to its ability to form 
resistant biofilms (Hotterbeekx et al., 2017). It has been estimated that about ten percent of 
all hospital-acquired infections are caused by P. aeruginosa, and for immune-compromised 
patients the mortality rate ranges from 20 to 70 % (Parsons et al., 2007). P. aeruginosa 
contain a battery of virulence factors that help facilitate colonization of the burn wound and 
translocation through the vasculature and into the bloodstream;  P. aeruginosa produce both 
extracellular and cell-associated virulence factors products (Kipnis et al., 2006). The secreted 
virulence factors maintain the chronic wound in a persistent inflammatory phase. Exotoxins 
are secreted which bind to specific sites on the ribosomes in host cells, resulting in inhibited 
protein synthesis and cell death (Leid et al., 2005). Several enzymes are produced by P. 
aeruginosa. For instance, proteases and phospholipases that disrupt host cell structures, and 
adhesins that allow for binding to epithelial cell receptors (Gellatly & Hancock, 2013). 
Bjarnsholt et al (2008) suggest that the virulence factor rhamnolipid plays an important role 
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in chronic P. aeruginosa infections. Rhamnolipids destroy neutrophils, resulting in leakage of 
several different substances with harmful effects on both tissue cells and bacteria (Bjarnsholt 
et al., 2008). On the outer surface of the bacterial cell are lipopolysaccharides deposited, 
which contribute to attachment to host cells but also stimulate inflammatory responses 
(Kipnis et al 2006). Other cell surface structures such as flagella also allow for adherence to 
endothelial cells. Another important virulence factor for P. aeruginosa is the toxic blue 
pigment phenazine pyocyanin, which is a redox-active toxin that causes cellular destruction, 
increased expression of IL-8 and disruption of calcium homeostasis (Winstanley & 
Fothergill, 2009).  
The ability of P. aeruginosa to form biofilms is critical for its survival in wound 
infection and enhances its resistance to antimicrobial treatment and host defense mechanisms 
(Meluleni et al., 1995). For instance, P. aeruginosa PA 01 produce at least three 
exopolysaccharides alginate, Psl, and Pel polysaccharides, that play major role in biofilm 
formation and resistance to antimicrobial agents (Periasamy et al., 2015). One third of P. 
aeruginosa clinical isolates are resistant to three or more antibiotics, including third-
generation cephalosporins and imipenem, which have been the gold standard antibiotics for 
P. aeruginosa infection (Hirsch & Tam, 2010). 
 
1.2.4 Escherichia coli 
Gram-negative rods ,facultative anaerobic, normal flora of the lower intestine and are 
part of the normal microbiota of the gut. Most Es. coli strains are non-pathogenic, and can 
assists in digestion by producing vitamins B12 and K2 (Blount, 2015). There are more than 
700 different serotypes of Es. coli, distinguished by different surface proteins and 
polysaccharides (Kumar et al., 2015). Many serotypes can cause variety of infection such as 
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urinary tract infection, bacteraemia , neonatal meningitis, soft tissue infection and wound 
infection. However, various virulence factors associated structures or produced by Es. coli 
such as Pfimbriae, type I fimbriae, capsule, siderophores, haemolysin, proteases and 
cytotoxic necrotizing factors (Kumar et al., 2015). These bacterial toxin production in wound 
infection, causing collagen degradation, stress, and malnutrition, preventing the normal 
healing of wounds. In addition, pathogenic Es. coli produce biofilm on acute wounds to turn 
into chronic infection. The biofilm structure is significant factor that contributes to antibiotic 
resistance. Estimates spectrum beta lactamase (ESBL) are encoded on plasmids on Es. coli 
and other member of Enterobactericeae are typical example of antibiotic resistance in wound 
infection (Palzkill, 2018). 
 
 
1.3 Bacterial Biofilms and Implications in chronic Wound Infections 
The microbial populations of infected wounds are typically biofilm associated and have 
shown significant resistance to antimicrobial agents (James et al., 2008; Zhao et al., 2013). 
 
1.3.1 Biofilm formation 
A biofilm is a complex and well-coordinated structure of adherent microorganisms 
surrounded by an extracellular polymeric matrix (EPM). The EPM is mainly composed of 
secreted polysaccharides, proteins and extracellular DNA (Bhattacharya et al., 2015). The 
phenotypic and biochemical properties of bacteria within biofilm matrices differ considerably 
from planktonic cells. They are more resistant to immune responses and antimicrobial agents 
and are, therefore, strongly associated with persistent infections (Sadekuzzaman et al., 2015). 
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The process of bacterial biofilm formation is complex and requires coordinated microbial 
activities, to pass through several stages Figure 1.4). The initial stage involves the reversible 
attachment of cells to a surface. Stronger adhesion then takes place via specific bacterial 
surface structures such as pili or lipo-teichoic acid and polysaccharides. Multiplication of 
bacterial cells occurs at the site of adhesion (Cramton et al., 1999). This increased cell 
density enables cells of immature biofilms to respond to quorum sensing signals with global 
changes in gene expression (Atshan et al., 2013). During these early stages, attached bacteria 
modify the expression of key genes involved in adhesion and motility. In particular, the 
production of flagella and pili and secretion of exopolysaccharides (EPS) are affected, 
resulting in more firm “irreversible” attachment and development of biofilm microcolonies. 
Maturation of biofilm architecture occurs over several days, with the formation of columns 
and channels through which nutrients and toxic metabolites can flow. This structure enables 
maintenance of polymicrobial communities within the matrix; as the biofilm develops, 
different micro-niches are established with varying oxygen and pH gradients (Koo & 
Yamada, 2016). Eventually, the mature biofilm will breakdown, followed by dispersion of 
single cells from the matrix (Kostakioti et al., 2013). Each stage of biofilm formation has 
distinguishing characteristic features depending on the species involved and each requires a 
complex network of regulatory systems to co-ordinate expression of specific adhesins, 
secretion, metabolism and signalling (Fleming & Rumbaugh, 2017).  
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Figure1.4 Development of biofilm formation (Sadekuzzaman et al., 2015). The 
biofilm formation passes via several stage 1) attachments and adhesion to surface. 2) 
Bacterial multiplication and irreversible mobility 3) EPS and quorum sensing 
production4) Biofilm growth and mature 5) planktonic cell dispersal. 
 
The key components of a biofilm matrix are exopolysaccharides. For example, the 
production and secretion of alginate exopolysaccharide, encoded by alg genes, is thought to 
be one the main survival strategies of P. aeruginosa in hostile environments. Alginate 
provides the bacteria with a selective advantage for colonisation, through increased resistance 
to opsonisation and phagocytic engulfment and binds many cationic antibiotics such as 
aminoglycosides (Fleming & Rumbaugh, 2017; Høiby et al., 2010a; Nivens et al., 2001). 
Other studies have shown an important role for capsular polysaccharide adhesin (PS/A) and 
intercellular polysaccharide adhesin (PIA) or poly-N succinyl-β-1, 6-glucosamine (PNAG), 
in biofilm formation by S. aureus, whose synthesis is encoded by the ica ABCD operon 
(Anjuman et al., 2014; Nourbakhsh & Namvar, 2016). S. aureus can develop at least two 
types of biofilm: intra cellular adhesion (ica)-dependent (promoted by the ica operon) and 
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ica-independent biofilm matrixes (Archer et al., 2011). The ica dependent biofilm formation 
plays an important role in persistent infections (Ghasemian et al., 2015) 
The other main characterisation in biofilm formation is Quorum-sensing signals. For 
example, S. aureus have chromosomal locus responsible for QS is accessory gene regulator 
(agr), RNA III, and luxS (Gupta et al., 2015; Le & Otto, 2013; Wang & Muir, 2016). The agr 
locus encodes a signalling circuit that both produces and senses the autoinducer, peptide 
(AIP). The agr system has been shown to contribute to virulence, biofilm formation and 
wound infection (Brackman & Coenye, 2015; Rutherford & Bassler, 2012). Agr-controlled 
pore-forming toxins, which includes γ-hemolysin,, Leuco toxin LukDE, LukAB and Panton 
Valentine Leukocidin (PVL) (Alonzo et al., 2014; Cheung etal., 2011; Le & Otto, 2013). The 
agr locus functionality and phenol soluble modulin PSM production play a major role in 
disrupting interactions of biofilm matrix molecules, such as the polysaccharide intercellular 
adhesin (PIA), with the bacterial cell surface (Dastgheyb et al., 2015), and decrease the 
expression of several surface adhesions, including protein A and the fibronectin-binding 
protein (Otto, 2013). The global transcriptional regulator RNAIII acts to increase secretion of 
virulence factors genes such as phenol-soluble-modulin (PSM), which play role in immune 
system evasion especially in CA-MRSA (Fechter et al., 2014). In addition, the autoinducer 
(AI-2)which is synthesized by the LuxS enzyme in a metabolic pathway in S. aureus, the 
LuxS/AI-2 system play role in bacterial behaviours and infection including biofilm formation 
and virulence factors (Zhao et al., 2010). The composition of biofilms matrix often varies 
considerably between different bacteria strains and between different sites of infection by the 
same strain (Cue et al., 2012). 
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1.3.2 Staphylococcus aureus regulation genes 
There is considerable variation between strains of S. aureus, which differ in the array 
of survival strategies and virulence factors that they express. For instance, the invasive S. 
aureus strain 6850 invades host cells and expresses a wide range of virulence factors that are 
absent in other strains that persist in vivo without causing inﬂammatory affects (Strobel et al., 
2016). Over 100 transcriptional factors (TFs) and a wide range of sigma factors have been 
identified within the S. aureus pan genome and these have been classified into 36 regulatory 
families. However, less than 50% of the identified sigma factors have been experimentally 
characterised (Ibarra et al., 2013). Diverse S. aureus virulence and survival strategies are 
controlled by multiple inter-linking regulatory systems (Bronesky et al., 2016). S. aureus uses 
these regulatory systems to modulate the expression to adapt to changing environmental 
conditions such as sensing nutrient concentration, the antimicrobial agents, and the regulation 
of virulence factor expression including hemolysins, leukocidins, super antigens, surface 
proteins, and proteases (Liu et al., 2016). Two-component systems (TCSs) of S. aureus 
consists of transcriptional adaptation system membrane-bound histidine kinase (HK) and a 
cytosolic response regulator and often circuit regulate and affect each other’s 
expression(Haag & Bagnoli, 2015). For example, S. aureus has encoded the BraSR/BraDE 
determinant that are two-component signal transduction systems and regulate bacitracin 
resistance. BraDE is involved in bacitracin sensing and signalling through BraSR, whereas 
the BraSR activate transcription of two operons encoding ABC transporters in presence of 
low concentration bacitracin, the two ABC transporters play significant role in Bacitracin 
antibiotic resistance (Hiron et al., 2011). In addition, S. aureus encoded VraSR two-
component sensory regulatory system. Inactivation of vraS by cell wall inhibitor vancomycin, 
overexpressed several genes such as (two-component response regulator vraR, Penicillin 
binding protein 2pbp2, Peptide methionine sulfoxide reductase msrA), at least 1.5-fold genes 
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expression increase in different S. aureus strains after treatment with vancomycin, which also 
causes reduction in the levels of resistance to beta-lactam antibiotics and vancomycin 
(Gardete et al., 2006). 
S. aureus co-ordinates global gene expression in response to density via a quorum 
sensing (QS) system named accessory gene regulator(agr) (Figure 1.3). The agr system is 
composed of two divergent transcriptional units, RNAII and RNAIII, which are driven by 
two P2 and P3 promoters, respectively. The RNAII locus contains four genes, agrB, agrD, 
agrC and agrA. Activation of the P2 promoter drives the expression of the components of the 
QS system (agrBDCA). The agrD and agr B combined in this system to control gene 
expression in a cell density-dependent fashion through the production an autoinducing 
peptide (AIP), which in turn acts as the ligand binding to the agrC receptor (Rutherford & 
Bassler, 2012). The agrC and agrA genes encode a two-component signal transduction 
system involving a histidine kinase sensor agrC, a transmembrane protein that is 
phosphorylated upon the binding of AIP, leading to dimerization and binding to the 
intergenic region between P2 and P3 promoters upregulating their expression (Wang & Muir, 
2016). Expression from the P3 promoter drives the synthesis of RNAIII, the molecule 
RNAIII is the major effector of agr system, affecting many cell-wall-associated and extra-
cellular proteins. RNAIII plays major role in controlling the production of the hla locus, 
which is one of the α-exotoxins produced by S. aureus during infection. Furthermore, RNAIII 
also has a role in mediating the switch from expression of surface proteins such as protein A 
(SpA) to enzymes and toxins such as alpha haemolysin and proteases (den Reijer et al., 
2016). 
The staphylococcal accessory regulator (sarA), family protein encodes at least 10 
transcriptional regulators that initiate intricate molecular cascades (Gordon et al., 2013). 
Transcriptional gene patterns have demonstrated that sarA regulates (either directly or 
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indirectly) over 120 genes including up-regulation of the expression of extracellular proteins 
such as TSST-1, staphylococcal enterotoxin B, fibronectin binding protein and α- and β-
hemolysins (Dunman et al., 2001). Sar A is a DNA-binding protein that positively regulates 
biofilm promotion factors, such as the biofilm-associated protein (bap) and the ica locus. The 
intracellular adhesion (ica) locus consists of the four genes ica ABCD, these genes encode 
proteins that mediate the synthesis of the polysaccharide intercellular adhesin PIA (Cramton 
et al., 1999). Furthermore, the accessory regulator sarA negatively regulates proteases and 
nucleases that can breakdown the biofilm matrix (Lister & Horswill, 2014). Expression of the 
sarAgene is increased under biofilm conditions compared with planktonic growth and sarA 
mutants are unable to form biofilms (Lister & Horswill, 2014). The sarA biofilm-negative 
phenotype is thought to be due to the over-expression of secreted proteases and nuclease as 
inhibiting these enzymes using chemical inhibitors restores sarA biofilm-forming capacity 
(Rowe et al., 2016).  
The stress response sigma factor B (sigB) is also key for the control of virulence gene 
expression. Sigma B(sigB) is an alternate sigma factor that is necessary for stringent 
responses to conditions including high temperature, and oxidative or alkaline stress (Ahmed 
et al., 2016). In addition, it has known roles in virulence, intracellular survival, and 
persistence within the host. Loss of function mutations in sigB up-regulate the agr system and 
result in the inability of the strain to form a biofilm (Lauderdale et al., 2009). While the 
mechanisms behind these phenotypes are not completely understood, it is known that sig B is 
a negative regulator of secreted virulence factors, which is largely due to the repressive effect 
exerted on the agr system (Mootz et al., 2013; Pané-Farré et al., 2006). 
At high bacterial cell density (Figure 1.3), AIP accumulates in the extracellular 
environment and triggers the agr QS circuit AIP binds to the agrC receptor, a 
membrane-bound histidine kinase activates the agrC kinase, resulting in 
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phosphorylation of the agrA response regulator and activation of the P2 and P3 
promoters. The transcription of sarA activation or repression regulator ultimately affects 
RNAIII expression which is the effector molecule of S. aureus virulence. RNAIII 
expression can be grouped into four strategies: competitive inhibitors of agrC (the agr 
histidine kinase receptor), inhibition of agrA P2/P3 interactions, RNAIII transcription 
inhibitors, and transcriptional regulator. The RNAIII transcript yields a regulatory RNA 
molecule that acts as the primary effector of the agr system by up-regulating 
extracellular virulence factors and down-regulating cell surface proteins.
Figure1.5 Schematic of the agr system and the SarA proteins family in S. aureus. 
AIP binding activates the agrC kinase, resulting in phosphorylation of the agrA 
response regulator and activation of the P2 and P3 promoters.  sarA contributes to the 
activation of agr expression and ultimately affects RNAIII expression. The sigB system 
is linked to the complex S. aureus regulatory network, as it increases sarA expression, 
but decreases RNA III production.  
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1.4 Management and treatment of wounds 
The variety of causes of chronic wounds and complexity of the healing process are 
major hurdles to effective treatments, which must be tailored to the individual. Medical 
history and physical examination of wounds are essential for every patient. Appropriate 
treatments of chronic wounds are determined according to location, severity and pathology 
(Anderson & Hamm, 2014). For example, a variety of strategies are used to relieve pressure 
on wounds and sores. Pressure ulcers are treated with off-loading devices and ambulation, 
whereas venous ulcers are relieved with compression therapy and diabetic ulcers with off-
loading and management of ischemia (Mrdjenovich, 2010). Since most chronic wounds are 
complicated by infection, some form of antimicrobial therapy is required for effective 
healing. Elimination of localised necrotic tissue is achieved using surgical, enzymatic, 
mechanical, biological or autolytic debridement. These processes minimize the bioburden of 
the wounds by decreasing the presence of bacteria, reducing the hypoxic part of the wound 
and diminishing the local inflammatory reaction (Avishai et al., 2017; Leaper et al., 2015). 
Surgical debridement is the fastest method to remove the necrotic tissue from the wound. It is 
particularly important in life- or limb-threatening infections with necrotic eschar or gangrene 
(Leaper et al., 2015). Mechanical debridement methods include wet-to-dry dressings, which 
are performed by leaving wet gauze in direct contact with wound surfaces and removing 
when dry, together with any adhering slough. This is usually followed by pressure irrigation, 
which uses a syringe to force saline through cannulas to remove necrotic tissues that are loose 
and superficial (Fonder et al., 2008). Enzymatic debridement eliminates necrotic tissue using 
endogenous enzymes, derived from plants or micro-organisms (e.g. collagenase, varidase, 
papain, and bromelain) (Strohal et al., 2013). Occlusive (air and water-tight) and semi-
occlusive dressings maintain a moist wound environment, which speeds up the processes of 
epithelialisation and collagen synthesis (Kirketerp et al., 2011). However, occlusive dressings 
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can also promote the growth of anaerobic bacteria (Nayeri, 2016). In contrast, where moisture 
retention is apparent in the site of wound bed, highly exudative wounds require moisture 
removal. This has been achieved using absorbent dressings. Selection of a wound dressing 
should, therefore, consider quantities of exudate, level of necrotic tissue and bacterial burden. 
Dressing choice can thus change as the wound progresses or deteriorates (Benbow, 2016). 
 
1.4.1 Antimicrobial treatments and resistance profiles of chronic wound infections 
It has been reported that more than quarter of patients suffering with chronic wounds 
are receiving antibiotics at any one time. Furthermore, 60% will have received systemic 
antibiotics during the previous 6-month period (Landis, 2008). Management of acne relies on 
the application of benzoyl peroxide (BPO), salicylic acid and certain antibiotics such as 
tetracyclines, levofloxacin and doxycycline MR (Sardana et al., 2015). S. aureus skin and 
wound infections are typically treated with fusidic acid, mupirocin, neomycin or retapamulin 
(Williamson et al., 2017). Alternatively, polyhexamethyl biguanide (PHMB),used in 
cosmetics and cleaning solutions, has been formulated as foam and shown to significantly 
reduce bacterial load of chronic wounds when impregnated into dressings (Sibbald et al., 
2011). Wound dressings have become available that contain antiseptic agents such as silver. 
Nano-crystalline silver has been shown to kill a wide range of wound-infecting 
microorganisms including MRSA and vancomycin-resistant enterococcus (VRE) (Boonkaew 
et al., 2014). However, some of these agents are associated with undesirable side effects such 
as skin irritation and, of wider concern, is the increasing incidence of antibiotic resistance 
(Castanheira et al., 2010; Fritz et al., 2013).  
Bacterial resistance to antibiotics can occur by de-activation of the antibiotic activity 
(by modification or destruction); alteration of the target site to prevent binding; or 
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modification of surface permeability to prevent an effective concentration of antibiotic 
reaching the target site. All of these strategies can be exemplified in different resistance 
mechanisms against β-lactam antibiotics, including the production β-lactamase enzymes, 
alternative cell-wall trans-peptidases known as penicillin-binding proteins, or over-expression 
of efflux pumps to reduce the concentration of antibiotics at the target site (Høiby et al., 
2010; Molin et al., 2003). The presence of an antibiotic within a chronic wound bed, exerts 
selective pressure on the microbial colonisers and promotes the emergence of resistant 
microbial populations. MRSA is considered one of most common multidrug resistant 
pathogens in chronic wounds. A longitudinal study of diabetic foot ulcer infections 
demonstrated the rapid evolution of MRSA, whose prevalence almost doubled over a three 
year period (Howell-Jones et al., 2005). One hospital in-patient study found as many as half 
of all S. aureus isolates from infected leg ulcers to be MRSA and more than one-third of P. 
aeruginosa isolates to be resistant to ciprofloxacin (Bowling et al., 2009). 
More recently VRSA have presented new challenges. The first clinical VRSA was 
isolated from diabetic foot ulcers in 2002 (Appelbaum, 2007). These strains reportedly 
acquired the van A gene from vancomycin resistant enterococci (VRE). Vancomycin is 
currently the most frequently used antibiotic in the treatment of severe MRSA infections. 
Therefore, there is an urgent need for alternative treatments for such infections. Both forms of 
methicillin sensitive S. aureus (MSSA) and MRSA, are common opportunistic pathogens, 
responsible for most of acute and chronic wound infections, resulting in significant increases 
in health-care costs and morbidity (Berenholtz et al., 2004; Bode et al., 2010). 
P. aeruginosa has also been shown to adapt to sub-inhibitory antibiotic treatment of 
wounds. For instance, exposure of P. aeruginosa biofilms to azithromycin induced the 
expression of the MexCD-OprJ efflux pump (Gillis et al., 2005). Another study reported that 
P. aeruginosa can modify the targets of antibiotic action, for example by methylation of 
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16srRNA to prevent aminoglycoside binding, or modification of DNA topoisomerase to 
prevent binding of quinolones (Gorityala et al., 2016). This species has also been reported to 
possess multidrug efflux pumps, such as AdeABC and AdeDE systems that confer resistance 
against a number of antibiotics (Chua et al., 2015; Kobayashi et al., 2015). 
Increasing resistance to macrolides, such as erythromycin, is of major concern. This 
antibiotic has a relatively narrow spectrum of activity against Gram-positive bacteria, mainly 
staphylococci and streptococci (Deng et al., 2015). Resistance has developed by ribosomal 
modification, mediated by 23S rRNA methylases, encoded by erythromycin ribosomal 
methylase (erm) genes. Erythromycin can also be expelled via active (ATP-dependent) efflux 
systems (Gatermann et al.,2007). 
The incidence of wound treatment failures due to MDR infections is of major concern 
worldwide and there is increasing demand for novel treatment strategies. 
 
1.4.2 Effects of Polyunsaturated Fatty Acids (PUFA) on wound healing. 
Unsaturated fatty acids have the potential to decrease inflammation and it has been 
suggested that they may be effective in treatment of wound infection (Alexander & Supp, 
2014; McDaniel et al.,  2008). Polyunsaturated fatty acids (PUFAs), which cannot be 
synthesized de novo by mammals, consist mainly of two families, n-6 (omega-6, found in 
soybean oil) and n-3 (omega-3, found in fish oil) (Arnold & Barbul, 2006). Fish oil has been 
widely reported to have health benefits for brain function, support cardiovascular conditions 
and inflammatory disease (Assiri & Hassanien, 2013; Calder, 2013; Domingo, 2016). 
Omega-3 poly-unsaturated fatty acids include Eicosapentaenoic acid (EPA; C20:5 double 
bond) and Docosahexaenoic acid (DHA; C22:6 double bond) and their chemical structure are 
shown (Figure 1.6). Furthermore, PUFAs have been shown to exhibit antimicrobial activity 
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against several Gram-positive and some Gram negative bacterial species (Chitra Som & 
Radhakrishnan, 2011; Desbois & Lawlor, 2013; Kim et al., 2018; Mil-Homens et al., 2012; 
Sun et al.,2017). Classical resistance mechanisms against these compounds have not, so far, 
been identified (Desbois et al., 2013; Sun et al., 2016). PUFAs are suggested to have multiple 
effects, such as alteration cell membrane hydrophobicity, disruption cell surface charge, and 
membrane integrity, which lead to electron leakage resulting in bacterial cell death (Chanda 
et al., 2018; Desbois & Smith, 2010; Sun et al., 2016). 
 
 
Figure1.6 Chemical structure of Docosahexaenoic acid (DHA, C22H32O2) and 
Eicosapentaenoic acid (EPA, C2OH30O2) (Assiri & Hassanien, 2013). 
 
DHA and EPA are expected to trigger anti-inflammatory protective effects by acting 
as antagonists to arachidonic acid metabolism (Das, 2018). The arachidonic acid are 
prostaglandins such as prostacyclin (PGI2), leukotrienes (LTs) and thromboxane’s (TXs). 
They are produced by immune cells that inhibit the production of inflammatory eicosanoids, 
adhesion molecules, and cytokines (Calder, 2013). Thus, by preventing the breakdown of 
arachidonic acid, PUFAs could prolong their anti-inflammatory effects and have been 
DHA, C22:6n-3 EPA, C20:5n-3 
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suggested widley to enhance healing of wounds (Oh et al., 2015). In vivo experiments 
provide evidence for the value of PUFAs as wound-healing treatments. For example, the 
DHA-derived pro-resolving mediatorResolvin D1 (RvD1) has been shown to reduce the 
volume of necrotic cells, macrophages and microorganisms in chronically inflamed tissues of 
theexperimetaldibetic mouse model (Tang et al., 2013). Topical treatment with DHA has also 
been shown to significantly enhance healing in a wounded-rat model (Arantes et al., 2016). 
This PUFA has been shown to reduce production of pro-inflammatory cytokines such as IL-
1b whilst causing increases in the expression of IL-6 and transforming growth factor b (TGF-
b). These cytokines play important roles in the recruitment of inflammatory cells to the lesion 
site and activation of keratinocytes to promote wound healing (Arantes et al., 2016). Zhuang 
et al., (2013) used cell culture models to investigate the role of EPA and DHA on vascular 
endothelial wound repair in vitro. Anti-proliferative and anti-migratory effects of both DHA 
and EPA treatments were observed, evidenced by decreased proliferation of human 
microvascular endothelial cell lines (HMEC-1) and reduced expression of vascular 
endothelial growth factor (VEGF)was confirmed (Zhuang et al., 2013). Clinical studies of the 
effects of PUFAs on the healing of blisters have reported a significant increase in re-
epithelialisation and collagen synthesis compared to the control group (McDaniel et al., 
2011). There is published evidence that PUFAs have antibacterial activity against S. aureus 
and Propionibacterium acnes (Desbois & Lawlor, 2013). They have also been reported to 
have intrinsic antibacterial properties, shown by findings of activity against oral 
pathogens(Choi et al., 2013). Furthermore, PUFA compounds have shown no cytotoxic effect 
on human tissue cells (Yang et al., 2013). DHA or EPA did not reduce cell viability when at 
concentrations between 100 and 200 μM (Sun et al., 2016; Yang et al., 2013). A similar 
study reported 95% viability of C2 C12 myoblast cells after exposure to 50 μM and 100 μM 
33 
of EPA and DHA respectively (Peng et al., 2012). All these studies indicated that EPA and 
DHA did not show any cytotoxicity or reduce cell viability at 100 μM concentrations.   
Taken together, there is clearly sufficient evidence to support further research to 
explore the therapeutic potential of PUFAs. Thus, the aims of this present study were to 
evaluate the properties of two PUFA compounds (DHA, and EPA) against biofilm formation 
and resistance development by bacterial species commonly involved in chronic wound 
infection. The antimicrobial effects of PUFAs were investigated using in vitro; in vivo and 
ex-vivo experiments. 
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1.5 Models for testing antimicrobial efficacy 
1.5.1 In vitro Antimicrobial sensitivity tests and biofilm assays 
Antimicrobial sensitivity tests (AST), to determine the minimum inhibitory 
concertation (MIC), play a significant role in selection of an appropriate antimicrobial agent, 
particularly in an environment where the prevalence of resistant strains is high (Wellington et 
al., 2013). In vitro susceptibility data from wound isolates cannot always predict therapeutic 
success, as in vitro and in vivo conditions are variable (Dowd et al., 2008; Høiby et al., 
2010b). Laboratory investigation does not reflect the reduced metabolic activity that is 
characteristic of bacterial cells within an extracellular biofilm matrix (Høiby et al., 2010). 
Often the MIC required to neutralize a microbial biofilm population is well above the 
concertation that is clinically and safely achievable (Fricks-Lima et al., 2011; Wu et al., 
2015). Some antibiotics, such as linezolid, rifampicin, and daptomycin can penetrate biofilms 
(Barber et al., 2014; Seaton et al., 2013). However, limited antimicrobial penetration, poor 
nutrient acquisition, slow growth, adaptive stress responses, and formation of phenotypic 
variants are hypothesized to mediate resistance to a wide range of antibiotics and biocides 
(Song et al.,et al., 2016; Zhao et al., 2013). In certain conditions, biofilm bacteria have a 10-
1000fold higher intracellular survival rate than planktonic bacteria (Fastenberg et al., 2016; 
Rasmussen & Givskov, 2006; Song et al., 2016). In addition, the physiological conditions of 
biofilms promotes an increase in the rate of horizontal gene transmission among 
microorganisms (Periasamy et al., 2012). These physiological conditions have been shown to 
enhance β-lactam resistance in S. aureus and P. aeruginosa biofilms by promoting over-
production of β-lactamases that are concentrated in the biofilm matrix. These enzymes will 
hydrolyse the β-lactam antibiotics before they reach the bacterial cells (Hodille et al., 2017; 
Moradali et al., 2017). Tests to assess the efficacy of antimicrobials on biofilm shave been 
implemented over the last decade. Microtiter plate-based assays, the Calgary biofilm device, 
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substratum suspending reactors and the flow cell system are some of the most used in vitro 
biofilm models for susceptibility studies. The application of pharmacodynamic parameters, 
including minimal biofilm inhibitory concentration, minimal MBIC, biofilm-eradication 
concentration MBEC, have been shown in recent years to quantify antimicrobial activity in 
biofilms. Theses parameters have shown several advantageous for assessing the effect of 
quantitative and qualitative differences for the effects of most antibiotics when acting on 
planktonic cells or biofilm matrix (Macià, Rojo-Molinero, & Oliver, 2014). 
 
1.5.2 Skin/wound models 
Normal wound healing is a series of dynamic and complex biological processes that 
cooperate to reorganise the injury site. Wound healing processes are subdivided into three 
distinct phases: an inflammatory phase, a proliferative phase and a remodelling phase (Harper 
et al., 2014). Experimental wound models aim to recapitulate each phase to understand the 
mechanistic features of wound repair and to evaluate the efficacy of wound-healing 
treatments (Nunan et al., 2014). Different models (animal, cell -culture, 3D cell culture and 
ex-vivo skin models) have been developed, using a range of parameters that can vary 
depending on the research questions being asked (Antoni et al., 2015; Gottrup et al., 2000; 
Pastar et al., 2014).  
Animal skin models have largely focused on mice, rats and guinea pigs (Delfan et al., 
2014; Fukunaga et al., 2017), attempting to cover different phases of wound healing. The 
advantage of animal models is the host's vasculature, immune systems, and the external 
environment, can be considered to most-closely resemble human cases (Dorsett-Martin, 
2004). Moreover, these models are well-characterised, and the availability of mutant clonal 
replicates allows for controlled experiments. However, the cost of experimental animal 
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facilities is high. More crucially, the contradiction between human skin and rat skin are 
clearly evident. For example, wounded rats heal by contraction of a subcutaneous muscle 
layer (panniculus carnosus), these layers do not exist in human skin and the re-
epithelialization process contributes to a different healing mechanism (Li et al., 2015). 
Furthermore, the tissue of mice, rats and other animals possess the enzyme L-gluconolactone 
oxidase (not present in human skin) that converts L-gluconogamma lactone to vitamin C 
(Blais et al., 2017), and plays- a major role in collagen synthesis (Takahashi et al., 2014). The 
variation in anatomy and physiology and the fundamental genetic differences between human 
and rat skin should be considered. 
In vitro cell culture experiments, using either transformed skin cell lines or primary 
skin cells are cheaper and more easily reproduced in a well-controlled environment that 
contains suitable medium with essential nutrients such as (amino acids, vitamins, 
carbohydrates growth factors, and minerals), (Coulomb & Dubertret, 2002). Carefully 
controlled CO2 and O2 levels can create the correct physio-chemical environment. Most cells 
are adherent on surfaces by using artificial substrate or others can grow free floating in 
culture medium (Mehling&Matthias, 2014). These experimental conditions allow for high-
throughput testing of wound-healing treatments, using scratch test assays. However, they 
provide limited information about skin structure or the role of immune-modulators.  
More sophisticated 3D cell culture wound healing models have been developed, using 
fibroblast cells cultured in 3D matrices, generally containing fibrin or type I collagen. 
Collagen production is decreased whereas collagenase is increased by fibroblasts integrated 
into relaxed type I collagen gels (Eckes et al., 1995). The gel composition can be modified by 
incorporating different types of collagen, fibronectin or glycosaminoglycans to imitate the 
early granulation tissue deposited during wound repair (Xu & Clark, 1996). Another example 
of a novel 3D wound healing model was presented by Chen et al., (2014). This model 
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introduces multiple cell types such as fibroblasts, keratinocytes, monocytes, and 
mesenchymal stem cells. Cell migration and proliferation can be screened by adding different 
growth factors during the 3D fibrin construction. This model has been used in to study the 
effect of different drugs on cell migration during wound healing process (Chen et al., 2014). 
There are several limitations to the use of in-vitro and animal models to investigate 
wound healing. High cost, poor reproducibility or poor resemblance of actual human skin are 
common pitfalls. Therefore, researchers are keen to find alternative models able to screen the 
effects of different compounds and conditions on the wound healing process, in a system that 
more closely resembles natural human wounds. Ex-vivo skin models have been developed, 
using human skin left over from routine elective surgery such as cosmetics (Groeber et al.,  
2011). These skin explants are cut with a full thickness punch biopsy and contain both dermis 
tissue (fibroblast and collagen) and epidermis tissue (keratinocytes). The punch biopsies are 
then placed in tissue support systems and growth media. This approach has an advantage over 
other model systems, as it enables the study of re-epithelialization that occurs in epidermal 
and dermal layers. The ex-vivo skin can be maintained under controlled experimental 
conditions, however, variation in host factors of the donor can affect reproducibility. Cell 
proliferation and death during reepithelization can be measured by immunofluorescence 
markers (Mendoza-Garcia et al., 2015).  
Thus, a further aim of this project is to investigate the effects of PUFA compounds on 
the growth of S. aureus on wounded and non-wounded ex vivo skin. 
  
38 
1.5.3 Invertebrate and non-vertebrate models of infection 
The study of infectious diseases and toxicity using invertebrate models has given 
insights into host pathogen interaction for several bacteria. In addition, several alternative 
invertebrate models have been developed based on their experimental advantages, low cost, 
ease of maintenance, high throughput capabilities and the various aspects of the innate 
immune response are conservative between invertebrates and mammals, makes these 
invertebrates an effective method for identifying microbial virulence factors and testing 
potential antimicrobial agents. 
Among the alternative models to study microbial infection are amoebas (Trevijano-
Contador & Zaragoza, 2014). For example, the acanthamoeba model which are considered a 
typical model for studying microbial phagocytosis. Macrophages and acanthamoeba have 
lysosomal enzymes responsible for the digestion and nutrient acquisition (Marciano-Cabral & 
Cabral, 2003), which gives advantageous to evaluate the microbial interaction and virulence 
factors. In addition, comparison the gene expression between the A. canthamoeba model and 
mammalian cells, might provide the knowledge on how pathogenicity enhanced and on how 
pathogens evolved and adapted to distinct hosts. 
Drosophila melanogaster has been used to investigate whether these insects are 
potential vectors of human and plant pathogens. Genomic analysis of Drosophila 
melanogaster revealed that similarity to the mammalian innate immune system (Marcu et al., 
2011). Furthermore, D. melanogaster have been used to explore pathogen interactions and 
host factors that promote or inhibit infection by pathogens like S. aureus (Tabuchi et al., 
2010), and P. aeruginosa (Kim et al., 2008). 
The nematode Caenorhabditis elegans is multicellular organism and has been the 
subject of intense study for decades. The genome sequence for C. elegans is available and 
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many functional genomic approaches have been developed to study the innate immunity of 
humans or other animal hosts. C. elegans has an innate immune response, involving the 
activation of specific signalling pathways and leading to the production and release of 
defence molecules such as antimicrobial peptides, caenopores, caenacins, and lysozymes 
(Dierking et al., 2016). This nematode worm has been applied to the study of host-pathogen 
interactions, immune response and used for antimicrobial discovery and development. For 
example, community-associated MRSA strains have been shown to be more pathogenic than 
hospital-associated MRSA in C. elegans and support the use of this model for studying the 
virulence of S. aureus strains (Wu et al., 2010). This model has also been useful in testing the 
efficacy of novel antibiotics. For example, cytolex, a magainin AMP derived from frogs, has 
been identified as a topical antibiotic for treating diabetic foot infection. Its efficacy has been 
tested using the C. elegans model, with promising result for AMP derivatives. The nematode 
could be a rich source of potential leads for the future development of such drugs (Ewbank & 
Zugasti, 2011). 
 
Galleria mellonella is high-throughput model that mimics the key features of 
microbial pathogenesis, interactions, and studying the microbial virulence. It can also be used 
to screen novel antimicrobial drug candidates. G. mellonella has two major parts of innate 
immune system, the cellular and the humoral immune response that play significant role to 
eliminate infecting microbes. The cellular response includes phagocytosis, encapsulation and 
clotting. The humoral response is coordinated by soluble complement-like proteins, melanin, 
and anti-microbial peptides. Several studied have been established that use the invertebrate G. 
mellonella model for virulence determinant, host response and antimicrobial efficacy, with a 
range of pathogens such as S. aureus (Desbois & Coote, 2011; Silva et al., 2017), P. 
aeruginosa (Koch et al., 2014), and Candida albicans (Mowlds et al., 2008). The 
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invertebrate G. mellonella are ethically more acceptable and practically more-challenging 
than the use of vertebrates meaning larger group sizes can be used to enhance reproducibility. 
This study focused on exploring the interaction between S. aureus and PUFA 
compounds using ex-vivo skin and G. mellonella as infection models. 
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1.6 Aims and Objectives 
This study focused mainly on a clinical wound isolate of S. aureus, because it is the 
pathogen most commonly associated with wound infection. The experimental approach had 
three major aspects, the first aim was to evaluate the activity of polyunsaturated fatty acids 
(PUFA) (DHA, EPA and both DHA+EPA) in-vitro as potential antimicrobial and anti-
biofilm agents. Furthermore, to assess the effect of the inhibitory levels of PUFAs on global 
gene regulation involved in virulence and biofilm formation. The second aim of this study 
was to assess the effect of PUFAs in vivo on S. aureus on the growth and infection using G. 
mellonella model and ex-vivo skin models. Finally, this study observed the phenotypic and 
mutational variance that occurred after environmental stress caused by PUFA compounds 
compared to standard antibiotics (LZD and VAN).  
Specific objectives 
1. Assess the antibacterial and anti-biofilm activity of PUFAs on bacterial species that 
commonly cause wound infection using MIC, MBC, MBC and MBEC assays and in-
vitro biofilm assays. 
2. Estimate the effect of the inhibitory concertation’s of PUFAs on global regulatory genes 
of S. aureus using RT-q PCR. 
3. Assess the efficiency of PUFA compounds and standard antibiotics (LZD and VAN) on 
the virulence of S. aureus using G. mellonella and ex-vivo skin models. 
4. Assess variation in antibiotic sensitivity and virulence of S. aureus SA3 following 
prolonged exposure to PUFAs and clinically relevant antibiotics. 
5.  Evaluate single nucleotide polymorphisms (SNPs) associated with S. aureus adaption to 
PUFAs, LZD and VAN using the whole genome sequencing.  
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Chapter 2 Materials and Methods 
 
2.1 Bacterial culture 
All bacterial strains and species used for this study are listed (Table 2.1). These 
species were chosen as they have been commonly associated with wound infections (Cooper et 
al., 2014). Each strain/isolate was identified and confirmed using standard microbiological 
culture techniques such as Gram stain, Coagulase test, Catalase test, and Analytical Profile Index 
(API 20 E). The range of solid media used in this study included Columbia agar (Lab M, UK) 
for inoculating organisms from -80°C, for propagation of organisms for total viable count and 
for growing organisms for stock cultures. The liquid media include Luria-Bertani (LB) broth 
(Oxoid, UK), for liquid cultures of reference organisms. S. aureus isolates were sub-cultured 
on mannitol-salt agar plates (Oxoid, UK). Muller Hinton broth (MHB, Oxoid, UK) was used 
for antimicrobial susceptibility tests by broth dilution to determine the minimum inhibitory 
concentrations. All confirmed isolates were stored in LB with 20% glycerol and frozen at -
80°Cuntil required for further investigation. 
Table 2.1 Bacterial species/strains and their origin 
 
Strains /isolates Strain Origin and source Source References 
S
. 
a
u
re
u
s 
*SA2 Forearm wound  SRFT This study 
*SA3 Ulcer swab SRFT This study 
*SA4 Ulcer swab  SRFT This study 
#6538 ATCC reference strain 
Major  
Salford 
University stock 
(Nicolaou et 
al., 2007) 
252 MRSA strains found 
in British Hospitals  
Salford 
University stock 
(Holden et 
al., 2004) 
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E. faecalis #13280 NCIMB reference 
strain  
Salford 
University stock 
(Thomson 
et al.,2011) 
P
. 
a
er
u
g
in
o
sa
 
#PA01 Wound isolate IGH, 
University of 
Liverpool 
(De Soyza 
et al.,2013) 
#PA14 Human burn isolate IGH, 
University of 
Liverpool 
(De Soyza 
et al.,2013) 
Es. coli #10536 ATCC reference strain Salford 
University stock 
(Mogna et 
al., 2012) 
*Clinical wound isolate; #Standard reference strain; Salford Royal Foundation Trust 
Hospital; IGH – Institute of infection and Global Health. 
 
 
 
2.2 Antimicrobial susceptibility testing (AST) 
2.2.1 Disk diffusion assays 
The disk-diffusion (Kirby Bauer) method is the traditional method used in clinical 
setting when testing bacteria for antimicrobial susceptibility patterns. This method has been 
standardised as detailed in the standard susceptibility testing guidelines of European 
Committee on Antimicrobial Susceptibility Testing EUCAST (EUCAST, 2018). Overnight 
bacterial cultures were prepared on Luria agar and suspended in phosphate-buffered saline 
(PBS Thermo Fisher Scientific, UK) then adjusted to a 0.5 McFarland turbidity standard and 
swabbed evenly onto Mueller Hinton agar in accordance with EUCAST guidelines. 
Appropriate antibiotic discs (Oxoid, UK), were then placed on the agar surface (Table 2.2). 
The antibiotics used were chosen as important representatives of ten different antibiotic 
classes. After incubation at 37 ºC, for 18 h. The break points were determined by measuring 
the diameter of each zone of inhibition, as a function of the amount of drug in the disk and 
susceptibility of the microorganism. Each bacterial strain or isolate was classified as 
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susceptible or resistant by comparing the diameters of inhibition zones with the breakpoints 
according to EUCAST recommendations (EUCAST, 2018). 
Table 2. 2 Antibiotics and break points (EUCAST Clinical Breakpoint Tables v. 6.0) 
Classes 
Antibiotics (Oxoid) Disk 
content  
(µg) 
Inhibition Zone 
diameter (mm) 
Target Range 
β-lactam 
Tazobactam (TAZ) 
Cefoxitin (FOX) * 
85 
30  
Vary 17-28 
 
NA 
14-20 
Glyopepetide 
Vancomycin (VAN) 5 13 10-16 
Aminoglycoside 
Gentamicin (CN) 
Tobramycin (TOB) 
10  
10  
22 
22 
19-26 
18-26 
Lincosamide 
Lincomycin (MY)) 2  26 22-29 
Macrolide 
Erythromycin (E) 15 26 23-29 
Fluoroquinolone 
Ciprofloxacin (CIP) 5  24 21-27 
Tetracycline 
Tetracycline (TE) 
30 27 
23-31 
Oxazolidinone 
Linezolid (LZD) 
10 24 
21-27 
*Cefoxitin (FOX)30 µg used for identification of MRSA in accordance with 
EUCAST recommendations. 
 
Notes: - Break points size are used for most Staphylococcus aureus references strains 
(EUCAT, 2018), therefore the size of inhibition is varying that dependent on the strains type. 
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2.2.2 Detection of PUFA antimicrobial activity by disk diffusion assay 
Polyunsaturated fatty acid such as DHA and EPA have been recognised as 
antimicrobial inhibitors for several pathogens (Desbois and Lawlor, 2013; Sun et al., 2016). 
This study sought to confirm these reports and further characterise such activity against 
several clinical isolates of S. aureus. Briefly, overnight cultures of S. aureus isolates SA2, 
SA3, SA4, SA 6538 and MRSA 252 were prepared on Luria agar and 2 -3 colonies of each 
isolate are inoculated into 5ml of Phosphate buffer saline (PBS, Thermo Fisher Scientific, 
UK). These bacterial suspensions were adjusted to a turbidity of 0.5 McFarland standard. 
Bacterial suspensions were swabbed onto Mueller Hinton agar plates using a sterile cotton 
swab within 15 min of preparation. DHA and EPA (Cambridge Bioscience) were solubilised 
in Ethanol and diluted with sterile H2O to 100µg ml
-1. Diluted compounds (25 µL) were 
absorbed onto 6mm sterile filter paper discs (Whatman) and allowed to dry for 1h. Control 
discs were prepared using diluted ethanol. Disks were placed onto inoculated MH agar, 
incubated and interpreted as described for AST (section 2.2). 
 
2.3 Detection of Minimum Inhibitory Concentration (MIC) and Minimum bactericidal 
concentration (MBC) 
The antimicrobial effect of PUFAs (DHA and EPA, Cayman, Cambridge Bioscience) 
and relevant antibiotics was tested by determining the minimal inhibitory concentration 
(MIC) and minimum bactericidal concentrations (MBC). All bacterial cultures were grown 
for 18h at 37°C under aerobic conditions on Columbia base agar (Oxoid, UK), then 
inoculated in to 5 ml Mueller Hinton (Oxoid, UK) broth for further incubation at 37 °C with 
shaking 18-20h. The OD600 nm of bacterial cultures were measured and adjusted to OD600 
0.05 in MH Broth. The MIC assay was carried out according to standardised broth dilution 
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methods (Andrews, 2001). Briefly, DHA and EPA (100 mg) were solubilised in ethanol 
(100%) to prepare stock concentrations of 50 mg ml-1. Two-fold serial dilutions (100 µL) 
were then prepared in MH broth in a sterilized 96-well compound plate (Sigma-Aldrich, 
Costar, USA) as detailed in Table 2.3. The Gentamycin antibiotic (20 µg ml-1) was 2- fold 
serial diluted in ds H2 O as positive control. Each dilution was then diluted further (1:20) by 
introducing to a dosing plate, each plate containing 190 µL of MH broth. A final MIC plate 
was prepared using 100 µL from each well of dosing plate plus 100 µL diluted bacterial 
suspension (Table 2.3). Broth only wells were used as negative controls. MIC plates were 
incubated for 18-20 h at 37oC. The MIC values were determined as the minimum 
concentration of PUFA or antibiotic that prevented any bacterial growth (measured as 
turbidity above background levels) and recorded using a plate reader (FLUOSTAR omega, 
BMG, UK) at wavelength 600 nm.  
Table 2.3 Preparation template for dilution of PUFA compounds for MIC assays 
 
The Minimum Bactericidal concertation (MBC) values were determined by spreading50 µL 
of bacterial culture from wells containing the determined MIC, and wells on either side, to 
MH agar plates. The solution was spread using a sterile loop and each plate was inverted and 
incubated for 24h at 37°C. In order to determine the MBC, the colonies were counted and the 
lowest concentration plates that contained no growth were designated the MBC.  
 
Compound plate50mg 
ml-1stock 
1:2 1:4 1:8 1:16 1:32 1:64 1:128 
Dosing plate (1:20) 1:40 1:80 1:160 1:320 1: 640 1:1280 1:2560 
MIC plate (100uL of 
dosing plate+100uL 
bacterial suspension) 
1250µg 
ml-1 
625µg 
ml-1 
312µg 
ml-1 
156µg 
ml-1 
78µg 
ml-1 
39 µg 
ml-1 
19.5µg 
ml-1 
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2.4 Detection of antimicrobial tolerance. 
The measurement of MBC/MIC ratios to detect the ability of bacteria for prolonged survive 
underexposure of bactericidal without acquired phenotypic resistance (Biedenbach et al., 
2007; Jones, 2006). 
 
2.5 Biofilm assays 
2.5.1 Congo red agar assay 
The Congo Red Agar assay (CRA) allows for detection of certain exopolysaccharides as an 
indicator of biofilm forming capability by variation in the colour of bacterial colonies grown 
on the specialised solid medium (Kaiser et al., 2013). Congo Red agar was prepared using 
sterile Brain Heart Infusion (BHI) broth (Oxoid, UK) supplemented with sucrose (5% w/v); 
and Congo red stain indicator (0.08% w/v; Oxoid, UK; Sharvari & Chitra, 2012). Bacterial 
isolates were streak inoculated on to Congo Red Agar plates and incubated at 37oC under 
aerobic conditions for (24 and 48 h). The biofilm producer strains formed black colonies with 
a dry crystalline consistency indicating a good capacity for biofilm production, while the non-
biofilm producer strains formed red colonies. The experiment was performed in triplicate and 
repeated three times. 
 
2.5.2 Crystal Violet Assay 
The crystal violet microtiter plate assay is a simple method for biofilm detection. This semi-
quantitative test, was performed according to the method (O’Toole, 2011). Bacterial strains 
were grown aerobically (16-18h) on Columbia base agar (Oxoid, UK). Selected colonies 
were inoculated in 5 ml of Brain Heart Infusion (BHI) broth and incubated at 37ºC for further 
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24 h. The cultures were then adjusted to OD600 0.05 by diluting in Tryptic soy broth (TSB) 
supplemented with 1% glucose for enhancing the biofilm formation in staphylococci (Reiter 
et al., 2013). The bacterial culture was adjusted to OD600 0.05 and subsequently 200 µL were 
filled in sterile 96 well flat-bottom polystyrene plates (Sigma-Aldrich, Costar, USA). 
Negative control wells, containing broth only were included. Two microtiter plates were 
incubated aerobically at 37°C for 24 h and 48 h. A reading of optical density (OD600) was 
taken as an estimation of the total growth in each well. Planktonic cultures were removed, 
and the wells were washed with 200 µL of PBS (pH 7.2) x3.  This removed any non-biofilm-
associated bacteria. Biofilms adhered to the bottom and side of the wells were stained by 
adding crystal violet (0.1%; SIRCHIE, USA) to each well and incubating at room 
temperature for 15 min. Excess stain was removed and biofilms were washed again with PBS 
as previously. Plates were dried completely at incubator for 2 h before 100 µL of 100% 
ethanol was added (Cargill, UK). All plates were incubated at room temperature for 15min 
with gentle shaking. Total biofilm density was quantified by reading OD at wavelength 
(OD600) using a plate reader (FLUOSTAR omega, BMG, UK). Each experiment was 
performed in triplicate and repeated 3times. The biofilm index score based on the optical 
density and crystal violet stain were recorded. The average OD values were calculated for all 
tested strains and negative controls. Final OD values of a test strain was expressed as average 
OD value of the strain reduced by OD cut-off value (ODc) of negative control. Then the 
interpretation for biofilm production was carried out according to the criteria of Stepanovic et 
al.(Stepanovic et al., 2007). ODc was defined as three standard deviations (SDs) above the 
mean OD of negative control. 
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2.5.3 Detection of Minimum Inhibitory Concentration (MIC) of PUFA on the biofilm 
formation 
The effect of PUFAs on biofilm formation was assessed by setting up 96-well plates in the 
same way as the MIC assay (section 2.3), then measuring biofilm formation in each well after 
24-48 h using the crystal violet assay (Stepanovic et al., 2007). 
 
2.5.4 Assessment of PUFA compound efficacy on biofilm disruption by using (MBIC 
and MBEC assays) 
The minimum biofilm inhibitory concentration (MBIC) and Minimum Biofilm 
Eradication Concentration (MBEC) methods are easy to perform and applicable to high 
throughput screening for assessing anti-biofilm activity using the Calgary Biofilm Device 
(MBEC™ Biofilm Technologies Ltd. Calgary, AB, Canada). The Calgary biofilm system 
was designed to allow growth of biofilms, for longer periods in 96 wells values in clinical 
situations; determination of Antibiotic Susceptibilities of Bacterial Biofilms and assessing 
potential efficacy of treatments for chronic biofilm-associated infections (Ceri et al., 1999). 
The Calgary system is a two-piece disposable plastic 96-well plate designed for the growth of 
biofilms on pegs that are attached to the lid and bathed in liquid contained within each well. 
This system was used to evaluate the ability of PUFA compounds to disrupt biofilms of nine 
bacterial strains / clinical isolates, as previously described (Girard et al., 2010; Reiter et al., 
2013) with slight modifications. Briefly, single colonies of test bacteria were inoculated into 
5 ml of sterile tryptone soy broth (TSB) with1% glucose and incubated at 37°C in a shaking 
aerobic incubator (100 rpm) for 18-20 h. Bacterial culture densities were normalised by 
diluting to McFarland standard 0.5 using fresh growth medium. Next, 100 µL of bacterial 
inoculum was added to each well of the Calgary biofilm plate and incubated at 37°C and 30 
rpm for 48 h to allow biofilm formation on the pegs. Biofilms were exposed to doubling 
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dilutions of PUFAs (150 µL) in sterile broth across a 96-well microtiter plate by transferring 
the Calgary plate lid into the freshly prepared challenge plate and incubated for 24 h at 37°C 
and 100 rpm. After incubation, the lid was transferred to a 96-well recovery plate containing 
200 µL of sterile broth and incubated for 18 h at 37°C. Different controls of broth only and 
bacterial suspension (containing the equivalent concentration of ethanol used to initially 
solubilise each PUFA), were prepared as negative controls. The MBECs were determined as 
the lowest concentration for which bacterial growth did not occur. Growth was viewed as 
turbidity compared to an un-inoculated well (negative control) and was detected using a 
microtiter plate reader (FLUOSTAR omega, UK). The cut-off was defined as three standard 
deviations above the mean ODc. Each isolate was classified as follows: weak biofilm 
producer OD = 2 × ODc, moderate biofilmproducer 2 × ODc < OD = 4 × ODc, or strong 
biofilm producer OD > 4 × ODc. 
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2.6 Galleria mellonella as a model to assess virulence of S. aureus and antimicrobial 
activity of PUFAs in vivo. 
2.6.1 G. mellonella challenge experiments to compare virulence of S. aureus strains 
G. mellonella larvae were purchased (next-day delivery) from Live Foods Direct 
(Sheffield, United Kingdom), stored in the dark at 4°C and used within 14 d of delivery. The 
virulence of 5 different strains (or adapted strains) of S. aureus were compared using the 
Galleria mellonella (wax moth larvae) infection model, carried out according to Latimer et al 
(Latimer et al., 2012). Briefly, all bacterial cultures were grown in on Luria agar plates before 
overnight culture in LB broth at 37°C with 200 rpm shaking. Three times in PBS washing 
and diluting appropriately to a desired OD600 of 0.1 (5 x10
5 - 8x 105 CFUml-1). Colony counts 
were confirmed by preparing a dilution series and spreading 100 µL on Mannitol Salt Agar 
(MSA) (Lab M, UK) for each suspension then incubating at 37°C for 30 min. All 
experiments used groups of 16 larvae per treatment. Each larva from each group was injected 
with 5µL prepared inoculum into the hemocele of the last left proleg larvae by using 
Hamilton syringe (Sigma-Aldrich Ltd, UK) with needle. The syringe was cleaned between 
tested strains with sequential washes of PBS, 70 % ethanol and sterile water. Two negative 
control groups were always prepared: one group that underwent no manipulation to control 
for background larval mortality and other group was injected with PBS only (uninfected 
control) to control any effect of physical trauma. Larvae were incubated in sterile Petri dishes 
in the dark at 37°C for up to 7 days and inspected every 24h so that the number of dead 
larvae could be recorded and removed, and percentage survival could be calculated for each 
group. The experiment was terminated once two larvae from either control group had died. 
Larvae were considered dead if they turned black in colour due to melanisation as a result of 
bacterial multiplication and infection. Each experiment was repeated 3x. To assess the 
bacterial burden of infection, each dead larva was crushed and homogenised in sterile PBS. 
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The homogenate was serially diluted, and the colony counts were performed by spreading 
100 µL on MSA. Viable colony forming units per mL were determined by calculating the 
mean colony count x dilution factor x 10 for each treatment. 
 
2.6.2 G. mellonella challenge experiments in the presence of PUFAs 
Further challenge experiments were carried out using the clinical S. aureus wound isolate, 
SA3. Assays were set up as described in section 2.4.1, but bacterial cultures were inoculated 
in the presence or absence of different concentrations (MIC or 2x MIC) of PUFAs (DHA or 
EPA) or antibiotics (LZD or VAN). 
 
2.7 Ex-vivo Human Skin Model 
2.7.1 Development, and testing of a bacterial burden on wound infection based on ex 
vivo human skin model 
Fresh human skin specimens were obtained from (a licenced research tissue bank housed at 
the University of Bradford). Skin samples (5 x 5 cm) were taken from abdominoplasty 
patients at Bradford Royal Infirmary, processed at Ethical Tissue and dispatched by courier to 
Salford. Samples were typically processed in our laboratory within 24 h of surgery and were 
transported on cooling packs (dry ice box) in a sealed container of saline solution. All Details 
of the facility and Ethics are supplemented (Supplement 12 chapter3 in appendices) and more 
details : https://www.bradford.ac.uk/business/ethical-tissue/about-us/. 
The experiments were performed using antiseptic technique in a containment level 2 
biological safety cabinet. Briefly, the surface of the ex vivo skin (free of injuries or redness) 
was cleaned with double distilled water. All excess subcutaneous adipose tissue and fats were 
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removed using a pair of blunt stainless-steel scissors and coated stainless steel dissection 
forceps (Fisher Scientific UK Ltd) to yield full-thickness skin. Skin samples were washed 
twice in Williams E medium (Fisher Scientific UK Ltd), in a sterile plastic Petri dish and then 
bathed in the medium for 10 min to refresh the skin. The skin biopsies were prepared using a 
5.0 mm Biopsy Punch (Selles Medical Ltd, UK) and transferred in to fresh Williams E 
medium. For the wounded-skin model, superficial wounds were introduced using a 2.0mm 
Biopsy Punch (Selles Medical Ltd, UK), taking care to only cut through the surface 
epidermis. Unwounded and wounded skin biopsies were mounted into 6-insert Trans-wells 
(24mm) containing TC Treated PC Membrane (pore size 0.4µm) (Fisher Scientific UK Ltd). 
Biopsy skin samples were pulled through a pin-prick hole in the centre of each trans-well 
membrane as shown (Figure 2.1). Biopsies were bathed, from the basal side in wells 
containing 1 ml serum-free Williams E culture medium (Thermo-Fisher Scientific™, 
Basingstoke, UK) supplemented with 10 µLml-1 insulin, 10 ngml-1 hydrocortisone and 2mmol 
L-glutamine (Sigma-Aldrich Company Ltd). A series of experiments were designed and set 
up in sterile 6 well tissue culture plates and trans-well inserts (Fisher Scientific UK Ltd) as 
shown (Table 2.4). Overnight bacterial cultures of clinical S. aureus isolate SA3 were 
prepared by incubating for 20 h in tryptic soy broth at 37˚C with shaking (180 rpm), then 
washed 3x in sterile PBS to desired OD 600 nm of 0.1 (3.5 x10
7 to 8x 107 CFUml-1), the 
colony counts of each inoculum was confirmed on MSA agar. A total volume of 5 µL of each 
inoculum (containing ≅ 3.5 x104 CFUmm2) was deposited on to the surface of each wounded 
or non-wounded biopsy sample. For treatments in the presence of PUFA, DHA or EPA was 
solubilised in ethanol and diluted in MH broth to a final concentration of 130 μg ml-1 (2x 
MIC). PUFA preparations (100 µL at 2 MIC µg ml -1) were mixed with 100μl suspensions of 
diluted SA3 in sterile microfuge tubes. Mixtures (5 µL) were pipetted on to the surface of 
wounded and non-wounded biopsy samples. An alternative experiment was set up, in which 
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bacteria were inoculated on to the skin surface and allowed to absorb, 15 min before the 
addition of PUFAs (Table 2.4). In this case, SA3 suspensions (5 µL) were laid on top of 
wounded and non-wounded biopsy samples then after 15 min, 2x MIC of DHA compound 
(5μl) was added. Media was added to the skin surface as negative control. Each test setting 
was performed in triplicate (3 wells) with a total of at least three repeat plates. All plates were 
incubated overnight in a CO2 incubator (5% CO2) (LEEC, UK) at 37˚C. 
 
Figure 2.1 Schematic of ex-vivo skin model set up. Modified from (“Skin - 
Predictive Drug Discovery Services”). Biopsy samples taking from Human skin ex-
vivo model for 1stExperiment wounded and Nonwounded biopsy, 2nd Experiment were 
treated with SA3 + DHA (2 MIC,130µgml-1), Biopsy samples with bacteria only and 
with DHA 2 MIC only were included as controls. Each experiment was done 3times in 
triplicate. 
 
Each time skin was delivered, 4 assay plates were prepared, 5mm skin biopsies were inserted 
into the centre of each trans-well and bacterial culture (SA3), PUFA (DHA) or media (5µL) 
was inoculated on to the surface. 
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Table 2.4 Conditions used for each ex-vivo skin model assay 
Assay 
Plate 
Row 1: Wounded (3 replica wells) Row 2 Non-wounded (3 replica wells) 
1 SA3 ≅1 x107 CFUmm2 SA3 ≅1 x107 CFUmm2 
2 Media only control Media only control 
3 SA3 ≅1 x107CFUmm2+ DHA (2 
MIC130 µg ml -1) 
SA3 ≅1x107CFUmm2 + DHA (2 MIC130 
µg ml -1) 
4 SA3 + delayed* DHA (2 MIC µg ml 
-1) 
SA3 + delayed* DHA (2 MIC µg ml -1) 
 
Determination of bacterial burden and the activity of PUFAs on the ex-vivo human skin 
model was performed by using a sterile cotton swab to collect bacteria from the surface of 
each skin biopsy. Bacteria were recovered from the swab by agitation in sterile PBS (1 ml), 
which was serially diluted and then 100 µL of each dilution was spread plated on MSA for 
overnight culture at 37˚C. Colony forming units on each skin biopsy (5 mm2) were 
calculated. 
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2.8 Effect of the inhibitory concentrations of DHA and EPA on growth of S. aureus 
clinical wound isolate SA3 
This study aimed to investigate potential mechanisms by which PUFAs affect the growth or 
virulence of S. aureus. Growth and expression of key virulence regulator genes were 
observed in the presence of different concentrations of DHA and EPA. Briefly, fresh cultures 
(50 ml) of clinical wound isolate, SA3 were prepared in MH broth from overnight cultures to 
a starting density of OD600 0.1 corresponding to 10
6 CFUml-1 (as confirmed by serial dilution 
and spread plating on MSA). Cultures were exposed to two different concentrations (50µg 
ml-1 or 100 µg ml-1) of DHA, EPA or both together, in triplicate and incubated at 37oC. 
Samples (4 x 1.5 ml) were taken from each culture vessel at time points 0, 6, 12 and 24 h. 
Optical density measurements and broth dilution CFU ml-1 assays were performed at each 
time point. Negative controls used MH, supplemented with diluted Ethanol in place of 
PUFAs. Bacterial cells were harvested from each 1.5 ml sample by centrifugation (13,000 
rpm, 2min) using bench top microfuge, bacterial pellets were stored at -20oC for total RNA 
extraction. 
 
2.9 Adaption Experiments 
Since PUFAs could be applied to wound dressings to enhance the treatment of chronic 
infections, this study investigated whether S. aureus was able to adapt to prolonged exposure 
of PUFAs or clinically relevant antibiotics. Experiments were set up to monitor resistance, 
tolerance and virulence of the clinical wound isolate, SA3 after sequential sub-culture in below-
MICs of DHA, EPA, or both DHA+EPA, vancomycin or linezolid. Briefly, single colonies of 
SA3 were inoculated in to MH broth for culture at 37oC for 24h. Bacterial suspensions were 
standardised by dilution to OD600 0.05 using fresh growth medium. MIC assays were prepared 
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in 96-well microtiter plates (96-well) (according to section 2.3), using a 2-fold dilution series 
of each test agent (2x above and 2x below the MIC – see table 2.5). ‘Bacteria only’ and ‘MH 
broth only’ conditions were included in triplicate as negative controls. Growth was observed 
after 20 h by measuring absorption using a microplate reader (FLUOSTAR omega, BMG, UK) 
and compared to negative control. Each day, after recording MIC, wells containing bacterial 
growth at the highest possible concentration of antimicrobials, were sub-cultured (2 l) in to a 
fresh MIC assay plate, prepared as before. Concentrations were adjusted each time, according 
to any change in MIC, to ensure that an appropriate range was used (2x above and 2x below 
MIC). A loopful of culture from the same well was streaked onto MSA to check for purity. The 
remaining cultures, from each assay plate, were stored in 20% glycerol at - 80°C.  
Table 2.5 Concentrations of test agents (PUFA or antibiotics) used for adaptation 
experiments 
Test agent Concentration range (μg ml-1) 
DHA 312 156 78 65 52 39 
EPA 312 156 78 65 52 39 
DHA+EPA 312 156 78 65 52 39 
Linezolid 16 8 4 2 1 0.5 
Vancomycin 0.25 0.12 0.06 0.03 0.015 0.0075 
*Concentrations were adjusted each time to maintain 2 below and 2 above the MIC (MIC highlighted in grey) 
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2.10 Detection and quantification of S. aureus enzymes 
2.10.1 Coagulase Assay 
Coagulase production was measured following the method of (Aldridge et al., 1984). Briefly, 
bacterial suspensions were prepared in MH broth (1 ml, OD600 0.4) and added to 3 ml rabbit 
plasma supplemented with EDTA (Sigma-Aldrich., UK). The suspensions were then 
incubated at 37 °C and monitored for signs of coagulation for up to 3 h. Extent of coagulation 
was judged using a 4-timepoints scale. 
 
2.10.2 Deoxyribonuclease Assay 
Deoxyribonuclease (DNase) production was measured following the method of ( Choi & 
Szoka, 2000). Briefly, fresh bacterial cultures were inoculated onto DNase test plates 
containing Soya peptone, Deoxyribonucleic acid (DNA), Sodium chloride and agar (Thermo 
Fisher Scientific, UK) and incubated for 18-20 h at 37 °C. Once cultures had grown, the 
surface of the plate was flooded with 1N HCl (Sigma-Aldrich, UK), poring the excess into a 
designated waste pot. Polymerised DNA precipitated in the presence of HCl, making the 
medium opaque. If the bacteria growing on the agar produced DNase enzymes in sufficient 
quantity to hydrolyse the DNA, then clear zones were observed around the bacterial growth.  
 
2.10.3 Haemolysin Assay 
Haemolysin production was measured following the method of (Cheung et al., 2012). Briefly, 
fresh bacterial cultures were grown to early exponential phase (OD600 0.3) in MHB. Positive 
and negative controls were prepared using sd H2O and sterile MHB respectively. Whole 
defibrinated horse blood (TCS) (50 µL) was added to each culture (0.95 ml) to a final 
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concentration of 5%. Mixtures were incubated at 37°C for up to 3 h. After incubation, un-
lysed red blood cells were removed from suspension by centrifugation (13,000 rpm) using a 
table top Microfuge for 4 min at room temperature. The supernatant was transferred to a 
clean cuvette and absorbance was measured at OD540 using a spectrophotometer (WPA 
Biowave, fisher-scientific, UK). 
 
2.11 DNA Extraction 
Bacterial cultures were grown in Luria Bertani (LB) broth for 18-24h at 37°C and DNA was 
extracted from 1ml using the Isolate II Genomic DNA Kit (Bioline, UK) according to the 
manufacturer’s instructions. An extra pre-treatment step was conducted for efficient lysis of 
Gram-positive cells. Briefly pellets of harvested bacteria were washed twice with 0.15 M 
NaCl (Fisher Scientific, UK), 10 mM EDTA (pH 8.0) (Fisher Scientific, UK) and re-
suspended in lysozyme (Sigma Aldrich, UK) solution (10 mM Tris-HCl (pH 8.0), 0.1 m M 
EDTA, 10 mg ml-1 lysozyme and 1mg ml-1 lysostaphin (Sigma Aldrich, UK), and incubated 
for one hour at 37°C. Further breakdown of proteins was achieved by adding proteinase K 
(20 ug ml-1) (Bioline, UK) and 200 µL GL buffer, samples were mixed and incubated at 56 
°C for 30 min. DNA was precipitated by adding 210 µL 100% ethanol and vortexed to 
homogenise the solution. DNA was purified by transferring in to a mini spin column and 
centrifuged for 1 min at 11,000 x g. Columns were placed in new 2 ml collection tubes, 500 
µL GW1 buffer were added and centrifuged for 1 min at 11,000 x g, finally 500 μl GW2 
buffer were add and centrifuged for 3 min at 11,000 x g. Pure DNA was eluted from the 
column with sterile, distilled H2O. DNA quality was verified by agarose gel electrophoresis 
and quantified using a Nanodrop spectrophotometer.  
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2.12 DNA and RNA Quality Control 
In this study, both the purity and concentration of DNA and RNA samples was measured by 
the ‘Nano Drop 2000’ spectrophotometer (Thermo-Scientific, UK). This was done by 
Dispensing 1 μl of dsH2O (Elution buffer) a blank onto the lower optical pedestal of the 
spectrophotometer, then 1 μl of extracted nucleic acid samples was measured. Sample purity 
ratios were calculated at 260/230 nm and 260/280 nm for the purity.  
 
2.13 Polymerase Chain reaction (PCR) 
Standard PCR technique was used to confirm the identification of S. aureus and detection of 
antimicrobial resistance genes in particular erythromycin resistance (erm A, erm B and erm 
C). PCR reactions were prepared using 1x of My Taq Red Mix (Bioline, UK), 10 pmole of 
each primer; 1 µL template DNA and sdH2O to final volume 25 µL. Cycling conditions and 
primer sequences are in detailed (Table 2.6). Positive controls (University confirmed stock 
strain) and negative controls (sdH2O) were used as appropriate. After thermocycling had 
completed 5 µL was removed and subjected to agarose gel electrophoresis to determine 
quantity, quality, purity, and appropriate size of amplicons.  
 
2.14 Agarose gel Electrophoresis 
Extracted DNA and PCR amplicons were analysed by gel electrophoresis. Agarose gels 
(1.5% (w/v)) (Sigma Aldrich, UK) were prepared using 1x Tris Borate buffer (TBE, Thermo 
Scientific) supplemented with 1.5 % gel red (Biotium, USA). Sizes were estimated by 
comparison with 1kb Hyper ladder (Bioline, UK). Samples were separated by size at 70v for 
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1 h in an electrophoresis tank (Life Technologies, USA; model 250) filled with 1x TBE. 
DNA was visualized using UV transilluminator (SYNGENE G: BOX-XT14). 
 
Table 2.6 Primers and cycling conditions 
Primers  Sequences (5′-3′)  Cycling 
condition 
Size 
bp  
Ref 
16SrRNA F5′CGGTCCAGACTCCTACGGGAGGC
AGCA’3′ 
R5′GCGTGGACTACCAGGGTATCTAA
TCC3′ 
96°C 3 min 
96°C 10 sec 
60°C 10 sec 30 
cycle 
72°C 50 sec 
72°C 5 min 
191 (Schlegelova 
et al., 2008) 
ermA  F- 5′GCGGTAAACCCCTCTGAG3′ 
R- 5′GCCTGTCGGAATTGG3′ 
96°C 3 min 
96°C 10 sec 
57°C 10 sec 
30cycle 
72°C 50 sec 
72°C 5 min 
434 (Schlegelova 
et al., 2008) 
ermB  F- 5′CATTTAACGACGAAACTGGC3′ 
R- 5′GGAACATCTGTGGTATGGCG3′ 
96°C 3 min 
96°C 10 sec 
57°C 10 sec 30 
cycle 
72°C 50 sec 
72°C 5 min 
425 (Schlegelova 
et al., 2008) 
ermC  F- 5′ATCTTTGAAATCGGCTCAGG3′ 
R- 5′CAAACCCGTATTCCACGATT3′ 
96°C 3 min 
96°C 10 sec 
57°C 10 sec 30 
cycle 
72°C 50 sec 
72°C 5 min 
295 (Schlegelova 
et al., 2008) 
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2.15 RNA extraction and purification 
RNA was extracted from frozen bacterial pellets using the RNeasy Mini Kit (Qiagen, 
Germany) in combination with the RNase‐free DNase kit (Qiagen, Germany) according to 
the manufacturer’s instructions. S. aureus cell pellets were re-suspended in lysozyme solution 
[10 mM Tris-HCl (pH 8.0), 0.1 mM EDTA, 10 mgml-1 lysozyme, 1 mgml-1 lysostaphin and 
Proteinase K (Bioline, UK) and incubated for 30 min at 37°C with shaking. Lysis buffer (350 
µL) was prepared with β - mercaptoethanol (10 μl-1, Sigma- Aldrich) to reduce the disulfide 
bound and then vortexed for 1 min. 700 µL of ethanol (70%) was added to the lysate. A 
binding step was carried out by adding 700 µL of the lysate to a Mini Spin column and RNA 
purified according to the manufacturer’s instructions (Qiagen, Germany). For DNase 
digestion, 80 µL of DNase (10 µL of DNase stock solution to 70 µL buffer RDD was added 
to the column and incubate for 15min). As DNA digested, the RDD buffer provides efficient 
bound to the RNA in the column. The washing step was proceeded by adding 350 µL of 
washing Buffer RW1 that removes biomolecules such as carbohydrates, proteins, and fatty 
acids and then added 500 µL Buffer RPE to spin column respectively, then centrifuged for 15 
secs at 8000 xg. Finally, the spin column was placed in new 2ml collection tube with 30-50 
µL RNase free water for elution RNA. Eluted RNA was further treated with Turbo DNase 
(Thermo-Fisher, UK), 1 U/ 1 μg of total RNA at 37°C for 20-30 min according to the 
manufacturer’s instructions to digest single and double stranded DNA. DNase I was 
inactivated by addition of 2 µL DNase inactivation reagent and incubation for 5 min at room 
temperature. Finally, the mixture was centrifuged for 2 min at 10,000 xg, and the pure RNA 
without genomic DNA contamination was aliquoted to a fresh tube. Removal of genomic 
DNA was confirmed by PCR with erm C primers (Table 2.6). The SA3 was previously 
confirmed positive for this gene. Integrity of total RNA was evaluated by gel electrophoresis 
at 70 V for 1 h using a 2% (w/v) agarose gel and stained with Gel Red (Biotium, UK), RNA 
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concentrations were measured by Nano Drop 2000 spectrophotometer (Thermo Scientific, 
UK) and three independent measurements of the same sample were performed. All RNA 
isolations resulted in acceptable levels of purity (A260/A280 ≥1.95), ratio of sample 
absorbance at 260 and 280 nm of ~2.0, samples were stored at - 80°C for further use.  
 
2.16 Realtime PCR 
2.16.1 Complement DNA (cDNA) synthesis 
Complement (c)DNA was synthesized with integrated removal of genomic DNA 
contamination by using QuantiTect Reverse Transcription (Qiagen, Germany). One 
microgram of each purified RNA sample was incubated in gDNA Wipe-out Buffer at 42°C 
for 2 minutes to effectively remove any traces of contaminating genomic DNA. Then the 
reverse-transcription master mix (containing 1 µL of Quantiscript Reverse Transcriptase and 
4 µL of Quant script RT Buffer) was prepared on ice, and then the Reverse-transcription 
reaction components added to purified g DNA. Wipe-out Buffer and incubated at 42°C for 15 
min. The cDNA sample was incubated for 3 min at 95°C to inactivate Quantiscript Reverse 
Transcriptase. The whole cDNA volume was diluted 10-fold for subsequent quantitative real-
time RT-PCR reactions. The quality of the cDNA was assessed by using standard PCR with 
specific primers (erm C gene). The SA3 was previously confirmed positive for this gene. The 
cDNA samples were stored at –20°C.  
 
2.16.2 Design of Primers for RT-PCR gene expression studies 
The assembled sequence output from whole genome sequencing of clinical S. aureus isolates 
(see section 2.17) were used for the design of primers. The Artemis Comparison Tool (ACT) 
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(Sullivan et al., 2011), an online software tool for visualizing and comparing multiple DNA 
sequences was used to identify regions of similarity, insertions and rearrangements across the 
whole genome of three S. aureus wound isolates (SA2, SA3 and SA4). Primers (Table 2.7) 
were designed to investigate the expression of several genes involved in global regulation, 
adhesion and biofilm formation by Quantitative real time PCR for all 3 isolates. The 
following parameters were used for primer design: length (between 18 and 25 residues), 40 to 
50% GC content, and melting temperature (ranging from 57 to 63°C), amplicon less than 200 
bp. Primer sequences were chosen using primer 3 software (Wang & Seed, 2003) and further 
verified for absence of dimerization or hairpin formation using the web-enabled Auto Dimer 
interface. 
Table 2.7 Nucleotide sequences and anticipated amplicon sizes for the S. aureus SA3 gene-
specific oligonucleotide primers used for RT-q PCR in this study (Atshan et al., 2013). 
Gene Function primers sequences (5′-3′) Siz
e 
Ref 
16S rRNA Internal standard 
gene 
F-5′-CGGTCCAGACTCCTACGGGAGGCAGCA 
3′ 
R 5′-GCGTGGACTACCAGGGTATCTAATCC 3′ 
191 
bp 
(Sugiyama 
et al., 
2009) 
agr A Accessory gene 
regulator 
F/ 5′-TTCCCTCGCAACTGATAAT 
R/ 5′-ACCAACTGGGTCATGCTTAC 
 
149
bp 
This study 
sar A Synthesis of 
fibronectin and 
fibrinogen binding 
proteins 
F/5′-ACGTAATGAGCATGATGAAAGAAC3′ 
R/5′-TGTTTGCTTCAGTGATTCGTTT3′ 
 
110
bp 
This study 
ica A Intracellular 
adhesion 
F/5′-GTAAAGCCAACGCACTCAATC3′ 
R/5′-ACCTGTAACTGCACCAAGTT3′ 
 
149
bp 
This study 
pro C Pyrroline-5-
carboxylate reductase 
F/5′-GGCAGGTATTCCGATTGA 3′ 
R/5′-CCAGTAACAGAGTGTCCAAC 3′ 
106 
bp 
This study 
pyk A Pyruvate kinase 
F/5′-ATCGCGGCGTTATTTCATTCG 3′ 
R/ 5′-ATCCGGCAACGTACTTACTC 3′ 
99b
p 
This study 
fabD  Malonyl CoA-acyl 
carrier protein 
transacylase 
F/5′-TGGCTGCAGTATTGGGATTAG 3′ 
R/5′- GGGCAATTAATGTTTGCTGGT 3′ 
100 
bp 
This study 
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2.16.3 Real-time- quantitative PCR 
cDNA samples generated from SA3cultures exposed to different concentrations of 
DHA and EPA were used as templates in RT-PCR assays to identify any changes in the 
regulation of gene expression. As described elsewhere (Paniagua-Contreras et al., 2012), RT-
q PCR was performed using SYBER green super-mix (SensiFAST™ SYBR, Bioline) and 
various genes (16SrRNA, pro C, fab D, and pyk A) were explored for use as internal controls 
(Theis et al., 2007). Reactions were set up in triplicate with 1µL cDNA, primers (250µM) 
and 1x SYBR green supermix. The RT-PCR cycling conditions included initial denaturation 
at 95o C for 5min followed by 40 cycles of denaturation at 95oC for 15 secs, annealing at 
60oC for 15 sec and extension at 72oC for 30 sec. The delta-delta ct method was used to 
assess changes ion gene expression (Rao et al., 2013). Briefly, differences in gene expression 
between “treated” and “untreated” cultures were compared to differences in control gene 
(proC) expression at each time point. 
 
2.17 Whole Genome sequencing 
Whole genome sequencing of 3 clinical wound isolates of S. aureus and the well-
characterised MRSA 252 strain was performed as part of a demonstration by representatives 
from Illumina during onsite installation of a MiSeq (illumina, USA). The genome libraries 
were prepared using a Nextera XT library preparation kit according to the manufacturer’s 
instructions. Samples were multiplexed on a single MiSeq flowcell using Nextera XT 
barcodes and normalised using the bead-based normalisation kit. Sequencing was performed 
using a TruSeq v2 500 cycle kit (2x250bp reads). Raw data was processed and assembled by 
Dr Ian Goodhead. Reads were trimmed for adapter sequences and low quality using 
trimmomatic (v 0.35) and assembled using SPADES v3.8.2. The resulting assemblies were 
67 
annotated using PROKKA v 1.11. These assembled genome sequences were compared using 
the Artemis Comparison Tool (ACT) (Sanger) and used to design primers for real time (RT) 
PCR. 
The genomes of parent and adapted strains of S. aureus clinical isolate SA3 exposed 
to DHA (SA3-DHA); EPA (SA3-EPA); both PUFAs (SA3-DHA+EPA); linezolid (SA3-
LZD) and vancomycin (SA3-VAN) were sequenced by Microbes NG. Bacterial cultures were 
sent to the service on beads according to their instructions. Microbes NG completed DNA 
extraction, sequencing, trimming and assembly of each genome. Further bioinformatics 
analysis was performed by Dr Ian Goodhead. The online webtool: Pathogen Watch (formerly 
WGSA; https://pathogen.watch)software was used to cluster the annotated genomes of each 
isolate with other S. aureus genome sequences from other submitted sequences and to 
generate a phylogenetic tree to demonstrate relatedness, and to predict antibiotic resistance 
profiles. Pathogen Watch uses PAARSNP, bespoke software that uses BLAST against a 
custom database (combined from public AMR databases such as CARD, ResFinder and 
NCBI) to highlight the presence or absence of genes and SNPs implicated in antimicrobial 
resistance and infers their combined effect (https://cgps.gitbook.io/pathogenwatch/technical-
descriptions/antimicrobial-resistance-prediction/paarsnp). Single-nucleotide polymorphisms 
(SNPs) in evolved strains compared to parent SA3, were detected using “Snippy” and “Free-
bayes bioinformatics analysis software tools. This program identified synonymous (silent) 
and nonsynonymous (missense or nonsense) SNPs. Synonymous mutations do not change the 
encoded amino acid but a change in general the DNA sequence, while nonsynonymous SNPs 
do change the amino acid sequence, more likely resulting of differences in the encoding 
protein function. The nonsynonymous SNPs consist of two types of mutation, missense and 
nonsense mutation.  
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Chapter 3 Antimicrobial and Anti-Biofilm Activity of PUFAs 
and Antibiotics against Wound Pathogens 
 
3.1 Detection of antimicrobial activity 
3.1.1 Introduction 
Treatment of wound infections has become more challenging due to widespread 
antimicrobial resistance (AMR), which can develop and spread by mutation selection and 
horizontal gene transfer (HGT) in protected polymicrobial biofilms within the wound 
(Bjarnsholt, 2013; Kibret & Abera, 2011; M. Wu et al., 2018). Multidrug resistant strains of 
species such as S. aureus, E. faecalis, P. aeruginosa, and Es. coli spp. are commonly found in 
skin and wound infections (Bessa et al., 2015; Kane et al., 2014; Phillips et al., 2016). Thus, 
investment has promoted the development of alternative wound-treatment strategies. 
Dressings have been developed that are impregnated with metal nanoparticles such as silver 
(Raghavan etal., 2016), gold (Cabuzu et al., 2015)or zinc (Yang et al., 2017) or with natural 
antimicrobials such as honey or Manuka honey (Kwakman et al., 2010), and essential oils 
(Seow et al., 2014). These antibacterial agents have showed impressive properties that 
accelerate wound healing processes (Negut et al., 2018). However, a more detailed 
investigation is required to justify the use of alternative antimicrobial agents in wound 
treatment. 
 
As most infected wounds are complicated by biofilms, it is important to consider the 
efficacy of any wound treatment in this context. Bacterial cells within a biofilm matrix are 
less susceptible to antibiotic treatments due to slowed diffusion through the matrix and 
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slower growth, promoting persistence. The cells are protected within a biofilm matrix that 
contains mainly bacterial extra polysaccharide( EPS), extracellular protein and DNA as well 
as excreted host cellular products such as muco-polysaccharides, fibrin, collagen and water 
(up to 95–99%) (Kostenko et al., 2007).This physiological composition plays a significant 
role in preventing the binding or transport of antimicrobial agents to the cells by either 
sorption with the bactericides, or electrostatic and hydrophobic interactions, or size exclusion, 
or degradation of antimicrobial agent (Stewart, 2015). For example, a comparison study of 
clinical S. aureus wound isolates revealed that 87%of biofilm-positive isolates were MDR 
organisms, and all the biofilm non-producers were non-MDR isolates (P<0.05) (Neopane et 
al., 2018). 
Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) are two major 
compounds of omega-3 polyunsaturated fatty acids (n-3 PUFAs) that have been shown to 
have diverse beneficial effects on human health, including wound healing (Turk et al., 
2013a). The beneficial effects are believed to be related to the anti-inflammatory and 
antimicrobial action of PUFAs (Park et al., 2015; Choi et al., 2015). The antimicrobial 
activity of polyunsaturated fatty acids (PUFAs) has been demonstrated against several 
pathogens, including S. aureus, S. mutans, B. cereus, P. gingivalis, P. aeruginosa and Es.coli 
(Chitra Som & Radhakrishnan, 2011; Kim et al., 2018; Le & Desbois, 2017; Sun et al., 
2016).  
Several studies are attracting attention to PUFA compound as potential antimicrobial 
agents, due to their safety, high efficiency, wide spectrum of activity and the lack of 
resistance mechanism (Chanda et al., 2018; Desbois et al., 2013). Other studies have shown 
differences in effectiveness and the potency of DHA and EPA as antibacterial and anti-
biofilm agents against several Gram positive and Gram-negative bacteria (Arantes et al., 
2016; Ilievska et al., 2016; Sun et al., 2017). The high genetic variations between different 
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strains would lead to different results (Correia et al., 2012; Andrew P. Desbois & Smith, 
2010) 
This results chapter details an extensive study of the antibacterial activity of DHA and 
EPA on common wound pathogens. The minimum inhibitory and bactericidal concentrations 
(MIC and MBC) were determined for these compounds and compared with commonly used 
antibiotics against a range of clinical and reference strains of bacteria. Biofilm assays 
provided information about the ability of these strains to form biofilms, and of PUFAs to 
disrupt their biofilm formation. Whole genome comparison of clinical wound isolates 
identified a candidate strain on which to base further investigations. 
 
3.1.2 Antibiotic sensitivity tests (AST) 
Phenotypic antimicrobial susceptibility testing (AST) measures the susceptibility of 
microorganisms to different concentrations of antimicrobial agents and enables a drug 
resistance profile to be determined. Antibiotic susceptibility assays were performed to 
determine the sensitivities of wound pathogens to various antibiotics that are commonly 
administered for Gram positive and Gram-negative bacteria in wound infections. 
Standardised EUCAST protocols were used to expose each strain to set of recommended 
antibiotic concentrations impregnated into filter paper disks. The method enabled a simple 
screen of susceptibilities to multiple antibiotics on agar plates. Resistance profiles were 
determined by comparing zones of inhibition to breakpoint tables for each antibiotic 
according to EUCAST V8 2018 guidelines (Table 3.1). 
Gram-positive bacteria and Gram-negative bacteria did not show the same resistance 
profiles. Reference strain MSSA 6538 was susceptible to all tested antibiotics while S. aureus 
252 (MRSA) was resistant to five out of ten antibiotics including imipenem, remaining 
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susceptible to gentamycin, vancomycin and tetracycline. The E. faecalis reference strain 
13280 showed resistance to vancomycin, erythromycin and tetracycline. Reference strains of 
Gram-negative bacteria (P. aeruginosa PA01, PA014 and Es. coli 10536) were susceptible to 
the all antibiotics tested. Several clinical wound isolates of S. aureus (SA2, SA3 and SA4) 
were provided by Salford Royal Foundation Trust. SA2 showed resistance to representatives 
from two different classes of antibiotics lincomycin and erythromycin, whereas the clinical 
isolate SA3, showed resistance to three different classes of antibiotics (lincomycin, 
erythromycin, cefoxitin). The cefoxitin is indicative of MRSA.  
Conversely, clinical isolate SA4 was susceptible to all classes of antibiotics tested 
except for erythromycin, lincomycin and cefoxitin. This demonstrated that there is 
considerable diversity of resistance profiles of S. aureus that infect wounds. The most 
effective antibiotic treatments for this group of isolates and reference strains would be the 
aminoglycosides (gentamycin and tobramycin), and ciprofloxacin. Finally, these assays 
suggest that linezolid would be the most effective antibiotic for treating S. aureus infection. 
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Table 3.1 Antimicrobial sensitivity test (AST) against wound pathogens 
Antibiotics 
Aminoglycoside β-lactam Glycope
ptides 
Lincos-
amides 
Macrol-
ides 
Oxazolid
ine 
Quino-
lone 
Tetra-
cycline 
Carbape
nem 
S
. 
a
u
re
u
s 
species 
C
N
 1
0
 µ
g
 
 
T
O
B
 1
0
µ
g
 
F
O
X
 3
0
µ
g
 
V
A
N
 5
 µ
g
 
M
Y
 2
 µ
g
 
E
 1
5
 µ
g
 
L
Z
D
 1
0
 µ
g
 
C
IP
 5
 µ
g
 
T
E
 3
0
 µ
g
 
IM
P
 1
0
 µ
g
 
 
SA 2 S (23) S (19) S (22) S (12) R (12) R (13) S (26) S (25) S (25) S (26) 
SA 3 S (25) S (23) R (10) S (25) S (14) R (15) S (24) S (23) R (7) S (22) 
SA4 S (19) S (21) R (13) S (24) R (12) R (14) S (25) S (24) S (25) S (25) 
6538 S (25) S (25) S (17) S (17) S (23) S (24) S (27) S (26) S (25) S (26) 
MRSA 252 S (25) R (8) R (10) S (11) R (11) R (12) S (22) R (16) S (25) R (8) 
E. faecalis 13280 S (14) S (10) S (20) S (17) S (19) R (16) S (22) S (20) R (8) S (25) 
P. aeruginosa 
PAO1 
PA 14 
S (20) S (24) NA NA NA NA NA S (27) S (24) S (24) 
S (23) S (19) NA NA NA NA NA S (32) S (25) S (21) 
Es. coli 10536 S (23) S (20) NA NA NA NA NA S (38) S (23) S (23) 
KEY: S= Sensitive     R= Resistance     NA = Not applicable for these strains according to EUCAST 2018 
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3.1.3 Minimum Inhibitory Concentration (MIC) of PUFA compounds compared to 
Linezolid and Vancomycin against wound pathogens 
Using a broth microdilution method to determine the minimum inhibitory 
concentrations (MICs) of antimicrobial agents. The PUFA compounds (DHA and EPA) were 
found to have varied inhibitory effects on the growth of Gram-positive and Gram-negative 
bacteria (Table 3.2) compared to the gold standard antibiotics linezolid and vancomycin that 
are commonly used for treating wounds infected with MRSA.  
Table 3.2 Minimum inhibitory concentration (MIC) of PUFAs and antimicrobial 
agents against common wound pathogens 
Species Strain DHA EPA DHA +EPA LZD VAN 
S
. 
a
u
re
u
s 
MIC (µg ml-1) 
*SA2 78 117 78 3.9 0.18 
*SA3 65 78 65 3.9 0.093 
*SA4 65 156 156 1.9 0.062 
#6538 65 78 78 1.9 0.12 
252 78 156 117 3.9 0.25 
E. faecalis #13280 156 312 156 3.9 0.062 
P. aeruginosa #PA01 117 234 156 94 0.62 
#PA14 156 234 234 125 1.25 
Es. coli #10536 156 312 156 62.5 0.74 
The values in the table represent the minimum inhibitory concentration (MIC), a measure 
of the effectiveness of PUFAs compounds and the antibiotic concentrations in µg ml-1 
against wound pathogens. *Clinical wound isolate; # Standard reference strain; MRSA 
 
The MIC values of DHA against clinical wound isolates SA2, SA3, SA4, and 
reference strains MSSA6538 and MRSA 252 were very similar 65 - 78 µg ml-1. DHA 
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displayed different activity against E. faecalis 13280, PA14 and E coli10536 (156 µg ml-1) and 
PA01 (117 µg ml-1). The PUFA compound, EPA showed slightly different levels of 
inhibition, with the strongest activity against SA3 and MSSA 6538 (MIC 78 µg ml-1) and 
weakest activity against E. faecalis 13280 and E coli10536 (MIC 312 µg ml-1). Interestingly, 
the combination of DHA+EPA together did not result in any synergistic effect. The MIC of 
the combined compounds was comparable with DHA alone and lower than that of EPA alone 
against clinical isolates SA2 and SA3 and reference strains of E. faecalis and Es. coli. 
Conversely, the activity of the combination was more comparable with EPA alone against 
SA4, MSSA6538 and PA14. Finally, the MIC of the combination was in between the MICs 
for DHA and EPA when tested against PA01 and MRSA reference strains. 
In general, linezolid was observed to be more potent than the PUFA compounds and 
showed higher inhibitory activity against Gram-positive bacteria than Gram-negatives. This 
antibiotic was most active against MRSA252 and the clinical isolate SA4, with MICs of 1.9 
µg ml-1. Linezolid also effectively inhibited the Gram-positive bacteria SA2, SA3, 
MSSA6538 and E. faecalis at a MIC of 3.9 µg ml-1. However, this antibiotic linezolid 
showed much less potency against Gram-negative bacteria as expected. The MIC for Es. coli 
was 62.5 µg ml-1 and even less active against P. aeruginosa strains PA01 and PA14 with 
MICs of 94, 125 µg ml-1 respectively.  These MICs are in line with expectations since 
linezolid has been reported to be effective against these Gram-positive bacteria (MIC 0.5 – 4 
µg ml-1) and that aerobic Gram-negative bacteria are largely resistant (Livermore, 2003).  
This study showed vancomycin to be the most highly potent inhibitor of the Gram-
positive bacterial strains tested, with the highest activity against clinical S. aureus isolate SA4 
and E. faecalis reference strain 13280 (0.062 µg ml-1). The lowest activity was observed 
against MRSA (MIC 0.25 µg ml-1). Vancomycin was less active against Gram-negative 
bacteria (P. aeruginosa strains PA01 and PA14, and Es. coli strain 10536) with MICs of 0.62, 
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1.25 and 0.74 µg ml-1 respectively. However, these MICs were lower than reported elsewhere 
(4 – 128 µg ml-1; Hamoud et al., 2014). 
 
3.1.4 Minimum bactericidal concentration (MBC) of PUFA compounds compared to 
Linezolid and Vancomycin against common wound pathogens 
Further analysis of the antimicrobial effect of PUFAs was determined using 
bactericidal assays. The minimum bacteriocidal concentration (MBC) for each PUFA 
compound was compared to that of classic antibiotics linezolid and vancomycin. Liquid 
culture from each well of the micro-dilution plate was spread onto MH agar plates and colony 
forming units (CFU ml -1) were recorded (Table 3.3).  
Table 3.3 Minimum bactericidal concentration (MBC) of PUFAs and antibiotics 
against common wound pathogens 
  MBC (µg ml-1) 
Species Strain DHA EPA 
DHA 
+EPA 
LZD VAN 
S
ta
p
h
yl
o
co
cc
u
s 
a
u
re
u
s *SA2 312 468 312 15.6 0.72 
*SA3 260 312 260 31.2 0.37 
*SA4 520 520 625 31.2 0.48 
#6538 260 312 312 31.2 0.48 
 520 625 520 15.6 1 
E. faecalis #13280 625 936 936 31.2 0.48 
P. 
aeruginosa 
#PA01 468 625 625 376 1.86 
#PA14 520 625 520 375 2.5 
Es.coli #10536 625 936 625 250 2.96 
* Clinical wound isolate; #Standard reference strain; MRSA 
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Of the PUFAs, the MBC of the DHA compound exhibited the highest bactericidal 
effect, with most killing activity against S. aureus. The highest activity was observed against 
the clinical wound isolate SA3 and the MSSA reference strain 6538 (MBC 260 µg ml-1). The 
lowest killing activity was observed against Es. coli and E. faecalis reference strains (MBC 
625 µg ml-1). Differences were observed in the bactericidal activity of EPA compared to 
DHA. Slightly higher MBCs of EPA were recorded for all bacteria tested, except for clinical 
isolate SA4, which was equally susceptible to the bactericidal effects of EPA and DHA 
(MBC 520 µg ml-1). The highest activity was still observed against SA3 and 6538 (312 µg 
ml-1) and the lowest against E. faecalis 13280 and Es. coli 10536 (MBC 936 µg ml-1). As 
observed during MIC assays, the combination of PUFAs (DHA+EPA) had no synergistic 
effect on killing. The lowest MBC of the mixed compound was 260 µg ml-1, comparable with 
DHA killing of SA3. The highest concentration of this mixture of PUFAs was required to kill 
the reference strain of E. faecalis 13280 (936 µg ml-1), comparable with EPA alone.  
Linezolid was clearly more effective at killing Gram-positive bacteria than Gram-
negative bacteria. This antibiotic showed most killing activity against clinical S. aureus 
strains, SA2 and MRSA (MBC 15.2 µg ml-1), while still effectively killing SA3, MSSA 6538, 
MRSA 252 and E. faecalis 13280 (MBCs 31.2 µg ml-1). Considerably higher concentrations 
of linezolid were required to kill P. aeruginosa strains (PA01 and PA14 – MBC 375 µg ml-1) 
and Es. coli strain 10536 (MBC 250 µg ml-1). The bactericidal activity of vancomycin was 
the strongest, with an MBC of 0.37 – 1.0 µg ml-1 against all S. aureus and E. faecalis strains. 
Higher MBCs were observed for Gram-negative bacteria (between 1.86 and 2.96 µg ml-1). 
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3.1.5 Tolerance of common wound pathogens to PUFAs and antibiotics 
Tolerance and persistence refer to the capacity of bacteria for prolonged survival 
under exposure to bacteriocidal agents without acquiring phenotypic resistance. Treatment 
failures can often result from tolerance of the infecting pathogen to antibiotics (Gefen et al., 
2017; Gonzalez et al., 2013). One method for quantifying tolerance is by calculating the ratio 
MBC/ MIC.Table 3.4 reveals that P. aeruginosa strain PA14 has the lowest tolerance 
capacity (in the range of 2 – 3.3) and S. aureus strain SA4 had an increased tolerance to all 
compounds overall (in the range of 3 – 16). In general, the bacterial strains tested showed 
least tolerance to the PUFA compounds (MBC/MIC ratios of 2.2 - 8). Moreover, the most 
predominant tolerance value was 4 with most pathogens. Surprising, the SA4 strain and 
MSSA 6538 strain had the highest tolerance to Linezolid (16.4) compared to other strains, 
while SA4 and E. faecalis 1328 showed high tolerance to vancomycin (7.7). 
 
Table 3.4 Wound pathogens tolerance to antimicrobial compounds. 
Species Strain 
DHA 
EPA 
DHA 
+EPA 
LZD VAN 
S
. 
a
u
re
u
s 
*SA2 4 4 4 4 4 
*SA3 4 4 4 4 3.9 
*SA4 8 3.3 4 16.4 7.7 
#6538 4 4 4 16.4 4 
 6.6 4 4.4 4 4 
E. faecalis #13280 4 3 6 4 7.7 
P. aeruginosa 
#PAO1 3 2.6 4 4 3 
#PA14 3.3 2.6 2.2 3 2 
Es. coli #10536 4 3 4 4 4  
*
Clinical wound isolate; 
#
Reference strain; 

MRSA; LAZ: Linezolid; VAN: Vancomycin  
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3.2 Quantification of biofilm formation by wound pathogens 
3.2.1 Biofilm detection on Congo Red Agar plates (CRA) 
The growth of common wound pathogen representatives was observed on Congo red 
agar (CRA) plates. Black colonies with a dry crystalline consistency reported 
exopolysaccharide production in the presence of Congo red indicator, suggesting capacity to 
form biofilms (Sharvari & Chitra, 2012). The clinical S. aureus isolates SA2 and SA3, and 
the characterised MRSA 252 strain, produced dark black colonies within 24h, indicating 
strong production of exopolysaccharides which is the staphylococcal polysaccharide 
intercellular adhesin (PIA) and capacity to form biofilms (Otto, 2008). Conversely MSSA 
reference strain 6538, clinical S. aureus SA4 and Es. coli 10536 all produced colonies that 
appeared brown to black after 24 h, being classified as weak exopolysaccharide production 
(Sharvari & Chitra, 2012). P. aeruginosa strains PA01 and PA14 showed dark black colonies 
within 24 h and were classified as being strong biofilm producers.  
 
3.2.2 Crystal violet assay to compare densities of biofilms formed by wound pathogens 
The Congo red assay only indicates the production of certain exopolysaccharides. 
Biofilm formation can be screened using a basic crystal violet assay to measure the density of 
biofilms produced on the solid surfaces of microtiter plates. This study grew each 
representative wound pathogen in Luria Bertani broth (LB) and measured biofilm density 
after 24h and 48 h. After removal of planktonic cells and washing, crystal violet stained the 
biofilm complex that was adherent to the wells of the microtiter plate. Following 
solubilisation with ethanol, the optical density of biofilms was measured (OD600).  
Biofilm density readings indicated that all representative wound pathogens were strong 
biofilm producers. S. aureus SA2, SA3, SA4 and MSSA 6538 showed a similar pattern of 
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biofilm growth after 24 h, with the mean OD600 of 1.1. These densities all increased after 48h 
incubation to 2.0, significantly denser compared to 24 h biofilms (P = 0.00037). MRSA strain 
252 produced the thickest biofilm compared to other S. aureus strains (mean OD600 1.9 after 
24h, increasing to 2.4 after 48h (P= 0.000135). P. aeruginosa strains, PA01 and PA14, were 
indicated as the strongest biofilm producers, with OD600 2.2 within 24 h, increasing to 3.3 
(P=0.00008). E. faecalis 13280 and Es. coli 10536 produced the weakest biofilm growth 
measurements of 0.35 and 0.8 respectively, increasing to 0.75 and 1.5 respectively after 48 h 
with (P =0.003473).  
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Figure 3.1 Quantification of biofilm density formed by representative wound 
pathogens Detection of biofilm-formation against wound pathogens within 24h and 
48h. This assay was performed using the CV method, the error bars represent standard 
deviation. Un-inoculated, sterile LB was used as a negative control. The values are 
plotted as mean ± SD obtained from three representative experiment performed in 
triplicate.  
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3.2.3 The efficacy of antimicrobial agents on biofilm disruption 
The Calgary biofilm device was designed to allow growth of biofilms for longer 
periods than the basic microtiter plate assays. A 96 well plate with pegs built into the lid 
allowed the biofilm to develop on the pegs attached to the lid, which can be transferred to a 
2nd plate containing fresh media. The device is also useful for directly comparing the ability 
of multiple test agents to inhibit or eradicate biofilm formation. The Minimum biofilm 
inhibitory concentration (MBIC) is the lowest concentration that inhibits and prevents initial 
biofilm formation, defined as the last well in which there is no visible biofilm growth after 
incubation. The minimum biofilm eradication concentration (MBEC) is defined as the 
minimum concentration of antimicrobial agent required to disrupt the already formed biofilm 
(Reiter et al, 2013). MBIC and MBEC assays were used to quantify the ability of PUFAs and 
antibiotics (linezolid and vancomycin) to disrupt biofilms formed by representative wound 
pathogens. Sterile MH broth alone served as a negative control. OD values of these wells 
were subtracted from the OD values of the test wells (Figure 3.2). 
Antibiotics were clearly the most effective biofilm inhibitors, with much lower MBIC 
values than those for the respective PUFAs. Vancomycin inhibited Gram-positive bacterial 
biofilms with MBICs between 1.25 and 2.5 µg ml-1. Linezolid was more effective at 
inhibiting biofilms formed by Gram-positive bacteria (MBIC ranging from 20.5 to 83.5 µg 
ml-1) than Gram-negative bacteria (MBIC ranging from (300 to 416 µg ml-1). PUFAs were 
also more effective at inhibiting biofilms formed by Gram-positive bacteria than Gram 
negative bacteria. DHA treatment (MBIC 195- 468µg ml-1) was more effective than EPA 
(MBIC 260- 520 µg ml-1) and co-treatment with both PUFAs (MBIC 260 - 520 µg ml-1). 
Although less effective, DHA was also better than EPA at inhibiting the biofilms formed by 
Es. coli 10536 (MBICs 625 and 520 µg ml-1 respectively) and P. aeruginosa strains (MBICs 
937 - 1250 µg ml-1 respectively) (Figure 3.2A) 
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MBEC assays were used to assess the disruption of biofilms that were grown on pegs 
in 96 well micro-titre plates. As expected, a higher concentration of each agent was required 
to disrupt pre-formed biofilms than to inhibit their growth. Vancomycin was the most potent 
biofilm disrupter, with MBECs ranging from 5-12.5 µg ml-1. These concentrations were 35-
fold lower than the MBECs recorded for linezolid (125 -500 µg ml-1). Considerably higher 
concentrations of PUFA compounds were required to disrupt biofilms. The MBECs of DHA 
ranged between 750 and 3125 µg ml-1. EPA was found to be more disruptive than DHA 
(MBECs ranging between 500 and 2250 µg ml-1), while the MBECs of combination 
treatment with both PUFAs (DHA+EPA) ranged from 750 - 1500 µg ml-1 (Figure 3.2B).  
Although the antimicrobial properties of PUFAs have already been reported, the data 
presented in this chapter demonstrate antimicrobial activity against growth and biofilm 
formation of clinical wound isolates of S. aureus with different antibiotic sensitivity profiles. 
Although the antibiotics (vancomycin and linezolid), were more potent inhibitors, the PUFA 
compounds have additional immunomodulatory effects for the promotion of wound healing 
(Allam-Ndoul et al., 2017; Magee et al., 2008; Turk et al., 2013). In addition, bacteria 
generally showed reduced tolerance to PUFAs compared to antibiotics.  
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Figure 3.2: A- Minimum biofilm inhibitory concentration (MBIC) of PUFAs compound 
and antibiotics against wound pathogens. The static biofilm assay was performed with the 
Calgary biofilm device., bar graph shown the difference between PUFAs compounds and 
Antibiotics groups. Statistical analysis was performed using the unpaired t test using graph 
pad V8. Significant differences with all mean concentrations of MBICs antibiotics vs All 
mean MBIC PUFA s = <0.0001, significant differences MBICs antibiotics Gram +ve vs 
MBICs antibiotics Gram -ve = 0.012. 
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Figure 3. 3: B- Minimum biofilm eradication concentration (MBEC) of PUFAs 
compound and antibiotics against wound pathogens. Significant difference to All MBICS 
VS All MBECS P value = <0.0001, significant difference to all MBECs antibiotics vs all 
MBEC PUFA= <0.0001, No significant MBECs antibiotics Gram +ve vs MBECs antibiotics 
Gram -ve = 0.053, significant MBEC PUFA Gram +ve VS MBEC PUFA Gram-ve = 0.0074.  
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3.2.4 Selection of isolates for further investigation 
The whole genome of each clinical S. aureus isolate (SA2, SA3 and SA4) was sequenced to 
determine their relatedness and their similarities to other reported S. aureus strains. The 
genetic basis of their antibiotic resistance phenotypes was also investigated. Isolates SA3 and 
SA2 clustered most closely with the sequence types (ST) 398 and 36 that included the MRSA 
strain 252. Isolate SA4 clustered more closely with a separate clade, showing most similarity 
to ST 72 (Figure 3.3). Genes associated with resistance to β lacatams antibiotics such as 
mecA gene, which encodes for an alternative penicillin-binding protein, PBP 2a were 
identified in SA2 and SA3 (Wielders et al., 2002). The genes encoding for the ribosomal 
methylase have been designated ermA, ermB, and ermC that are involved in macrolides, 
lincosamide, and streptogramin B (MLSB) (Ghanbari et al., 2016) and were also detected in 
SA2 and SA3.No obvious antibiotic resistance genes were identified in the SA4 genome 
(Table 3.5). These genetic profiles do not fully match the phenotypic profiles observed using 
the Kirby Bauer disk diffusion assay. This differences may be of multiple resistance alleles 
occur on the same genome or plasmid (Allen et al., 2017). Since SA3 most resembled an 
MRSA profile, this isolate was chosen for further analysis of PUFA activity. 
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Figure 3.4 Relatedness of Clinical S. aureus wound isolates. Comparison of 
phylogenetic tree of the staphylococcal species and clinical S. aureus isolates generated 
under the illumina Next generation sequencing  
 
Table 3.5 Presence of antibiotic resistance genes in clinical S. aureus genomes (from 
pathogen watch online webtool https://pathogen.watch) 
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3.3 Discussion 
The major findings presented in this chapter suggest that PUFAs have bacteriostatic, 
bactericidal and anti-biofilm activity against wound pathogens, particularly S. aureus. A 
diversity of resistance profiles was recorded for different S. aureus strains. As expected, the 
MSSA strain 6538 was susceptible to all antibiotics used in the study and the MRSA strain 
252 strain showed resistance to cefoxitin, erythromycin, lincomycin, ciprofloxacin and 
imipenem. Clinical isolates of S. aureus were resistant to lincomycin and erythromycin.  
This study compared the antimicrobial activity of PUFAs with the gold standard 
antibiotics currently recommended for treating S. aureus infected wounds. The data presented 
in this chapter shows that linezolid and vancomycin were much more active than PUFAs 
against a range of common wound pathogens. The MICs presented in this chapter were 
similar to the findings of others. For example, Vanegas et al., (2017) found an isolate of 
MRSA to be sensitive to linezolid (ranged from 0.38 to 4.0μgml-1) (Vanegas et al., 2017). 
Similar findings were reported by Mottola et al., (2016) who found no resistance to linezolid 
when testing bacterial isolates from diabetic foot patients (MICs ranged from 1-2 µg ml-1). 
Vancomycin was also highly effective against these strains (MICs 0.062 - 0.25µg ml-1) 
(Mottola et al., 2016) . These results are in range with another study (Gonzalez et al., 2013), 
and within the desired range (0.5–2 µg ml-1) as recommended by the EUCAST 2018 V8 for 
vancomycin MICs guidance (EUCAST, 2018).  MICs of vancomycin against 30 clinical 
isolates of S. aureus were all observed to be  ≥1.5µg ml-1 (Fabri et al., 2018). Despite 
evidence that vancomycin and linezolid are still largely effective, there have been reports of 
resistance developing. The determination of MIC by using Epsilometer test (E test) study 
found that 3.1% of MSSA isolates and 14.8 % of MRSA isolates to be resistant to 
vancomycin (Azhar et al., 2017). These resistance profiles confirm the urgent need for 
alternative therapeutic strategies for wound treatment. 
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The antimicrobial effects of DHA and EPA observed during this investigation are 
consistent with previously published studies. In general, there are consistent reports that 
PUFAs have bacteriostatic activity; that they are more effective against Gram positive 
bacteria than Gram negative bacteria; that DHA is more potent than EPA and that there is no 
synergistic effect, when bacterial cultures are exposed to the two PUFAs together.  There are 
however, differences in reported MICs. For example, Le and Desbois (2017) found that EPA 
inhibited the growth of S. aureus with MICs of 64 µg ml-1 (Le & Desbois, 2017). Others have 
reported that PUFAs are slightly less effective against MRSA, with MIC 128 µg ml-1 
(Desbois & Lawlor, 2013). Furthermore, Shin et al., (2007) reported much higher MIC of 
EPA against S. aureus strains ranging from 750 to 1350 µg ml-1. This same study reported 
higher MICs against P. aeruginosa (MIC 500 µg ml-1) compared to this study (MIC 156 µg 
ml-1), but they used strain KCTC2004, whereas this study used strains PA14 and PA01 (Shin 
et al., 2007). These observed differences in MICs can be explained by different strains been 
used or genetic variation of the strains.  
The antibacterial activity of DHA and EPA against other bacterial species have been 
demonstrated in several studies. For example, DHA has been shown to inhibit the growth for 
B. cenocepacia K56-2 with comparable MICs ranging from 100 - 175 µg ml-1 (Mil-Homens 
et al., 2012) and EPA is effective against Bacillus cereus (MIC128 µg ml-1) (Le & Desbois, 
2017a) and Bacillus subtilis (MIC 500 µgml-1) (Shin et al.,2007). There is also reported 
activity against non-aerobic species. PUFAs have been shown to inhibit growth of the oral 
pathogen Porphyromonas gingivalis KCTC 381 (EPA MIC 9.7µg ml-1) and P. gingivalis 
KCTC 5352 (EPA MIC 78 µg ml-1) and DHA MIC 9.7, 312 µg ml-1respectively , and 
Streptococcus mutans KCTC 3065 (DHA MIC 625µgml-1) and S. mutans KCTC 3289 (DHA 
MIC1250 µgml-1)and EPA MIC 625,9.7 µgml-1) respectively (Choi et al., 2013). The same 
89 
authors also reported antifungal activity against Candida albicans KCTC 17484 (DHA MIC 
1250 µgml-1 and EPA MIC 625µgml-1) (Choi et al., 2013). 
This chapter observed the bacteriocidal activity of DHA and EPA and revealed a 
broad spectrum of activity against various Gram-positive bacteria and Gram-negative 
bacteria. Whilst this study shows MBC of 260 - 625 µgml-1 against S. aureus strains, PUFAs 
were less effective at killing other species (E. faecalis MBC, 625 -936 µgml-1). These results 
suggest that PUFAs are less bactericidal than other studies, that report MBC of 128 µgml-1 
for S. aureus (Le & Desbois, 2017). Other have shown that both DHA and EPA were capable 
of totally killing of S. aureus UA159, with the same MBC value of 100 mM (Sun et al., 
2017). Again, this current study suggests that, as with bacteriostatic activity, the killing 
activity of PUFAs was much weaker against Gram-negative species (MBC range 468- 936 
µgml-1) compared to Gram-positive species.  
The MIC and MBC activity of PUFAs compound showed slightly differences in 
bacteriostatic and bacteriocidal effect, This may be of unsaturation and chain length between 
the two compound (DHA and EPA) positively correlated with higher cytotoxic potencies of 
the tested compounds (Kinsella & Black, 1993). However, the concentrations of inhibition 
and killing vary depending on the bacterial strains and species, these results confirmed that 
PUFA have bacteriostatic and bactericidal activity against Gram positive and negative 
bacteria.  
 
Bacterial biofilms add challenges to the management of wound infection (Bjarnsholt, 
2013; Rhoads et al., 2008). Biofilm formation is a significant factor in the development of 
chronic infection and allows for immune evasion as well as resistance to antimicrobial agents 
(Bjarnsholt, 2013). The tissues surrounding a biofilm-infected wound remain in a persistent 
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inflammatory state (Zhao et al.,  2016). The biofilm matrix has been widely reported to 
confer decreased susceptibility to antibiotics (100 –1000 fold) (Beyth et al., 2015). It has 
been suggested that decreased susceptibility results from slower metabolic activity and 
growth rates, slower diffusion through extracellular polymeric substances and other specific 
resistance mechanisms. Thus, when assessing the efficacy of potential wound treatments, it is 
not sufficient to rely on the results of standard MIC and MBC assays that only involve 
planktonic culture. It is crucially important to assess the activity of wound treatments on 
biofilms. 
This study used semi-quantitative techniques to compare the biofilm forming capacity 
of a range of bacterial strains representative of common wound pathogens. The Congo red 
agar plate method was used to assess the production of exopolysaccharides. Some colony 
growth on the medium was observed to be typical dry crystalline and black in colour. Others 
produced black colonies but appeared smooth and non-crystalline when the test was repeated 
in triplicate. This method was used as an indirect indication of biofilm formatting capacity, 
but the results suggested it to be un-reliable. The micro-titre plate assay is a more reliable 
method for comparing the differences in the biofilm density. The results for this assay depend 
on the medium composition (Haney., 2018), growth phase, timescales and other 
environmental parameters such as temperature and pH (Speranza, 2011). 
This study observed that Pseudomonas species were the strongest biofilm producers, 
in particular, PA14 produced the most dense biofilms, and this corresponds with published 
data that investigate the metabolic activity of the biofilms formed by P. aeruginosa and 
MRSA following exposure to different antibiotics (Haney et al., 2018). The weakest biofilm 
producer was E. faecalis13280. All of the S. aureus strains showed similar biofilm forming 
capacities. MRSA252 was the strongest biofilm producer, followed by clinical isolates SA3 
and SA2, with strains 6538 and SA4 producing the least dense biofilms. Differences in 
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biofilm density compared to other studies may be due to strain differences. However, similar 
trends can be observed. For example, Sigh et al., (2012) investigated the effect of meropenem 
and vancomycin on biofilm production by P. aeruginosa ATCC 700888andmucoid S. aureus 
ATCC 29213. The biofilm density was significantly higher at all time points sampled for the 
P. aeruginosa strain compared to the S. aureus, and antibiotics were more effective in 
disruption of S aureus biofilms than P. aeruginosa biofilms (Singh et al., 2012). Meanwhile, 
Furukawa et al.,(2010) showed that S. aureus A 7510 formed thick biofilms and was more 
resistant to strong acidic /alkaline cleaning agents than Es. coli K-12 MG 1655 (Furukawa et 
al., 2010). 
The antibiofilm activity of PUFA compounds and antibiotics were measured using a 
microtiter plate Calgary device assay with pegs to determine MBIC and MBEC. PUFA 
compounds were found to be more effective at inhibiting biofilm formation by Gram-positive 
bacteria than Gram-negative species. The MBIC is a measure of early inhibition of biofilm 
formation rather than disruption of mature biofilms which required higher concentrations 
(MBEC). The same trend was observed, in both assays, with more efficient disruption of 
biofilms formed by Gram-positive bacteria. As expected, the observed MBICs of PUFAs 
were considerably higher than the MICs, and more closely resembled the MBCs recorded for 
each strain. These results are consistent with published data (Kim et al., 2018). However, 
there is considerable variation in the effective concentrations reported. This can be explained 
by an inconsistency in techniques used to assess the extent of biofilm inhibition. Kim et al 
(2018) used confocal laser scanning microscopy to quantify the effect of DHA and EPA on 
biofilm formation. They showed that concentrations as low as 20 µg ml -1 (>10-fold lower 
than this study) markedly inhibited biofilm formation by S. aureus 6538 (Kim et al., 2018). 
Confocal microscopy is a more precise and sensitive method, and conditions differed 
considerably to the parameters used for the Calgary plate assays. The most effective 
92 
treatment against wound infections is not only to prevent early biofilms but also to inhibit 
biofilms that have already formed. Interestingly, in our study, DHA and EPA not only 
inhibited biofilm formation but also disrupted pre-formed biofilms. The MBEC assays show 
that PUFAs, in the range of 750- 3125 µg ml-1, disrupted biofilms formed by all wound 
pathogens used in the study. However, the microtiter plate assay has limitations, and does not 
fully reflect a true biofilm. The nature of a closed system, as well as inconsistencies in crystal 
violet binding and in washing can contribute to misleading results. A further investigation of 
this activity with continuous flow and confocal laser microscopy would give a more accurate 
indication of antibiofilm activity.  Sun et al (2016) used confocal laser microscopy to 
evaluate the activity of PUFAs on P. gingivalis biofilms. They revealed that the viability and 
thickness of cells were reduced in the presence of PUFAs, and characterized obvious cellular 
distortion when mature biofilms were exposed to 100 mM of DHA or EPA (Sun et al., 2016). 
The present study shows that the antibiotics, linezolid and vancomycin have stronger 
anti-biofilm activity than PUFA compounds and that vancomycin was by far the most potent 
biofilm inhibitor in all cases. The activity against Gram-positive bacteria generally agree with 
other studies. However, this study has showed the disruption of biofilm with vancomycin in 
Gram positive bacteria (MBIC 1-2.5µg ml-1, and MBEC 5-8µg ml-1), while a higher 
concentration of linezolid was required to disrupt biofilms with (MBIC 20-85µg ml-1, and 
MBEC 62-500µg ml-1). Others have reported a wide range of MBICs for linezolid (1-1024 
µg ml-1) and vancomycin (1 -16 µg ml-1) depending on several clinical isolates of S. aureus 
from diabetic foot ulcers. The same study reported similar MBECs (4 - >1024 µg ml-1 for 
linezolid and 8 ->1024 µg ml-1 for vancomycin (Mottola et al., 2016). Another study on 
clinical methicillin-resistant isolates of S. epidermidis showed the MBIC for linezolid and 
vancomycin were 2-128µg ml-1and 4-256 µg ml-1respectively, while the MBECs of linezolid, 
ranging from 4-256  µg ml-1and 32 -256µg ml-1 for vancomycin (Reiter et al., 2013). 
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Vancomycin and linezolid clearly have better antibacterial and antibiofilm activity 
against common wound pathogens. However, DHA and EPA exhibited some activity and 
may be of additional use in wound treatments since they may impose less selective pressure 
and have other wound healing properties. Several studies have revealed that both DHA and 
EPA play significant role for resolving inflammation by reducing the levels of 
proinflammatory cytokines (IL-1, IL-2, IL- 6, IL-8, IL-1β, TNFa, TNF-2, and MCP1) (Cheng 
et al., 2015; Lu, et al ., 2010; Saini & Keum, 2018). Changet al., (2015) demonstrated that 
DHA enhanced the survival of transgenic zebrafish when challenged with Vibrio vulnificus. 
Anti-inflammatory effects of DHA were observed, resulting in decreased mortality and 
reduced hepatocyte damage (Cheng et al., 2015).  
In conclusion, PUFAs could be considered as key alternatives to antimicrobial 
treatment for multidrug resistant organisms that have developed resistance to vancomycin 
and linezolid. Although a higher concentration is required. PUFAs at these concentrations can 
be considered non-toxic (Sun et al., 2017), and have additional anti-inflammatory effects to 
promote wound healing. However, it is important to consider the efficacy of these 
compounds further in vivo and the likelihood of resistance development following long term 
exposure to sub-inhibitory concentrations. 
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Chapter 4 Effect of PUFA compounds and antibiotics on 
the virulence of S. aureus 
 
4.1 Introduction 
It is well known that antibiotics select for antibiotic resistant bacteria. The speed of 
bacterial replication and high rate of mutation allows rapid adaptation to stressful conditions. 
Any mutation that allows a bacterium to avoid growth inhibition or killing, confers a 
selective advantage, even if it affects important phenotypes. For example, the acquisition of 
phage-resistance to MRSA and VRSA strains can alter several characteristics including 
reduced growth rate, and reduced expression of virulence factors such as terminal N -
acetylglucosamine from cell wall teichoic (Capparelli et al., 2010). In the search for novel 
antimicrobials, agents have developed that have low killing activity, but inhibit virulence 
instead. For example, isothiocyanate iberin compound extracted from the crude horseradish 
plant exhibited remarkable activity against P. aeruginosa by interfering with quorum sensing 
(Jakobsen et al., 2012). Other quorum sensing inhibitors such as colostrum hexa saccharide,  
derived from mare colostrum showed significant inhibition of virulence factors secreted by S. 
aureus such as protease, haemolysis, and lipase activities, when applied at a rate of 5 mg ml-1 
(Srivastava et al., 2015). This strategy puts less selective pressure on the target bacteria, 
reducing the chance of resistance development.  
The data presented in chapter 3 show that PUFAs have some antimicrobial activity, 
particularly against S. aureus strains, but that they are much less potent than recommended 
antibiotics. The in vitro assays presented in chapter 3 quantify antimicrobial activity in 
laboratory conditions that do not represent the situation in vivo. This chapter investigated 
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whether the same PUFAs have any effect on the virulence of S. aureus in vivo. Two different 
infection model systems were used, an invertebrate and an ex-vivo skin model.  
Advanced next generation sequencing technology has revealed the whole genome 
sequences of wide-ranging pathogens, and their genes can provide clues about how they 
cause disease. Many novel virulence genes have been suggested and decoding their functions 
will increase our understanding of disease mechanisms and may ultimately represent novel 
targets for the development of novel therapeutic agents. Researchers studying the 
pathogenicity of Staphylococci face the challenge that many mammalian models, such as 
mice or pigs, are relatively resistant to staphylococcal infection (Polakowska et al., 2012). In 
addition, the amount of inoculum and the route delivery of bacteria cells significantly differ 
from that which occurs naturally, raising questions about the relevance of results. 
A variety of experimental animal models have been developed to help further 
understand the process of infection and the key determinants of pathogenicity. Widely used 
examples include rodents, such as the murine and rat models; the nematode worm, 
Caenorhabditis elegans; and the common fruit fly, Drosophila melanogaster. A range of 
larger mammalian models have been proposed, that better reflect human infection. For 
example, rabbit and guinea pigs have been used for skin infection models. These 
experimental models need special equipment and facilities to ensure the welfare of animals in 
the laboratory. As such, these experiments are expensive and require highly trained 
researchers and management and lengthy ethical approval procedures.  
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4.1.1 Galleria mellonella as a model to study virulence and antimicrobial activity in vivo 
Invertebrate models offer a simpler alternative to study bacterial virulence and 
antimicrobial activity. Galleria mellonella are larvae of the greater wax moth and have been 
developed as a simple model of infection, used widely in the past decade. This infection 
model is an alternative approach to studying microbial virulence factors, host immune 
responses to infection, antimicrobial activity and toxicity of drugs (Tsai et al., 2016). Unlike 
immune responses in vertebrates, the adaptive immune response in insects contains a limited 
type of B cells and T cells (Ribeiro et al., 2017). The immune response of G. mellonella has 
two major components; humoral and cellular. The cellular immune responses are mediated by 
phagocytic cells, named haemocytes. These cells are found within the haemolymph, which 
functions analogously to mammalian blood cells. Besides phagocytosis, these cells play a role 
in encapsulation and clotting. The humoral response is coordinated by soluble effector 
molecules that immobilize or kill invading pathogens. These effectors include complement-
like proteins, melanin, and anti-microbial peptides. The antimicrobial peptides (AMPs) are 
host defence peptides, found among all classes of life in G. mellonella and play a major role 
in innate immunity showing a broad-spectrum of bacteriocidal activity (Tsai et al., 2016). 
The major advantages of G. mellonella model over other invertebrate models are that 
it is considered the least complex model, easy to use and maintain and cheap to obtain in 
large numbers. These factors make it possible to carry out high throughput studies. The larvae 
are of undefined age or weight compared to mouse model, and do not need feeding. They can 
also survive at 37oC. Limited specialist equipment is needed to carry out G. mellonella 
experiments and there is no need of application for ethical approval. Thus, many have 
reported the usefulness of the G. mellonella model for evaluation of the efficacy of 
antimicrobial agents in vivo.  
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Several studies have demonstrated the susceptibility of G. mellonella larvae to 
infection. For example, 90% of larvae died 24h post infection with107 CFU S. pyogenes M3 
(Olsen et al., 2011). The efficacy of antimicrobial compounds can be tested in vivo to 
determine whether they can protect a host from infectious disease. These experiments can be 
done by injecting G. mellonella with both an infectious agent and an antimicrobial agent to 
demonstrate their abilities to control infections caused by a range of pathogens. A positive 
correlation has been found between the results of studies in humans and in G. mellonella 
(Kavanagh & Sheehan, 2018; Lange et al., 2018). For instance, microbial virulence in the G. 
mellonella infection model, larvae survival is typically assessed within 5-7 days post 
inoculation (Yang et al., 2017). When larvae are accurately injected with defined doses of 
bacteria and antimicrobial concentrations, the survival rate at different time points is endpoint 
can be calculated. Bacterial inoculum can be normalised and monitored by measuring CFU. 
ml-1. Several reports indicate that the G. mellonella model system has largely been one of 
convenience, to compare the virulence of different microbial strains or pathogenic species, by 
observing the relative time it takes for them to kill the larvae. Death is easily recognised, as 
the larvae stop moving and turn black (melanisation). Complete melanisation is typically 
distinctive with deposition of black spots on the cream-coloured larvae. Complete black 
larvae correlate with death. The time it takes for a larvae to die, post-injection, has been 
shown to correlate with the pathogenic potential of an infectious agent (Bokhari et al., 2017; 
Gundogdu, 2015). The health status of the larvae can be defined by assigning scores 
according to different observations: larvae mobility, cocoon formation, accumulation of 
melanin (melanisation) on the surface of larvae and survival rate  (Loh, et al., 2013).  
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Investigators have carried out a variety of measurements, including survival rate and 
importance of key virulence factors. For example, when 2.5 x 106 CFU ml-1 of S. aureus 
Newman strain were inoculated into the larvae, the survival rate was~10% at 120 h post 
infection (Quiblier et al., 2013). Others have shown that MICs of cefotaxime, ciprofloxacin, 
and imipenem significantly prolonged the live of G. mellonella infection with E. cloacae 
GN1059 (inoculum 5 × 105 CFUml-1; Yang et al., 2017). In assessing the efficacy of anti-
staphylococcal agents against S. aureus infection, the survival rate of larvae was enhanced by 
treating with MICs of daptomycin or vancomycin (Desbois & Coote, 2011).  
Furthermore, host responses to pathogen challenge can be investigated in G. 
mellonella. For example, Sheehan and Kavanagh (2018) measured the expression of anti-
microbial proteins in response to Candida albicans infection (Sheehan & Kavanagh, 2018), 
and Wanda et al., (2013) monitored the production of lactate dehydrogenase as a marker of 
cell damage during infection of G. mellonella with K. pneumoniae (Wand et al., 2013) 
G. mellonella has been used to study host-pathogen interactions for a range of 
organisms, including studying the virulence factors of Streptococcus suies (Velikova, K & 
Wells, 2016) and Shigella spp. Mortality rates were found to be dependent on the Shigella 
strain, the infectious dose, and the presence of the virulence plasmid (Barnoy et al., 2017). 
The model has been used to assess the activity of Myricetin in vivo, which was found to 
inhibit multiple virulence factors in S. aureus and protect G. mellonella larvae from death 
(Silva et al., 2017).  
There are few publications reporting the antimicrobial properties of PUFAs in vivo. 
Mil-Homens et. al., (2012) have studied the antimicrobial effects of DHA on Burkholderia 
cenocepacia using the G. mellonella model. A single dose of DHA (50 Mm and100 mM)) 
was injected 6 h post infection and the PUFA compound was found to significantly inhibit 
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the growth of B. cenocepacia and reduced the number of viable cells (Mil-Homens et al., 
2012). Taken together, previous infection experiments with G. mellonella suggest it to be a 
valid model for assessing the action of PUFAs in vivo. However, the model does not 
accurately reflect the conditions found in human wound infections.   
 
4.2.1 An ex vivo human skin model for assessing antimicrobial efficacy for wound 
treatment 
Patients with non-healing wounds are at a high risk of infection by colonisation of 
the wound with multi-drug resistant, biofilm forming bacteria. Chronic non-healing 
wounds are often inflamed due to an imbalance of the immune system (Metcalf et al., 
2016; Percival et al., 2015). It is thus important to assess the efficacy of wound treatments 
using infection models that better reflect these conditions. Several skin models have been 
developed to help better understand the pathogenicity of wound infections and the 
processes that delay wound healing. Ex vivo human skin models use skin biopsies from 
healthy volunteers and variations have been used to investigate the molecular interactions 
and cellular responses that occur during treatment of wound infection. A reliable ex vivo 
skin model must include the distinctive features of human skin such as full-thickness and 
multiple layers to reflect relevant tissue structures. Fresh skin is also required to enable 
investigation of relevant immune responses to control environmental changes. The model 
must be easy to generate wounds and wound infection and efficiently support the growth 
of clinically relevant bacterial species. Ex-vivo skin models that can maintain relevant 
structure, infection and host responses are of considerable value for investigating the 
efficacy of antimicrobial wound treatment (Schaudinn et al., 2017).  
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A further aim of this study was to demonstrate relevant wound infection with the 
clinical SA3 isolate and to evaluate the antimicrobial activity of PUFA compounds using 
an established ex vivo human skin model. These activities could then be compared to 
findings from in vitro and in vivo (G. mellonella) assays. 
S. aureus expresses an array of virulence factors that contribute to the pathogenesis of 
infection. Simple infection and treatment experiments with wildtype strains cannot identify 
whether PUFAs affect a particular virulence trait (e.g. surface adhesion, immune escape toxin 
production or tissue damage). However, they can determine whether the PUFAs inhibit 
growth or kill infectious agents in vivo, or whether they affect virulence in general. The 
antimicrobial and antibiofilm properties of PUFA compounds and antibiotics have been 
evaluated in vitro in the previous chapter 3. Thus, the aims of this chapter were:  
1) Compare the virulence of different strains of S. aureus (SA3, 252 and 6538) in vivo 
using the G. mellonella model. 
2) Evaluate the ability of PUFAs to protect G. mellonella from fatal infection.  
3) Evaluate the usefulness of an ex vivo skin model to assess the antimicrobial 
properties of PUFAs under more relevant conditions to chronic wounds. 
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4.2 Comparing the virulence of different S. aureus strains in the G. mellonella 
infection model 
The G. mellonella infection model has been used by others to assess the virulence of 
S. aureus and the ability of antimicrobial agents to protect the larvae from lethal infection 
(Latimer et al., 2012). The first experiment presented in this chapter was designed to 
determine how quickly the study strains of S. aureus killed the G. mellonella larvae. Three S. 
aureus strains were selected for this study: 1) SA3clinical isolate (resistant to erythromycin 
and lincomycin and susceptible to PUFA (MIC DHA 65µgml-1, EPA 78 µgml-1 ); 2) MSSA-
6538 (a standard reference strain, originally collected from a human lesion and considered 
susceptible to all antibiotics used in this study); 3) MRSA-252 (considered to be a major 
cause of community-acquired and hospital-acquired infections; resistant to the most 
antibiotics used in this study).  
Washed suspensions of each S. aureus strain were adjusted to OD 0.1 (5 x105 – 8 
x105CFU ml-1) then injected in to the G. mellonella larvae (n = 16 each strain) that were 
incubated in the dark at 37 oC for up to 7 days. Non-injected and mock-PBS-injected larvae 
(n=16 each) were included as controls. The number of surviving larvae under each condition 
were counted every 24 h (supplementary Table S1; appendix 1). Death of larvae was 
distinguished by melanisation of the larvae and lack of movement. All three S. aureus strains 
were observed to be virulent in the G. mellonella model, but to different levels. The 
percentage survival of larvae challenged with SA3, MSSA6538, and MRSA252 at day seven 
was 12.5%, 50%, and 6.5% respectively (Figure 4.1). The SA3 infected group were the most 
affected, with 6 larvae being killed rapidly within the first 48h, then 2 larvae died at each day 
until day 7. The 6538-infected group was least affected. One larva was observed to die each 
day of incubation, indicating this strain to be less virulent. The 252-infected group showed a 
similar trend to the SA3-infected group, with 2/16 larvae surviving the full 7 days. These 
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findingsdemonstrate that G. mellonella were more sensitive to infection by the S. aureus SA3 
and MRSA 252 than by MSSA 6538. No death rate was recorded with un-inoculated larvae 
and PBS inoculated controls over the seven days. These data indicate that the G. mellonella 
model was a valid system for evaluating the antimicrobial activity of PUFAs in vivo.
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Figure 4.1 Survival of G. mellonella following challenge with different strains of S. 
aureus. Larvae (n=16) were injected with MSSA6538, MRSA 252 or SA3 and survival was 
monitored for 7d. Negative controls included uninfected larvae (n=16) and injection with 
PBS (n=16). The figure shows example data chosen from 3 experimental replicates. Survival 
analysis was done using log-rank Mantel-Cox test in GraphPad prismV8. Statistically 
significant differences in virulence depending on the strain (significant difference SA3 vs 
MSSA P = 0.0051; significant difference MRSA vs MSSA P =0.0038; and not significant 
difference withSA3 vs MRSA P<0.837). 
 
104 
4.2.1 S. aureus growth recovery (CFU) from G. mellonella post infection 
The survival/growth of bacteria in the infected larvae was assessed by quantifying 
CFU ml-1 recovered from each dead larva that was homogenized in PBS, diluted and spread 
onto MSA. Uninfected and mock-infected larvae were included as negative controls. Colony 
counts recovered from dead larvae were compared to the initial inoculum (5 x105 - 8x 
105CFU. ml-1). The bacteria recovered from dead larvae infected with SA3 was between 6.8 x 
108 - 8.2x109 CFU ml-1and for MSSA 6538was 8.3 x 108 - 5.8x109 CFU ml-1and for MRSA 
252 was 3.7 x 108 - 7.4 x109 CFU ml-1 (Figure 4.2). These data suggest that S. aureus was 
able to survive and multiply within G. mellonella and that each strain had a similar fitness in 
vivo despite differences in virulence.  Although S. aureus SA3 growth were confirmed on 
MSA, Gram stain, and coagulase test, a few colonies of S. epidermidis and Es. coli were 
recovered from the dead larvae. However, these numbers were insignificant compared to the 
number of S. aureus recovered in each case. There was no a statically significant difference 
between infection groups of staphylococci P-value= 0.123.  
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Figure 4.2 Recovery of viable bacteria from G. mellonella post infection. Each dot 
represents the CFU recovered from each larva on death. Mean CFU and standard 
105 
deviation values are shown from three independent experiments. Even there are no 
statistically significant (P < 0.123) and even though bacterial numbers are the same – 
there is still a difference in larvae survival thus suggesting differences in virulence. 
 
 
4.2.2 The efficacy of PUFA compounds in the G. mellonella model 
In vitro assays suggested that PUFA compounds have both antibacterial and anti-
biofilm activity against different wound pathogens (chapter 3). Survival assays confirmed 
that G. mellonella larvae are a valid model for assessing the efficacy and toxicity of 
antimicrobial agents in vivo. These survival assays were therefore repeated, with additional 
challenge groups that were treated with different concentrations of DHA and EPA.  
Following initial inoculation with SA3 suspensions, larvae in the PUFA-treated groups were 
injected with either MIC or 2 MIC of DHA or EPA or both together. Control groups included 
SA3 challenge only; PUFA-treated in the absence of challenge; un-infected and mock-
infected (15 groups in total; n = 16 per group as detailed in supplementary Table S2 in 
appendix 2). The survival of G. mellonella in each group was compared over a period of 7 
days. A significant decrease in mortality was observed in the challenge groups that were 
treated with PUFAs. Percentage survival of groups treated with MICs of DHA, EPA and both 
PUFAs together were 68%, 56% and 62% respectively, compared to 6.25% survival in the 
SA3 untreated group after 7 days. Survival rates were observed to increase further when 
PUFAs were applied at 2 MICs 87%,75% and 75% respectively (Figures 4.3 and 4.4).  
 
Each larva was challenged with SA3 infection and treated with different concentrations of 
DHA (MIC 65µg ml-1 and 2 MIC 130 µg/ml) simultaneously. The experiment was repeated 
three times. Full details of the experiment can be found (supplementary table S2, appendix 1). 
Of the G. mellonella infected with SA3 and treated with DHA (65µg ml-1); only one larvae 
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had died on the 1st day, compared to 3 deaths in the untreated group. Eleven out of sixteen 
(68%) larvae remained alive on day 7 in the presence of DHA. The second group of G. 
mellonella larvae infected with SA3 and treated with 2x MIC DHA (130µg ml-1), were 
completely protected from S. aureus killing for the 1st 4 days of the experiment, then two 
larvae died each day from day 5 to day 7. All the larvae in the un-infected control groups 
(with and without DHA) survived for the entire 7 days (Figure 4.3).
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Figure 4.3 Effect of DHA treatment on the survival of G. mellonella larvae. Survival 
analysis was done using log-rank Mantel-Cox test in GraphPad prismV8. Statistically 
significant differences in virulence depending on the strain (Untreated SA3 vs SA3 DHA 
MIC significant P = <0.0001; Untreated SA3 vs SA3 DHA2MIC significant P = < 0.0001, 
and SA3 DHA MIC vs SA3 DHA 2MIC not significant P value = 0.1952). 
 
Treatment with EPA had similar, but slightly weaker protective effects compared to 
DHA. Each larva was challenged with SA3 infection and treated with different 
concentrations of EPA (MIC 78µg ml-1and 2 MIC 156µg ml-1) simultaneously. The 
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experiment was repeated three times and full details can be found (supplementary table S2, 
appendix 1). Groups of G. mellonella showed survival rates of 56% and 75% seven days post 
challenge and treatment with MIC (78µg ml-1) and 2 MIC (156 µg ml -1) respectively (Figure 
4.4). Of the G. mellonella group infected with SA3 and treated with EPA at MIC two larvae 
died on the first day, then one more died on each of days 2, 4, 5, 6 and 7 (56 % survival on 
day 7). The second group, infected with SA3 and treated with 2 MIC of EPA (156 µg ml-1), 
were completely protected by the PUFA from SA3 killing for the 1st 3 days. Only one larvae 
died on day 4, followed by one each day until day 7 (75% survival). 
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Figure 4.4 Effect of EPA treatment on the survival of G. mellonella larvae. Survival 
analysis of treatment group of EPA MIC and 2 MIC was done using log-rank Mantel-Cox 
test in GraphPad prismV8. Statistically significant differences in virulence depending on the 
strain (Untreated SA3 vs SA3 EPA MIC significant P =<0.0022; Untreated SA3 vs SA3 EPA 
2 MIC significant P = < 0.0001, and SA3 DHA MIC vs SA3 DHA 2MIC not significant P 
value = 0.21). 
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The percentage survival of G. mellonella was monitored over 7 days following 
infection with SA3 and treatment with two concentrations of both PUFAs together (MIC 
78µg ml-1 and 2 MIC 156 µgml-1). Each larva was challenged with SA3 infection and treated 
with different concentrations of DHA+ EPA (MIC 78µg ml-1and 2 MIC 130µg ml-1) 
simultaneously. Full details can be found (supplementary table S2, appendix 1). On day 7, 
survival was recorded as 62% and 75% for each of these groups respectively (Figure 4.5). 
When treated with MIC most larvae were protected from SA3 by DHA+EPA. One larvae 
were killed by the infection on each of days 1, 2, 4, 5, 6 and 7. When treated with 2 MIC, the 
larvae were completely protected for 3 days before the first killing was observed. Then one 
larvae died each day from day 4 to day 7, with a final percentage of survival of 75%.  
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Figure 4.5 Effect of DHA+EPA treatment on the survival of G. mellonella larvae.. 
Survival analysis was done using log-rank Mantel-Cox test in GraphPad prismV8. 
Statistically significant differences in virulence depending on the strain (Untreated SA3 
vs SA3 DHA+ EPA MIC significant P =<0.0004; Untreated SA3 vs SA3DHA+ EPA 2 
MIC significant P = < 0.0001, and SA3 DHA+EPA MIC vs SA3 DHA+EPA 2MIC not 
significant P value = 0.39). 
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Finally, both linezolid and vancomycin protected the G. mellonella larvae from SA3 
killing considerably. Each larva was challenged with SA3 infection and treated with 
concentrations of LZD MIC 3.9µg ml-1and VAN MIC 0.093µg ml-1simultaneously. Full 
details can be found (supplementary table S3, appendix 1). Only 1 larvae died on day 6 after 
being co-treated with MIC of linezolid. Similarly, only 2 larvae died after co-treatment with 
SA3 and MIC of vancomycin, 1 on day 5 and a second on day7. By comparison, in the 
absence of antibiotics, 93% (15/16) larvae died from SA3 infection within 7 days. 
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Figure 4.6 Effect of LZD or VAN treatment on the survival of G. mellonella larvae. 
Survival analysis was done using log-rank Mantel-Cox test in GraphPad prismV8. 
Statistically significant differences in virulence depending on the strain (Untreated SA3 vs 
SA3 LZD MIC significant P =<0.0001; Untreated SA3 vs SA3VAN MIC significant P = < 
0.0001, and SA3 LZD MIC vs SA3 VAN MIC not significant P value = 0.53). 
 
Taken together, these results demonstrate that, although S. aureus SA3 had significant 
virulence activity in G. mellonella, the PUFA compounds clearly protected the larvae from 
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lethal infection compared to the untreated groups, and this effect appears to be dose-
dependent, with higher concentrations of PUFAs delaying death for much longer. These 
experiments could not determine whether PUFAs were acting by preventing growth or 
inhibiting virulence of SA3. This could be better assessed by quantifying bacterial numbers 
following challenge and treatment. 
 
4.2.3 Bacterial growth (CFU) after infected G. mellonella with different concentrations 
MICs of PUFAs compounds 
Following the death of each larvae during the challenge-treatment experiment, G. 
mellonella were homogenized and serially diluted in PBS for bacterial counts, which were 
compared to the initial inoculum of SA3 (5x105 CFU.). The G. mellonella were not sterilised 
before inoculation, hence a small number of non-SA3 colonies were observed on recovery 
plates. However, this did not affect the recovery of high numbers of SA3, that were 
confirmed by plating on Baird-parker agar plates, coagulase test, catalase test and Gram stain. 
The recovered CFU from all treated G. mellonella groups was considerably lower that the 
numbers recovered from the untreated group in each case (Figure 4.7). Whilst 6.8 x 108 - 8.2 
x109 CFU. were recovered from each infected, untreated larva, roughly 10-fold less were 
recovered from larvae treated with DHA (9.7 x 107 - 5.6 x108CFU. larvae-1). Similar numbers 
were recovered from larvae treated with EPA (1.1 x 108 - 6.1 x108 CFU. larvae-1), and both 
PUFAs together (1.4 x 108 - 7.3 x108 CFU. larvae-1). There was no significant difference in 
recovery between the 3 treated groups. The SA3 numbers recovered from G. mellonella 
treated with double concentrations (2 MIC) of each PUFA were slightly reduced, but not to a 
level of statistical significance (3.9 x 107 - 3.4 x108 CFU. larvae-1).  
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These data indicate that PUFAs can either hinder growth or kill a proportion of SA3 
in vivo, but that much higher concentrations would be needed to eradicate the infection. 
Growth was not hindered completely, as SA3 was recovered from all treatments in much 
higher numbers than the initial inoculum. Interestingly, when the PUFA dose was doubled, 
the G. mellonella survival rate increased, but there was no significant decrease in SA3 
numbers recovered from dead larvae. This might suggest that the higher dose may have more 
effect on virulence, rather than a cumulative bacteriostatic or bacteriocidal effect. However, 
this might just be a reflection of genetic variation and susceptibility of individual larvae. 
Quantification of bacteria from the surviving larvae would have provided more insight into 
this. Uninfected larvae, that were treated with PUFAs remained 100% viable, confirming the 
non-toxic nature of the PUFAs at these concentrations. 
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Figure 4.7 Effect of different PUFA compounds on bacterial growth (CFU) of SA3 
in vivo. G. mellonella were inoculated with various concentrations of PUFA compounds 
MIC and 2 MIC) and LZD, VAN antibiotics. Each dot represents the number of viable 
bacterial cells recovered from dead larvae. All these experiments represent the means ± 
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SEM of three independent determinations. All medial the medians vary and statically 
significant compared to Untreated SA3. 
- *SA3 DHA MIC vs Untreated SA 3 P value = 0.0314      
- **SA3 EPA MIC vs Untreated SA 3 P value =0. 0092 
- ***SA3 DHA+EPA MIC vs Untreated SA 3 P value = 0.002 
- * SA3 DHA 2 MIC vs Untreated SA 3 P value = 0.0276 
- **SA3 EPA 2 MIC vs Untreated SA 3 P value = 0.026 
- ***SA3 DHA+EPA 2 MIC vs Untreated SA 3 P value = 0.024 
- *SA3 LZD MIC vs Untreated SA 3 0.020- 
*SA3 VAN MIC vs Untreated SA 3 = 0.022 
 
 
 
 
This chapter demonstrates the activity of PUFAs in more realistic conditions, but does 
not provide any information about how the PUFAs inhibit SA3 growth, or how they might 
interfere with virulence. G mellonella infection model is an alternative approach to studying 
microbial virulence factors, host immune responses to infection, antimicrobial activity and 
toxicity of drugs. There are several limitations of the G. mellonella model; and there is need 
for more realistic models to assess host responses through the development of standardised 
larvae for research, the whole genome sequencing projects and the development of pathology 
scores to achieve more reliable model. 
 
 
4.3 Detectionof the growth of SA3 on the ex vivo human skin model 
An ex-vivo human skin model was used to evaluate PUFAs as viable interventions for 
wound infection (Latimer et al., 2012). The skin model consists of punch biopsies, taken 
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from consenting donors undergoing elective surgery. The skin structure is maintained in 
culture well inserts, with a small amount of the bottom layer pulled through a central hole 
that feeds into the tissue culture media below. This set up allowed for multiple replicates 
(n=6) per plate. The skin can be “wounded”, using a smaller biopsy punch to remove a small 
amount of the top layer of skin. Experiments were performed, in which bacteria, PUFAs and 
controls were applied in different combinations. The initial inoculum of SA3 
≅1x107CFUmm2. Triplicate swabs samples were taken at time zero to evaluate the number of 
bacterial cell that located on biopsy samples. The growth and response of S. aureus SA3 on 
non-wounded and wounded skin were assessed 24 h post inoculation. The first experiment 
showed that SA3 could multiply on both the wounded and non-wounded skin surface to 
similar levels (Figure 4.8). The mean CFU. mm-1 of SA3 was 2.6 x108 CFU. mm-1 on 
wounded skin and 3.4 x108 CFU. mm-1 on non-wounded skin after 24 h recovery. These 
viable bacterial cell counts were significantly more than the “uninfected” wound inoculated at 
t= 0 with of 8 x104 CFU mm-1 (P =0.0160). Slightly more SA3 growth was observed on 
infected non-wounded biopsies compared to the “uninfected” (inoculated) nonwounded 
biopsies, (P =0.0028). No viable bacterial cells were recovered from negative controls 
biopsies (biopsy skin only).  
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Figure 4. 8 CFU viable SA 3 from wounded and non-wounded skin biopsies. The dots are 
represented as the mean ± SD of three donors. The term “un-infected” refers to skin biopsies 
at t = 0 that had just been inoculated with SA3. The term “infected” refers to skin biopsies 24 
h post inoculation with SA3. CFU growth of SA3 analysis was done using un-paired t test in 
Graph Pad prismV8. The CFU growth of SA3 revealed statistically significant differences 
between t = 0 h vs t = 24 h P value= 0.016, **significant uninfected non-wounded vs and 
infected non-wounded sample P value= 0.0028, No significant wounded sample and Non-
wounded sample P value= 0.97. 
 
The second experiment using the ex vivo human skin model was carried out to 
explore the wound model’s potential as a test system for local antimicrobial DHA treatment. 
The wounds and non-wounded samples were treated with DHA 130 µg ml -1 to evaluate the 
antimicrobial activity of DHA in a skin or wound environment. Briefly, the SA3 inoculum of 
SA3 ≅ 1x107 CFU mm2 was loaded on to the surface of wounded and non-wounded skin and 
allowed to adsorb. Triplicate swabs samples were taken at time zero to evaluate the number 
of bacterial cells that located on biopsy samples. The topical DHA (2 MIC130 µg ml -1) was 
added 15 min after inoculation. After 24 h bacterial cells were recovered from the surface of 
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each biopsy using a sterile swab. A decreased viable cell density was recovered from treated 
samples compared to non-treated samples (Figure 4.9), regardless of whether or not the skin 
was wounded. The mean number of SA3 cells recovered from infected wounded samples 
treated with DHA was 5.3 x 104 mm-1 compared to 2.6 x108 CFU mm-1 from untreated 
samples (P = 0.017) from the same experiment. Similarly, although significant mean number 
of SA3 cells (P = 0.0028), recovered from infected non-wounded samples treated with DHA, 
was slightly lower (1.3 x104 CFU mm-1), this number was still much less than recovered from 
the non-treated equivalents. The results show no significant differences between infected 
wound and infected non-wounded both were treated with DHA (P =0.658). No bacteria count 
could be recovered from negative controls (biopsy skin only). 
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Figure 4.9 Bacteria quantification and effects of topical DHA 130 µg ml -1treatment on 
wounded and non-wounded skin sample. The dots represent the mean ± SD of three 
experiments, each performed with skin biopsies from different donors. Recovery growth of 
SA3 analysis was done using un-paired t test in Graph Pad prismV8. The growth of SA3 
revealed statistically *significant differences between the infected wound vs treated wound 
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with DHA 130 µg ml -1 P value=0.017, ** significant infected non-wounded vs non-wounded 
treated with DHA 130 µg ml -1 sample P value= 0.0028. 
 
These data suggest that PUFAs are likely to have antimicrobial effects during wound 
treatment. As no growth of bacterial cells at negative control (biopsy skin only) suggest a 
thorough skin disinfection of each patient before surgery. However, the whole Williams E 
medium were preserved at -80 oC for future investigation such as the host immune response 
towards bacterial infection. Moreover, experiments are required to compare the action of 
PUFAs to the action of antibiotics in this model. 
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4.4 Discussion 
This study agrees with others, that G. mellonella is a useful alternative infection 
model for studying microbial virulence and the efficacy of antimicrobial activity in vivo. The 
virulence of Staphylococci in G. mellonella has been demonstrated by Silva et al (2017). 
They revealed that Myricetin, as alternative compound for inhibiting virulence factors of S. 
aureus (α- haemolysin activity, coagulase and staphylo xanthin production)without 
interfering with growth, and protecting G. mellonella infection (Silva et al., 2017). Although 
the antimicrobial activity of PUFA compounds has been studied in vitro against potential 
wound pathogens in chapter 3, this invertebrate model provided more realistic conditions for 
testing activity and for assessing the effect of PUFAs on virulence of SA3 during 
proliferation of the bacterial cells inside the larvae. These experiments demonstrated that G. 
mellonella was sensitive to infection by S. aureus SA3 and MRSA 252, and slightly less 
sensitive to MSSA 6538. An inoculum of 5 x 105 CFU. enabled comparison of virulence over 
a 7-days period. By contrast, Ignasiak et al, observed very rapid killing 60–80% of G. 
mellonella within 48h post infection with S. aureus ATCC 29213 (Ignasiak & Maxwell, 
2017). Others have compared a wider range of different strains and stratified them into high 
(90–100% mortality within 1-2 days), intermediate (50-90% mortality between 3-5 days) 
virulence phenotypes (Mannala et al., 2018). These reports demonstrate that the virulence 
and killing of G. mellonella by S. aureus are dependent on the strain. Differences in rates of 
killing by S. aureus indicate variation in the production of virulence factors during different 
stages of host colonization and infection (Kobayashi et al., 2015).  
The clinical wound isolate, SA3 was chosen as a relevant target to assess the 
pathogenic consequences of antimicrobial activity of PUFA compounds in G. mellonella. 
This strain was previously confirmed as a multidrug resistant organism, with a profile 
resembling MRSA determined by observing resistance to cefoxtime (chapter 3). This study 
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suggests that DHA was more effective at preventing SA3 from killing G. mellonella than 
EPA. The recovery of SA3 was significantly higher from EPA-treated larvae than from 
DHA-treated larvae. This might be due to activity of EPA that promoted more reduction of 
cellular inflammation than DHA. EPA is an inhibitor of the enzyme delta-5-desaturase (D5D) 
that produces arachidonic acid, which is precursor to pro-inflammatory eicosanoids, and 
could result in synergistic improvement in immune response (Yashiro et al., 2016). 
The killing activity of SA3 was significantly reduced when larvae were treated with 
higher concentrations of PUFAs compound. These findings indicate that PUFA compounds 
have encouraging inhibitory effects on the growth of the clinical SA3 isolate in vivo. 
Relatively high densities of viable SA3 were recovered from treated larvae, despite longer 
survival of the larvae. This suggests that the action of PUFAs affected virulence, not just 
growth inhibition. These findings agree with other study by Kim el al., (2018) investigated 
the effects of DHA and EPA on S. aureus virulence in the C. elegans model. The survival 
rate of C. elegans was increased more than seven and nine fold when worms were exposed to 
S. aureus in the presence of DHA or EPA at 20 µg ml-1 respectively (Kim et al., 2018) 
No toxic effects were observed when non-infected larvae were exposed to PUFAs, 
DHA, EPA or both DHA+EPA at 2MICs concentrations up to 156 µgm-1. These data agree 
with others who also report no toxic effects of PUFAs (up to 200 µM) on gingival epithelial 
cells (Sun et al., 2016).  
The experiments performed using the ex vivo human skin model presented 
encouraging results to further investigate the antimicrobial efficacy of PUFA compounds 
using this skin model. The clinical SA3 isolate grew well on wounded and non-wounded 
skin. The significant increase in bacterial density after 24 h incubation may be explained by 
the presence of nutrients in the skin wound biopsy, furthermore, our data from of infected ex 
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vivo wounds and infected non-wound treated with DHA 130 resulted in a reduction from 
~108to ~104 bacteria per wound, these results are consent with other study using the same 
model with other antibiotics. For example, Schaudinn et al., (2017) had demonstrated that 
topical treatment with ciprofloxacin (375 μg ml-1) for P. aeruginosa PA01 had reduced the 
bacterial count from 109 to 104 bacteria per wound, the same study revealed that 
interleukinIL-1α expression was significantly affected and distinguished between infected 
and uninfected wounds, indicating a response of skin cells to the infection of the PA01 strain. 
Furthermore, scanning electron microscopy confirmed the high number of bacteria that were 
interwoven in collagen bundles and apparently attached to the collagen fibres (Schaudinn et 
al., 2017). 
The significant reduction of bacterial cells at both infected wound and infected non-
wounded biopsies provide encouraging evidence for further investigation, such as 
comparison with other topical antibiotics for wound healing. Moreover, further investigation 
for testing different immune responses to infections and treatment. This is possible because 
the skin is maintained in a viable state by bathing the under-side in tissue-culture medium 
(Shah et al., 2012). Cytokines such as (IL-6, IL-8, IL-1α and IL-1β) are expressed and 
increase in inflammatory state and infections. The cytokines IL-6 and IL-8, are released by 
skin cells (fibroblasts and macrophages) and normally up-regulated during an infection 
(Arango Duque & Descoteaux, 2014). In addition, IL-1α is related to tissue damage and 
bacterial infections. IL-1β is known to be secreted by several skin cell types such as 
macrophages and dendritic cells, when bacterial components bind to the Toll-like receptor 
(Chamberlain et al., 2013). Measurement of these cytokines in skin biopsies exposed to SA3 
and PUFAs, would provide insight into the multi-faceted roles of PUFAs in chronic wound 
healing. 
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Chapter 5 Effects of the inhibitory concentrations of PUFAs on 
regulatory genes of S. aureus SA3 
 
5.1 Introduction 
S. aureus is an opportunistic pathogen that causes a wide range of acute and chronic 
infections including wound infections (Nairet al., 2014). These pathogenic bacteria have been 
shown to form extracellular biofilm matrix in the wound bed, and employ a wide range of 
virulence factors, such as adhesins, enzymes, toxins, and immune evasion proteins (Phillips et 
al., 2016; Powers & Wardenburg, 2014). There has been a significant increase in reports of 
antibiotic-resistant S. aureus such as MRSA and VRSA. With the increasing challenges of 
AMR, there is an urgent need for novel treatment strategies and, ideally, antimicrobial agents 
that impose less selective pressure but may inhibit virulence and biofilm formation. Previous 
chapters demonstrate antimicrobial and antibiofilm activity of PUFAs in vitro and in 
infection models. Results from G. mellonella challenge with SA3 show reduced killing of 
larvae, but little reduction on growth of the invading pathogens. These data suggest that 
PUFAs may have an inhibitory effect on the virulence of S. aureus. Others have reported that 
PUFAs may affect the expression of genes involved in adhesion, biofilm formation and 
virulence gene regulation (Choi et al., 2013). This chapter explores the effect of different 
concentrations of PUFAs on the expression of key target genes involved in the global 
regulation of biofilm formation and virulence. 
The formation of a mature biofilms is a complex process that can be subdivided into distinct 
phases of attachment, accumulation, maturation, and dispersal. The early stages of 
Staphylococcal biofilms (attachment and accumulation) rely on different types of adhesins. S. 
aureus adhesion occurs via a group of surface-exposed proteins collectively referred to as 
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MSCRAMMs (microbial surface components recognizing adhesive matrix molecules) and 
the polysaccharide intercellular adhesin (PIA) operon, whose biosynthesis is encoded by 
icaA, icaD, icaB, and ica C genes. S. aureus controls expression of these genes using 
different regulatory systems. The accessory gene regulator (Agr BDCA) is a quorum-sensing 
system (Foster et al, 2014)that regulates genes via an autoinducing peptide (AIP) in response 
to cell density. The response regulator (agrA) is activated on detection of AIP and acts as a 
global regulator of a wide range of virulence genes such as hemolysins, staphylococcal 
proteases, and lipases (Mannala et al., 2018). The Agr system is part of a more complex 
regulatory system and is linked to the staphylococcal accessory regulator nucleic acid-
binding protein, SarA. The sar locus consists of transcriptional units (sarB, sarC and sarA). 
The SarA subunit is constitutively produced throughout S. aureus growth phases (Morrison, 
2012) and plays a significant role in the control of virulence and biofilm formation (Arya et 
al., 2015; Dunman et al., 2001). For example, the study by Balamurugan et al., (2017) 
showed that the compound 2-[(Methylamino)methyl] phenol has significant inhibition the 
representative virulence genes RNAIII, fnbA, and hla genes, these genes are under control of 
global regulator sarA gene. Furthermore >70% of clinical S. aureus biofilm inhibition was 
observed when treated with 1.25 μM of this compound (Balamurugan et al., 2017). 
 
This chapter aimed to gain a deeper understanding of the mechanism of antibacterial 
action of PUFAs and assess whether PUFAs interfere with the activity of global virulence 
gene regulators. The main objective was to use RT-PCR to measure the differential 
expression of sarA and agrA by SA3 in the presence and absence of PUFAs. 
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5.1.1 Effect of DHA and EPA on SA3 growth curves 
The effect of different concentrations of PUFA compounds on the growth of SA3 was 
measured in liquid culture. Briefly, a fresh suspension (20ml) of SA3 was prepared in MH 
broth from overnight cultures to the density of 1.5x104 CFUml-1 as confirmed by serial 
dilution and spread plating on Columbia agar. Cultures were set up in triplicate (Table S4 in 
appendix) and exposed to two different concentrations (50µgml-1 and 100 µg ml-1) of DHA 
EPA or both together in triplicate for 24 h at 37 oC. Cultures were sampled for RNA 
extraction at several time points (t = 0, 6, 12 and 24 h). Optical density measurements 
(OD600) and broth dilution CFU ml
-1 assays were performed at each time point. Negative 
controls were not treated with PUFAs, instead, they were exposed to dilute ethanol (1:1000), 
used to solubilise PUFAs. Aliquots (1.5 ml) of bacterial suspension were collected at each 
time point and bacterial cells were harvested by centrifugation (15.000rpm, 2min) using a 
benchtop microfuge. Bacterial pellets were kept at -20 oC for total RNA extraction. 
DHA and EPA delayed the growth of SA 3 during the first 12 h. Cultures treated with 
50 µgml-1 and 100 µgml-1 DHA grew to OD 0.067 and 0.028 respectively compared to the 
untreated SA3 which grew to OD 0.55 (Figure 5.1-A). EPA showed slightly less inhibitory 
effect after 12 h, with treated cultures reaching OD600 0.13 and 0.077 when treated with 50 µg 
ml-1 and 100 µg ml-1 EPA respectively (Figure5.1-B). When SA3 was treated with a mixture 
of both compounds (DHA+ EPA) growth inhibition was similar to that observed with EPA 
alone (Figure 5.1-C).  After 24 h exposure to PUFAs, SA3 growth showed signs of recovery. 
The cultures treated with 50 µgml-1 and 100 µgml-1 DHA grew to OD600 0.29 and 0.15 
respectively, whereas those treated with EPA grew to OD600 0.35 and 0.25 respectively. 
Although growth was recovering, the optical density of all PUFA-treated cultures was still 
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considerably lower than the untreated cultures after 24 h (OD600 0.6). This experiment was 
repeated three times. Therefore, antimicrobial activity of PUFA against S aureus waspresent 
and considerable. 
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Figure 5.1 The mean OD600 measurements of SA3 in presence of 
different concentrations of PUFAs compounds. A) DHA with two 
concentrations 50 and 100 µg ml-1. B) EPA with two concentrations 50 
and 100 µg ml-1. C) Both mixture of DHA+EPA with two 
concentrations 50 and 100 µg ml-1. The data represent the average of 
triplicate independent essays, Bars indicate standard deviations. 
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Growth of SA3 exposed to 100 µgml-1 PUFAs was surprising, given that previous 
experiments determined the MIC of DHA and EPA to be below this concentration (65 and 78 
µgml-1 respectively). This may be explained by different culture volumes. To further 
establish the exact effects of DHA and EPA on the planktonic growth of SA3, viable bacterial 
cells were quantified at each time point. The number of viable SA3 cells did not increase 
from the initial inoculum for the first 6 h exposure to DHA. Colony counts from cultures 
exposed to 50 and 100 µg ml-1 were observed to be 9x 104 and 5x103 CFUml-1 respectively, 
compared to untreated SA3 that grew to 69 x 105 CFU ml-1 within 6 h. A slow, steady 
increase in growth was observed between 6 and 24 h with PUFA exposed cultures reaching 
between 16 x10 4 and 7 x 103 CFU ml-1 compared to untreated cultures that reached 13 x 106 
CFU ml-1 after 12 h and remained at this number after 24 h (Figure 5.2, A). A similar effect 
was observed in EPA treated cultures (Figure 5.2, B and C) with viable cells remaining at 13x 
103 and 1x 103 CFU ml-1 for the first 6 h treatment with 50 and 100 µg ml-1 respectively. Then 
slow growth was observed, reaching 17 x 104 and 85 x 103 CFU ml-1 after 24 h. The growth 
of SA3 was inhibited in a similar way by combined treatment with DHA and EPA and there 
was no additive effect of the two (Figure 5.2 C). RNA was extracted from culture samples at 
6 and 12 h for gene expression studies.
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Figure 5.2 Inhibition of SA3 growth over 24 h by different 
concentrations of PUFA compounds. A) CFU ml-1 SA3 exposed to 
DHA at 50 and 100 µg ml-1. B) CFU ml-1 SA3 exposed to EPA at 50 
and 100 µg ml-1. C) CFU ml-1 SA3 exposed to a 50:50 mixture of 
DHA and EPA at 50 and 100 µg ml-1. Viable cell counts from all 
treated cultures were compared to untreated cultures. Bars indicate 
standard deviations. The data represent the average of the triplicate 
independent essay. 
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5.1.2 The efficacy of complementary DNA (c DNA) synthesis 
To determine the effect of PUFAs on the expression of global gene regulators, RNA 
was extracted from untreated and PUFA treated cultures at 6 and 12 h. Complimentary DNA 
(cDNA) was synthesised from each sample and quality was determined by analysis on a 
Nanodrop 2000 and by checking for the presence of contaminating DNA. Since SA3 was 
found to be resistant to erythromycin, and the genome sequence confirmed the presence of 
the ermC gene (chapter 3), ermC primers were used to assess the quality of the cDNA 
samples by PCR. The primers amplified a 285 bp product from initial RNA samples, 
suggesting DNA contamination. Therefore, a second DNAse treatment was performed and 
the treated RNA samples no longer contained contaminating DNA. All cDNA was 
synthesised from DNAse treated RNA and the ermC product was amplified to confirm 
quality of the cDNA (Figure5.3).
 
Figure 5.3 Validation of the quality of RNA and cDNA. 1% agarose gel stained with 
Gel Red. PCR amplification of ermC (285 bp) confirms presence of SA3 DNA. Lane 1, 
Molecular weight marker (Hyperladder I – Bioline); Lane 2, ermC PCR product from 
example DNA contaminated RNA sample; Lane 3,  no PCR product indicates pure 
RNA; Lane 4, ermC PCR product from example cDNA synthesised from pure RNA. 
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5.4 Optimisation of primers for RT-PCR 
The optimisation of primers is important for improving the quality of RT-qPCR 
performance. Artemis Comparison Tool (ACT) software was used to view the SA3 whole 
genome and design primers for target genes. Since previous chapters indicated that the 
PUFAs affected both biofilm formation and virulence, primers were designed to quantify 
expression of global regulators of virulence and biofilm formation (agrA, sarA and ica A). 
Different house-keeping genes were also assessed as internal control genes (16S rRNA, fabD, 
pyk and proC). Standard PCR was performed validate each primer set and optimise cycling 
conditions. The cDNA template was used for each prime set, which all amplified the 
expected product size for each gene (Figure 5.4).
 
Figure 5.4 Confirmation of amplicon sizes for the RT-qPCR target genes. 1.5% 
agarose gel loaded with PCR products and run at 70V for 1 h. Lane 1, MW marker  
1kbase pair (Hyperladder I – Biolone); Lanes 1ica A149bp, Lanes 2-agrA149bp, Lanes 
3-sarA110bp, Lanes4-16s RNA191bp and Lanes 5-negative control H2O. 
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5.5Identification of suitable internal controls for gene regulation in SA3  
Three staphylococcal house-keeping genes (fabD, proC and pyk) were assessed for their 
suitability as internal control genes according to published work (Theis, et al., 2007). 
These house keeping genes are typically used because they are believed to be stable 
inthe presence of a range of concentrations of four structurally different antimicrobial 
compounds (Theis et al., 2007). The PCR produced of fabD and pyk, did not give 
reliable quantification as shown in figure 5.5. The proC gene (106 bp amplicon) was 
chosen in this study as an optimum internal control. Each single band of the correct size 
was purified by gel extraction to produce standard concentration controls (Figure 5.5).  
 
Figure 5.5 Primer validation for S. aureus housekeeping genes in SA3. 1.5% agarose 
gel analysis of housekeeping genes amplicons from standard PCR. Lane 1 MW marker 
(Hyperladder I – Bioline); Lanes 2-5 gene amplicons [2, fabD. 3, proC.4, pyK]. Lane 5, 
sarA as a positive control. Lane 6, negative control H2O template. 
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5.1.3 Effect of PUFAs on the expression of virulence genes and regulators regulation 
S. aureus coordinates the expression of a wide range of virulence genes by a complex 
network including multiple global regulator genes such as agr A, sarA. Disruption of these 
regulatory networks is an attractive strategy for novel therapeutics. This chapter focusses on 
the effect of PUFAs on the associated regulatory genes of virulence of clinical S. aureus 
isolate SA3. The Quantitative real-time PCR (qRT-PCR) of relative expression levels of three 
virulence-relatedeach gene agrA,icaA and sarA were determined using the 2−ΔΔCT method 
(Livak & Schmittgen, 2001). Gene specific primers were used, and pro C was used as the 
housekeeping control (Supplementary Table S1) to normalize the expressions of genes of 
interest. The q RT-PCR technique employed was an adaptation of a previously described 
method (Montgomery et al., 2010). RT-qPCR was performed using a SYBR Green supermix 
system (details in Chapter 2). 
Treatment of SA3 with DHA or EPA caused changes in expression of global regulator 
genes compared to no treatment. Relative transcriptional profiles were determined for 6 and 
12 h cultures by qRT-PCR with respect to proC expression. Within 6h, treatment of cultures 
with 50 µg ml-1 DHA up-regulated the expression of agr A and ica A genes by 4.7 and 5.5- 
fold, but dramatically down-regulated sarA 10-fold. This effect was more pronounced when 
cultures were treated with double the DHA concentration (100 µg ml-1). The expression of 
agrA and icaA increased 7.4 and 9-fold respectively, while sarA expression decreased 11.1-
fold compared to untreated cultures (Figure 5.5-A). After 12 h treatment with 50 µg ml-1 
DHA, at the same trend of differential expression was observed, but to different levels 
(Figure 5.5-B). The agrA gene was up regulated more (7.6 fold), but the icaA gene was only 
upregulated 4.6-fold, while sarA was down-regulated much more (16.6-fold) compared to 
untreated cultures. Moreover, when cultures were treated with double concentrations of DHA 
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(100 µg ml-1) the effect was more pronounced, with upregulation of agrA and ica A 33 and 
10-fold respectively, and downregulation of sarA 20-fold.  
EPA had a weaker effect on gene expression, but still induced the same general effect. 
After the first 6 h of 50 µg ml-1EPA treatment, the expression of agr A and ica A was up-
regulated by 3.5 and 2.8-fold, while sarA was down-regulated 5.5-fold (Figure 5.6-A). This 
effect was more evenly amplified when higher concentrations of EPA (100 µg ml-1) were 
used. The agr A and ica A genes were upregulated 6.6 and 5-fold respectively, while sarA 
was down-regulated 9-fold. After 12 h 50µg ml-1 EPA differential gene expression was 
further amplified, with agrA and icaA genes up-regulated 10 and 8.3-fold and sarA down-
regulated 9-fold (Figure 5.6-B). The higher concentrations (100 µg ml-1) caused much higher 
changes in expression of agrA (up 20-fold) and sarA (down 25-fold). However, the icaA gene 
expression was only increase 8.3-fold (the same effect as 50 µg ml-1) compared to untreated 
cultures. 
Thus, the present study indicates that PUFA compounds, DHA and EPA have the 
capacity to attenuate S. aureus virulence, as evidenced by considerably altering the 
expression of global gene regulators and adhesins. 
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Figure 5.6 RT-PCR analysis to quantify expression of three virulence-associated genes (agrA, icaR, and sarA) in SA3 cultures 
exposed to DHA(A) Treatment at the time six hours and (B) Treatment at the time of twelve hours. Data were expressed as the mean ± 
standard deviation (n = 3). Relative transcriptional profiles were determined with respect to the internal control gene proC expression. 
Statistical analyses were performed by GraphPad Prism v8.00, and an unpaired Student’s t-test with Welch’s correction was considered 
statistically significant P< 0.05. The p value table for both DHA at 6 and 12h are in Table S6 in appendixes. 
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Figure 5.7 RT-PCR analysis to quantify expression of three virulence-associated genes (agrA, icaR, and sarA) in SA3 cultures 
exposed to EPA(A) Treatment at the time six hours and (B) Treatment at the time of twelve hours. Data were expressed as the mean ± 
standard deviation (n = 3). Relative transcriptional profiles were determined with respect to the internal control gene proC expression. 
Statistical analyses were performed by GraphPad Prism v8.00, and an unpaired Student’s t-test with Welch’s correction was considered 
statistically significant P< 0.05. The p value table for both EPA at 6 and 12 h are in Table S 7 in appendixes.   
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5.2 Discussion 
S. aureus pathogenicity involves coordinated regulation of a wide range of genes that 
encode virulence factors, including adhesins, toxins and biofilm-associated proteins. Global 
gene regulators such as the accessory gene regulator, agrA and staphylococcal accessory gene 
regulator, sarA control the expression of most exotoxins produced by S. aureus during 
different stages of infection (Lee et al., 2014). In addition, S. aureus has been shown contain 
the intracellular adhesion operon ica which is responsible for slime layer production in 
biofilm formation (Cramton et al., 1999). Furthermore, the ica A gene encoded the enzyme 
N-acetyl glucosamyl transferase which is involved in synthesised of N Acetylglucosamine 
oligomers from UDP N acetylglucosamine, with the regulation of ica ADBC orthologous 
genes are playing significant role for synthesising the Polysaccharide Intercellular Adhesion 
(PIA) (Anjuman et al., 2014; Nourbakhsh & Namvar, 2016), which are highly contributed for 
cell to cell interaction during biofilm formation. However, its widely published that the 
global regulator, sarA, has a direct effect on the on P2 and P3 promoters, to which agrA 
binds, and on agrC-agrA interaction (Cheung & Manna, 2005; Reyes et al., 2011). 
Furthermore, SarA has been demonstrated to enhance biofilm formation directly by 
increasing PIA production (Valle et al., 2003). For example, mutation of sarA results in 
increased expression of proteinases and nucleases, which both enzymes have a negative 
impact on biofilm formation (Beenken et al., 2010). The transcriptional downregulation of 
agr expression has been attributed to the sequestration of the quorum-signalling molecule 
auto-inducing peptide (AIP) (James et al., 2013). A study by Otto, 2011 showed that 
expression of agr leads to increase expression of several toxins such as, serine protease, 
DNase, enterotoxin B, and toxic shock syndrome toxin-1, and the agr locus decreases the 
expression of colonization factors including ica gene (Otto, 2001). These studies suggested 
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that both global regulators genes agr A and sarA and the ica A gene play significant role in 
biofilm formation and S. aureus infections. 
The major aim of this study was to investigate the effect of PUFA compounds on 
global gene regulators agrA and sarA and further investigate the effect of PUFA compounds 
on icaA gene in biofilm formation. Disruption of virulence and biofilm gene regulation would 
be an attractive action for new wound treatments. Disruption of virulence, and growth rate, 
would exert less selective pressure and reduce the likelihood of resistance development. 
Notably, DHA and EPA significantly affected the expressions of all three genes 
(agrA, icaA and sarA). Thus, the present study indicates that DHA and EPA could attenuate 
S. aureus virulence. This is supported by evidence presented in chapter 3 that showed 
reduced biofilm formation in the presence of PUFAs and in chapter 4 that indicated reduced 
virulence in G. mellonella. Whilst agrA and icaA genes were up-regulated, sarA was down-
regulated by PUFAs. This study has shown the effect of DHA was more pronounced, with 
upregulation of agrA and ica A 33 and 10-fold respectively, and downregulation of sarA 20-
fold. Similarly, the higher concentrations of EPA caused much higher changes in expression 
of agrA (up 20-fold) and sarA (down 25-fold). These results disagree with Kim et al., (2018), 
who found that neither DHA, or EPA, significantly affected the expression of, agrA, sarA, 
icaA, and other related genes such as sigB, or spa. However, same study showed that DHA, 
and EPA attenuate S. aureus virulence, and reduction in biofilm formation (Kim et al., 2018). 
This may be because Kim et al., (2008) used much lower concentrations of PUFAs (20 µgml-
1) compared to this study (50 and 100 µgml-1). Sun et al., (2016) showed that exposing P. 
gingivalis to 100 Mm DHA significantly decreased expression of several virulence genes, 
including hagA and hagB genes by 3.8-, 7.3-fold, respectively, as well as proteases genes 
rgpB and kgp (5.5- and 4.2-fold, respectively). Similarly, treatment with 100 mM EPA also 
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markedly downregulated the expression ofhagA, hagB, rgpB and kgpby 5.5-, 10.53.4, and 
9.4- fold, respectively (Sun et al., 2016). 
The differential up and down regulation of agrA, and sarA loci during infection is 
widely reported. For example, the exposure to sub MICs of oxacillin resulted in higher levels 
of expression ofagr Ain S. aureusCC15 and CC45 strains while the same gene was down-
regulated in the CC30 strain (Viedma et al., 2018). It is conceivable that downregulation of 
agr activity, as part of bacterial colonisation, as agr dysfunction has been associated with 
persistent bacteraemia in MRSA, the innate immune response could in fact contribute to the 
formation of staphylococcal persisters leading to chronic infections (Chong et al., 2013). 
This effect on global regulators has been observed in response to other treatments, but 
usually, both agrA and sarA are down-regulated. For example, the novel drug candidate 
baicalein (a flavonoid, originally isolated from the Scutellaria baicalensis) has been 
investigated, for treatment S. aureus infections. At 32 μg ml-1 and 64μg ml-1this compound 
downregulated the quorum-sensing system regulators agrA, RNAIII, and sarA, and the gene 
ica (Chen et al., 2016). Choi et al., (2015) showed that the ethanolic extract of Artemisia 
princeps significantly down-regulated agrA, and sarA, expression by MRSA at the 
concentrations higher than 1mg ml-1 (Choi et al., 2015).  
The variation of activity of PUFAs on gene regulation could be dependent on the 
study strain or the concentration of PUFA used. This study just looks at two global genes and 
the ica gene at 6h and 12 h, and expression changes have only been assessed at the transcript 
level (not protein level changes). So, the actual overall effect requires clarification. Changes 
in agrA and sarA transcription does not fully explain the reduced virulence in vivo. It is 
important to consider the wide network of global regulator genes and other virulence 
regulators involved in the pathogenicity of S. aureus. For example sarU, sarX, codY, mgrA, 
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and sigB (Junecko et al., 2012; Lauderdale et al., 2009) that have a direct or indirect effect on 
the agr, sarA and icaA, that all play role for S. aureus infection. Although, it is widely 
reported and accepted that PUFA compounds could be used to treat S. aureus infections. The 
effects of the inhibitory concentrations of PUFAs on S. aureus infection need more 
assessment by looking to other genes regulators and to look for the activity of EPA and both 
mixture of these compound at different time point.  
Furthermore, it is important to consider the effect of sustained exposure to PUFAs on 
S. aureus isolates and to evaluate the effect on susceptibility and cross-resistance profiles as 
well as any effect on virulence. 
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Chapter Six 
 
Effects of sustained exposure to PUFAs and 
clinically relevant antibiotics on S. aureus resistance 
profiles and virulence. 
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Chapter 6 Effects of sustained exposure to PUFAs and clinically 
relevant antibiotics on S. aureus resistance profiles and 
virulence. 
 
6.1 Introduction 
Bacterial antibiotic resistance has become one of the greatest threats to public health 
throughout the world. According to the World Health Organisation, antibiotic resistant 
infections could claim at least 50,000 lives across the US and Europe each year, and that by 
2050 antibiotic resistance could account for 10 million deaths per year (O’Neill, 2014). 
Treatment of infections, such as in chronic wound infection, is further complicated due to 
their polymicrobial nature, biofilm formation and the prevalence of horizontal gene transfer 
(HGT). As a result, many wound-associated bacteria become multi-drug resistant (MDR). 
These bacteria have developed a diversity of mechanisms to overcome and survive 
environmental stresses posed by antibiotics and spread their resistance genes. Adaptation to 
antibiotics can be partly evidenced by comparing the genomes of resistant and sensitive 
strains. For instance, many strains of S. aureus have acquired resistance via external genetic 
transfer of the mecA gene that encodes an alternative penicillin-binding protein (PBP), 
conferring methicillin resistance (MRSA).  Other resistance mechanisms can occur by 
mutations. For example, modifications of antibiotic target sites such as domain V of the 23S 
rRNA subunit, and/or the ribosomal proteins L3 and L4 rplC and rplD, interfering with 
linezolid binding, hence encoding resistance (Munita & Arias, 2016).  
Development of resistance by mutation can be a stepwise and transient process in 
response to prolonged exposure to sub-inhibitory concentrations of antibiotics.  Stress 
responses such as reduced porin channel or increased efflux pump expression, can limit the 
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concentration of antibiotics at the target site and allow for the further development of 
resistance mechanisms (Pagès et al., 2008). The ability of bacteria to survive under treatment 
without developing resistance is called tolerance, which is a transient, non-heritable 
phenotype. A slow or non-growing tolerance phenotype can enable the bacteria to adapt and 
survive most bacteriocidal agents, which require active growth for action. Many reports have 
shown that interrupted antibiotic treatment leads to tolerance which could accelerate the 
evolution of antibiotic resistance (Fridman et al., 2014; Haaber et al., 2015; Novak et al., 
1999). For example, Habber el. al., (2015) revealed that when S. aureus strain USA300 was 
exposed to sub-inhibitory concentrations of colistin, a 50% increase in the vancomycin 
resistance was observed (MIC increase from 1.1 to 1.6 g ml-1). Colistin was found to induce a 
reversible tolerance to vancomycin action by reducing cell wall thickness, altered cell wall 
surface charge, and altered gene expression (Haaber et al., 2015). Others have shown that 
staphylococcal biofilm formation and density increased following pre-exposure to sub-
inhibitory concentrations of antibiotics, enhancing antibiotic tolerance (Felden & Cattoir, 
2018; Kaplan et al., 2012; Levin-Reisman et al., 2017). Adaptive responses have also been 
reported during treatment of S. epidermidis biofilms with sub-inhibitory concentrations of 
vancomycin. A two-fold increase in abundance of eDNA was observed, which has a strong 
binding affinity for vancomycin, preventing its access to the cells encased in the biofilm 
matrix (Hall & Mah, 2017). 
The global burden of multi-drug resistant bacterial infections has reached a critical 
point. Although effective new anti-bacterial therapies are dripping through the pipeline, 
resistant clinical isolates are usually reported shortly after their introduction. So far, this study 
has demonstrated the antibacterial activity of PUFAs and quantified their effective MICs in 
vitro and under more realistic conditions using an in vivo invertebrate model and ex-vivo skin 
model. PUFAs did not show any toxicity in the G. mellonella model. Furthermore, other 
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studies have shown that PUFAs can be used in humans from up to 200 µM. For instance, 
PUFAs have been shown to enhance cancer cell sensitivity to chemotherapy and radiation, 
and DHA and EPA concentration of 25–100 µM did not inhibit the growth of fibroblasts cells 
(Zajdel et al., 2015). Moreover, DHA and EPA have been shown to exhibit no cytotoxicity 
on human oral tissue cells when used at concentrations of 100 - 200 mM (Sun et al., 2016). 
However, little is known about the potential for bacteria to adapt to PUFAs and develop 
resistance and what effects this might have on virulence in vivo.  
Clinical surveillance and experimental evolution approaches have demonstrated the 
rate at which bacteria can adapt to stresses such as antibiotics. For example, Latimer et. al., 
(2012) demonstrated that during exposure of S. aureus 6538 to concentration gradients of 
triclosan, the phenotypic growth showed Small-Colony Variant (SCV) and significant 
reduction in biofilm formation capacity, and reduction in virulence factors such as coagulase, 
DNase, haemolysin, and attenuated virulence in the G. mellonella model of infection 
(Latimer et al., 2012). Others have reported reduced coagulase production when S. aureus 
was exposed to sub-inhibitory concentrations of roxithromycin, while cefalexin induced 
biofilm formation at a wide range of sub-inhibitory concentrations (Haddadin et al., 2010). 
Another recent study used the Hollow Fiber Infection model and showed that exposure of 
USA300 to lower vancomycin concentrations (0.5 - 4 g every 12h regimen) resulted in 
reduced expression of the global gene regulator agr genes. These genes have been shown to 
coordinate S. aureus virulence and reduced expression enhanced survival rate of infected G. 
mellonella larvae. In addition, as the exposure concentration of vancomycin increased the 
MICs of daptomycin and telavancin also increased, suggesting cross-resistance. Conversely, 
the bactericidal effects of Vancomycin (4 g every 12h regimen) suppressed vancomycin 
resistance and did not significantly alter the survival rate of G. mellonella model (Lenhard et 
al., 2016). 
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This study adopted an experimental evolution approach to investigate the ability of S. 
aureus SA3 to adapt to continuous exposure to PUFAs compared to antibiotics and to assess 
the effects on virulence using the G. mellonella model. 
 
6.2 Altered resistance profiles following prolonged exposure to sub-inhibitory 
concentrations of PUFAs and antibiotics. 
Following extended exposure of SA3 to sub-inhibitory concentrations of PUFA 
compounds (DHA and EPA) and antibiotics (vancomycin and linezolid), changes in 
resistance profiles were assessed. Notable differences in resistance profiles of evolved strains 
were observed compared to the parent SA3 strain (Table 6.1). The DHA and EPA-evolved 
strains (SA3-DHA, and SA3-DHA), tested after 14 passages in sub-inhibitory DHA or EPA, 
exhibited no reduced susceptibility to EPA, but surprisingly, a slight increase in susceptibility 
to DHA (MIC change from 65 to 39 µg ml-1) and linezolid (MIC change from 3.9 to 1.9 µg 
ml-1). Furthermore, both evolved strains were considerably more sensitive to vancomycin. 
SA3-DHA was 23 x more sensitive (MIC change from 0.093 to 0.0039) and SA3-EPA was 
13x more sensitive (MIC change from 0.093 to 0.007).  
Interestingly, the linezolid adapted strain (SA3-LZD) became more sensitive to 
inhibition by DHA (MIC reduced from 65 – 19.5 µg ml-1), but not to EPA after 5 passages in 
sub-inhibitory concentrations of linezolid. Conversely, SA3-LZD was found to have 
developed increased resistance to linezolid (MIC increased 8-fold from 3.9 – 31.2 µg ml-1). 
Moreover, there was slight increased resistance to vancomycin (MIC increased from 0.093 to 
0.12 µg ml-1). A similar phenomenon was observed for the vancomycin-evolved strain (SA3-
VAN) after 8 passages in sun-inhibitory concentrations of vancomycin. No significant change 
in sensitivity to PUFAs was observed, but a considerable increase in cross-resistance to both 
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linezolid (4 fold) and vancomycin (2.7 fold) was evident. Surprisingly, SA3-VAN showed a 
bigger increase in resistance to linezolid (MIC increased from 3.9 – 15.6 µg ml-1) than to 
vancomycin (MIC increased from 0.093 – 0.25 µg ml-1). 
 
Table 6.1 Sensitivity of SA3 to bacteriostatic effects of PUFAs and antibiotics 
following sustained exposure to sub-inhibitory concentrations. 
Strain  DHA EPA DHA 
+EPA 
LZD VAN 
Parent SA3 65 78 65 3.9 0.093 
Adapted SA3-DHA 
(passage 14) 
39 78 65 1.9 0.0039 
Adapted SA3-EPA 
(passage 14) 
39 78 65 1.9 0.007 
Adapted SA3-
DHA+EPA (passage 
14) 
39 65 65 1.9 0.015 
Adapted SA3-LZD 
(passage 5) 
19.5 78 65 31.2 0.12 
Adapted SA-VAN 
(passage 8) 
39 65 65 15.6 0.25 
Colours indicate extent of decreased (blue) or increased (green) resistance to bactericidal 
effect of each agent. Deeper colours indicate more pronounced change in MIC. Parent 
phenotypes are shaded in grey and white cells indicate no change from parent phenotype.  
 
The DHA and EPA-evolved strains (SA3-DHA, and SA3-DHA) exhibited 2-fold 
increased susceptibility to killing by both PUFAs (MBC change from 520 to 260 µg ml-1 
DHA and 312 µg ml-1). SA3-DHA also showed increased sensitivity to killing by linezolid, 
but SA3-EPA did not. Both evolved strains were considerably more sensitive to killing by 
vancomycin. SA3-DHA was 23 x more sensitive (MIC change from 1 to 0.062).  
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Again, the linezolid adapted SA3-LZD was observed to have become more sensitive 
to killing by DHA (MBC reduced from 520 – 78 µg ml-1), but not to EPA. This contrasted 
with a 4-fold increase in resistance of SA3-LZD to killing by both linezolid and vancomycin 
(MBC increased from 31.2 – 125 µg ml-1 linezolid and from 1 to 4.1 µg ml-1 vancomycin). 
Interestingly, the vancomycin-evolved strain (SA3-VAN) was somewhat sensitized to killing 
by DHA (MBC decrease from 512 to 156 µg ml-1), but not EPA. A 2-fold increase in cross-
resistance to linezolid killing activity was observed. Surprisingly, no change was observed in 
sensitivity of SA3-VAN to killing by vancomycin.  
 
Table 6.2 Sensitivity of SA3 to bactericidal effects of PUFAs and antibiotics following 
sustained exposure to sub-inhibitory concentrations. 
Strain  DHA EPA DHA +EPA LZD VAN 
Parent SA3 520 520 625 31.2 1 
Adapted SA3-DHA 
(passage 14) 
260 312 260 15.6 0.062 
Adapted SA3-EPA 
(passage 14) 
312 312 312 31.2 0.062 
Adapted SA3 
DHA+EPA(passage 14) 
260 260 260 31.2 0.062 
Adapted SA3-LZD 
(passage 5) 
78 312 260 125 4.1 
Adapted SA-VAN 
(passage 8) 
156 260 312 62.5 1 
Colours indicate extent of decreased (blue) or increased (green) resistance to bacteriocidal 
effect of each agent. Deeper colours indicate more pronounced change in MBC. Parent 
phenotypes are shaded in grey and white cells indicate no change from parent phenotype.  
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6.3 Changes in tolerance levels of SA3 evolved with prolonged exposure to sub-
inhibitory concentrations of PUFAs or antibiotics. 
According to the ratio MBC/MIC, SA3 that had been exposed to prolonged sub-
inhibitory levels of PUFAs or antibiotics showed stable or slightly reduced tolerance to DHA 
(ratios 8 - 6.6). However, a slightly more marked reduction in tolerance to EPA was 
observed, with rations reducing from 6.6 to 4 (Table 6.3). Conversely SA3 tolerance to 
antibiotics was increased following pre-exposure to PUFAs (ratios ranging from 8 to 16.4) 
but decreased following pre-exposure to antibiotics (ratios ranging from 4 – 0.5). A reduced 
tolerance value suggests that the evolved strain had become more able to grow but less able 
to resist killing by the antimicrobial agent. 
 
Table 6.3 Antimicrobial tolerance of SA3 to PUFAs and antibiotics  
Strain  DHA EPA DHA +EPA LZD VAN 
Parent SA3 8 6.6 8 8 10.7 
Adapted SA3-DHA 
(passage 14) 
6.6 4 4 8.2 15.9 
Adapted SA3-EPA 
(passage 14) 
8 4 4.8 16.4 8.8 
Adapted SA3-
DHA+EPA (passage 14) 
6.6 4 4 16.4 4.1 
Adapted SA3-LZD 
(passage 5) 
4 4 4 4 0.5 
Adapted SA-VAN 
(passage 8) 
4 4 4.8 4 4 
Tolerance = ratio of MBC/MIC *higher value = increased tolerance. Colours indicate extent 
of decreased (blue) or increased (green) tolerance to each agent. Deeper colours indicate 
more pronounced change in tolerance. Parent phenotypes are shaded in grey and white cells 
indicate no change from parent phenotype.  
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In summary, SA3 did not show any notable capacity to develop resistance or tolerance 
to PUFAs, which in turn were able to sensitize SA3 to antibiotics, particularly linezolid. By 
contrast, SA3 showed rapid development of resistance to linezolid and vancomycin, but 
generally no change in sensitivity to PUFAs. However, long-term exposure to linezolid 
resulted in slightly increased susceptibility to DHA only. 
 
 
6.3.1 Detection of Cross-resistance: 
Given the reduced sensitivity of SA3 following sustained exposure to antibiotics. This 
study used Kirby Bauer disk diffusion assays to investigate whether any cross-resistance had 
also developed to other antibiotics (Table 6.4). The antibiotic adapted strains (SA3-LZD and 
SA3-VAN) showed little change in susceptibility to most other tested antibiotics compared to 
the parent. However, a marked difference in sensitivities of the vancomycin adapted strain 
was observed for lincomycin, and erythromycin but not tetracycline. PUFA adapted strains 
showed no notable change in sensitivity to gentamycin, tobramycin, cefoxitin, vancomycin, 
oxazolidine or ciprofloxacin (despite small fluctuations in size of zones of inhibition). 
However, a marked difference in sensitivities was observed for lincomycin, erythromycin and 
tetracycline. For example, according to EUCAST guidelines, the SA3 parent was considered 
sensitive to lincomycin, with a zone of inhibition of 21mm diameter. This sensitivity did not 
change following prolonged exposure to linezolid (SA-LZD). However, SA3-DHA, SA3-
EPA and SA3-VAN showed reduced sensitivity and were considered resistant, with zones of 
inhibition measuring 13, 14- and 12-mm diameter respectively. The same phenomenon was 
observed with respect to sensitivities to erythromycin. Conversely, all adapted strains became 
considerably more sensitive to tetracycline compared to the parent SA3 (zones of inhibition 
increasing from 7 to 21-27 mm diameter). 
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Table 6.4 Antibiotics sensitivity test of SA3 after prolonged exposure to sub-inhibitory concentrations of PUFAs or antibiotics 
 
 
Antibiotics Disks (µg)  Aminoglycoside 
β-lactam Glycopepti
des 
Lincos-
amides 
Macrol-
ides 
Oxazoli
dine Quinolone Tetracycline 
A
d
a
p
ti
o
n
 o
f 
S
. 
a
u
re
u
s 
(S
A
3
) 
Strains 
C
N
 1
0
  
T
O
B
 1
0
  
F
O
X
 3
0
 
V
A
N
 5
  
M
Y
 2
  
E
 1
5
  
L
Z
D
 1
0
 
C
IP
 5
  
T
E
 3
0
  
Parent SA3 S (25) S (23) R (10) S (25) S (21) S (19) S (24) S (23) R (7) 
Adapted DHA SA 3  S (20) S (24) R (15) S (15) R (13) R (12) S (24) S (25) S (25) 
Adapted EPA SA3  S (22) S (25) R (11) S (14) R (14) R (13) S (21) S (22) S (26) 
Adapted EPA+DHA SA3 S (23) S (24) R (13) S (14) R (16) R (15) S (24) S (28) S (27) 
Adapted Linezolid 32µgml-1 
SA3  
S (19) S (21) 
S (25) R (10) 
S (24) S (22) 
R (11) 
S (27) S (22) 
Adapted Vancomycin 
0.25µgml-1 SA3 
S (20) S (24) 
S (26) R (9) 
R (12) R (10) 
R (14) 
S (26) S (21) 
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6.5 Quantification of biofilm formation by adapted SA3 strains 
RT-PCR data from chapter 5 of this study suggest that exposure to PUFAs can affect 
the expression of global regulators and genes associated with biofilm formation. Since 
prolonged exposure to PUFAs has affected resistance phenotypes, it was hypothesised that 
the PUFAs may also drive changes in biofilm forming capacity. Standard crystal violet assays 
in micro-titre plates were used to compare the biofilm densities of parent and adapted SA3 
within 24 h and 48 h. Biofilm density readings OD600 indicated that all adapted strains of SA3 
had 3-fold reduced capacity to form biofilms compared to parent SA3 (Figure 6.1). The mean 
OD600 of 24 h biofilms produced by adapted strains ranged from 0.14 to 0.31 (Table of P-
valuedata are supplemented in appendices). In all cases, adapted strains showed a decreased 
capacity to form biofilms. Biofilms formed by the vancomycin adapted strain were denser 
than those formed by the other adapted strains, but still 2-fold reduction compared to the 
parent SA3. 
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Figure 6.1 Quantification of biofilm formation by adapted SA3 compared to parent. The 
crystal violet microtiter plate assay was used to quantify biofilm density after 24h and 48 h. 
Un-inoculated, sterile LB was used as a negative control. The values are plotted as mean ± 
SD obtained from three representative experiments performed in triplicate. By using unpaired 
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t test data showed statically significant with all strains compared to Parent SA3, the statically 
table are in appendices (table S 7 chapter 6).  
 
6.4 Effect of prolonged exposure to PUFAs and antibiotics on susceptibility of SA3 
biofilms to inhibition and disruption 
Minimum biofilm inhibitory concentration (MBIC) and the minimum biofilm 
eradication concentration (MBEC) assays were used to quantify the ability of PUFAs and 
antibiotics to disrupt biofilm formation by adapted strains that were pre-exposed to sequential 
sub-inhibitory concentrations of each agent (Figure 6.2). In all cases, biofilm formation by 
adapted strains was much more readily inhibited and disrupted compared to the parent SA3 
(data for parent shown in chapter 3). Antibiotics were clearly the most effective biofilm 
inhibitors and disrupters. Vancomycin inhibited biofilm formation by the parent SA3 at 
MBIC 2 µg ml-1 but adapted strain biofilms were inhibited with much lower MBICs between 
0.019 and 0.0048 µg ml-1. Linezolid was less efficient than vancomycin at inhibiting biofilms 
formed by parent (MBIC 32 µg ml-1) and adapted strains (MBIC ranging from 0.97 to 3.9 µg 
ml-1). PUFAs were also more effective at inhibiting biofilms formed by adapted strains 
compared to the parent. The mean MBIC of DHA was between 6.1- 24.4 µg ml-1 for adapted 
strains compared to 256 µg ml-1for the parent SA3. The same was observed for EPA 
inhibition of biofilm formation by adapted strains, although it was less effective than DHA. 
The mean MBIC of EPA was 48.8- 97.7 µg ml-1 for adapted strains, compared to 384 µg ml-1 
for the parent SA3.  
MBEC assays were used to measure the eradication of biofilms formed around pegs 
after recovery in 96 wells plates. As shown in chapter 3, the concentrations required to 
disrupt biofilms (MBEC) were much higher than those required to inhibit biofilm formation 
(MBIC). The MBEC of vancomycin for adapted strains was between 0.125 and 0.5 µg ml-1; 
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considerably higher than the MBIC (0.08 - 0.125 µg ml-1), but at least 16 x lower than the 
MBEC for parent SA3 (8 µg ml-1). Again, linezolid was a less potent biofilm disrupter, with a 
MBECs of between 3.9 and 15.6 µg ml-1 compared to MBICs ranging from 0.97 to 3.9 µg 
ml-1 for adapted strains. A much higher MBEC of 128 µg ml-1 was required to disrupt parent 
SA3 biofilms.  As expected, higher MBECs of PUFA compounds were needed to disrupt 
biofilms compared to antibiotics. MBECs of DHA and EPA ranged between 24.4 and 97.7 µg 
ml-1 to disrupt biofilms formed by evolved strains.  
It should be noted that the evolved SA3 variants showed reduced ability to form 
biofilms that were much less dense than the parent SA3 biofilms after 24 and 48 h. This may 
explain why lower concentrations of PUFAs and antibiotics were needed to inhibit their 
growth or disrupt them.  
 
152 
 
Pa
re
nt
 S
A
 3
A
da
pt
ed
 D
H
A
 S
A
 3
 
A
da
pt
ed
 E
PA
 S
A
3 
A
da
pt
ed
 D
H
A
+ 
E
PA
 S
A
3 
A
da
pt
ed
 L
in
ez
ol
id
 S
A
3 
A
da
pt
ed
 V
an
co
m
yc
in
 S
A
3 
0.0625
0.25
1
4
16
64
256
1024
O
D
 6
0
0
A- MBIC assay for adapted SA3 strains
DHA
EPA
DHA +EPA
LZD
 VAN
Pa
re
nt
 S
A
3
A
da
pt
ed
 D
H
A
 S
A
 3
 
A
da
pt
ed
 E
PA
 S
A
3 
A
da
pt
ed
 D
H
A
+ 
EP
A
 S
A
3 
A
da
pt
ed
 L
in
ez
ol
id
 S
A
3 
A
da
pt
ed
 V
an
co
m
yc
in
 S
A
3 
0.0625
0.25
1
4
16
64
256
1024
O
D
 6
0
0
DHA
EPA
DHA+EPA
 LZD
VAN
B- MBEC assay for adapted SA3 strains
 
Figure 6.2 Susceptibility of evolved SA3 biofilms to PUFA and antibiotic compounds.  A) Minimum biofilm inhibitory concentration 
(MBIC). B) Minimum biofilm eradication concentration (MBEC). Statistically significant reductions were found in biofilm production 
according to the t-test (GraphPad v8). The multiple comparison data using unpaired test showed that No difference between all MBICS 
VS all MBECS P value= 0.3568, significant VAN MBICs vs All other MBICs =0.0467, significant VAN MBECs vs All other MBICs= 
0.0476, significant LZD MBICs vs all PUFA MBICs= 0.0091, significant LZD MBECs vs all PUFA MBECs= 0.0320, significant DHA 
MBICs vs EPA MBICs= 0.0020, No significant DHA MBECs vs EPA MBECs= 0.4113.The statically table are in appendices (table S 8 
chapter 6) 
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6.5 Effect of prolonged exposure to PUFAs and antibiotics on virulence of SA3 in the G. 
mellonella in vivo model of infection. 
Since biofilm formation and expression of global gene regulators are affected by PUFA 
compounds, this study investigated whether prolonged exposure to sub-inhibitory concentrations of 
PUFAs would also affect S. aureus virulence. This would be a desired effect for an ideal 
therapeutic. Virulence was determined by observing survival of G. mellonella infected with parent 
and PUFA-evolved variants (SA3-adaptes DHA and SA3-adapted EPA and SA3-adapted 
DHA+EPA), compared to the virulence of antibiotic-evolved variants (SA3-adaptedLZD and SA3-
adaapted VAN) and infection controls (PBS and mock-infected) (Table S 6 chapter6 in appendices). 
G. mellonella larvae were incubated in dark at 37oC for 7 days.  
The survival rate of each group is shown (Figure 6.3). The parent SA3 control group 
remained the most virulent strain, killing 6 larvae in the first 48 h then approximarely two larvae 
each day after that with 93% of all larvae killed within 7 days (6% survival). The DHA-evolved 
variant (SA3-DHA) had reduced virulence compared to the parent. All larvae in this group (16/16) 
survived for the first 5 days, and on day 7, 12/16 larvae (75%) had survived. The EPA-evolved 
variant was more virulent than SA3-DHA, with a survival rate of 63%. Two larvae died after 72 h 
then approximately one larvae died each day until day 7. Similarly, both compound DHA+ EPA 
had evolved variant more a bit virulent with a survival rate of 50%. Two larvae died after 72 h then 
approximately two larvae died each day until day 7. The infection experiments were repeated 3 
times and there was slight variation in number of larvae that died each day, but all experiments 
followed the same trend (Table S 6 chapter6 in appendices). 
The virulence of PUFA-evolved variants was compared to that of SA3 that had been 
exposed to prolonged sub-inhibitory linezolid (SA3-LZD) or vancomycin (SA3-VAN). In both 
cases, the survival rate if the infected G. mellonella larvae was 81% and 88% respectively. One 
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larva died 48 h after being infected with SA3-LZD, then a second died on day 6 and a 3rd on day 7 
(81% survival). The SA3-Van infection took longer to show any effect, killing 1 larva on day 5 then 
a second on day 7 (88% survival). No larvae in the negative control groups were observed to die 
during the 7-day experiment. 
These results demonstrate that, although S. aureus SA3 showed significant virulence in the 
G. mellonella model, sub-inhibitory concentrations of PUFA compounds and antibiotics (LZD and 
VAN) had driven a reduction in virulence. It is possible that the reduced virulence is due to serial 
passage in media, and not specifically driven by the antimicrobial agents. However, the different 
levels of virulence demonstrated by each evolved variant, and consistently across three repeat 
experiments, suggests that the may have been an agent-specific effect.  
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Figure 6.3 Survival of G. mellonella following challenge with PUFA and Antibiotics-evolved 
variants of S. aureus SA3. Groups of larvae (n = 16 each group) were injected with either SA3 or a 
variant that had been passaged (x 14) in sub-inhibitory PUFAS (SA3-DHA, SA3-EPA and both 
SA3 DHA+EPA) or antibiotics (SA3-LZD – 5 passages and SA3-VAN – 8 passages). Experimental 
controls included the PBS control group (n=16), and uninfected larvae (n=16). The figure shows 
example data chosen from 3 experimental replicates. Survival analysis was done using log-rank 
Mantel-Cox test in Graph Pad prismV8. Parent SA3 vs SA3 adapted DHA significant P = <0.0001; 
Parent SA3 vs SA3 adapted EPA significant P =0.0002; Parent SA3 vs SA3 adapted DHA+ EPA 
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significant P =0.0017; Parent SA3 vs SA3 adapted LZD significant P = < 0.0001, and Parent SA3 
vs SA3 adapted VAN significant P = < 0.0001. 
 
 
6.6 Quantification of viable bacterial cells recovered from G. mellonella lethally infected with 
evolved and parent SA3. 
Bacteria were recovered from each infected G. mellonella at time of death and numbers 
were compared to the initial inoculum (5 x105 - 8x 105 CFU ml-1). The results are summarised 
(Figure 6.4). The parent S. aureus strain SA3 was the most virulent and “fit” compared to the 
evolved strains. SA3 was recovered at densities between 4.6 x 108 - 1.1x1010 CFU ml-1, a 100-fold 
increase in viable cell numbers compared to the initial inoculum. SA3-DHA killed just four of the 
larvae during the experiment. Between 2.8 x 107 and 6.8 x108 CFU ml-1 of this variant were 
recovered, while between 2.1 x 108 and 1.2 x109 CFU ml-1 SA3-EPA were recovered (10 fold less 
than SA3 parent). In addition, SA3 DHA+EPA 8/16 larvae killed about 50 %, between 3.2 x 108 
and 1.0 x109 CFU ml-1. Similarly, significant growth of the antibiotics-evolved variants was 
observed in vivo with 6.5 x 108 - 3.1x109 CFU ml-1 SA3-LZD and 9.9 x 108 - 3.7x109 CFU ml-1. 
Recovered from the SA-VAN infected group. 
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Figure 6.4 Recovery of viable bacteria from G. mellonella post infection with parent SA3 and 
variants evolved in the presence of PUFAs or antibiotics (LZD or VAN). Larvae (n=16) were 
injected with parent or evolved variants. Negative controls included injection with PBS (n=16), and 
uninfected larvae (n=16). Each dot represents viable bacteria recovered from each dead larva. Initial 
inoculum of SA3, and the recovery from adapted DHA, adapted EPA, adapted DHA+EPA, adapted 
LZD, and adapted VAN. Mean CFU and standard deviation values are shown from three 
independent experiments. There are no statistically significant (P < 0.135) and even though 
bacterial numbers are the same – there is still a difference in larvae survival thus suggesting 
differences in virulence. 
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6.7 Effect of prolonged exposure to PUFAs and antibiotics on coagulase activity of SA3 
Coagulase activity of SA3 parent and evolved variants was examined periodically over 24 h 
(1, 2, 4, and 24 h) at 37°C incubation. Formation of a complete clot that stayed in place when the 
assay tube was tilted or inverted was considered positive for coagulase activity. Clot formation was 
observed in all strains within 24 h (Table 6.5). The parent SA3 had the strongest coagulase activity, 
causing full clotting within 1 h. By comparison, all evolved variants had weaker coagulase activity, 
only causing partial clotting within the first hour, and then a gradual increase in clotting, which was 
only complete after 24h.  
 
Table 6.5 Coagulase activity of S. aureusSA3 and PUFA or antibiotics-evolved variants 
Time (h) Coagulase activity of strains 
 Parent 
SA3 
Adapted 
DHA 
Adapted 
EPA 
Adapted 
DHA+EPA 
Adapted 
LZD 
Adapted 
VAN 
1 ++++ + ++ ++ ++ + 
2 ++++ ++ ++ ++ ++ ++ 
4 ++++ ++ +++ +++ +++ ++ 
24 ++++ +++ ++++ ++++ ++++ +++ 
>75% coagulase +ve, coagulase Negative: No clot (plasma remains wholly liquid). Data represents 
the mean of triplicate experiments with H2O as a negative control 
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6.8 Effect of prolonged exposure to PUFAs and antibiotics on haemolytic activity of SA3 
The ability of SA3 to lyse erythrocytes was investigated compared to evolved variants. The 
haemolysin assay measured the release of haemoglobin by lysed horse blood erythrocytes in the 
supernatant. The parent SA3 showed the strongest haemolysin activity, and SA3-DHA had the 
weakest haemolysin activity (Figure 6.3). T-test analysis identified a significant difference in 
reduction of haemolytic activity compared to the Parent SA3.  
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Figure 6.5 Haemolytic test of S. aureus SA3 and evolved variants. Cultures were incubated 
with horse blood and haemolytic activity was measured after 1 hour of incubation (n = 3). 
Data are expressed as mean value by using GraphPad prismV8 un paired t test showed that all 
adaption strain compared Parent SA3 are statically difference and the P value = < 0.002  
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6.9 Effect of prolonged exposure to PUFAs and antibiotics on DNase activity of SA3 
The activity of DNase was detected by culturing SA3 and evolved strains on DNase 
detection agar, which changes colour on addition of HCl in the presence of the degraded DNA. This 
assay indicated that the parent SA3 had much more DNase activity than evolved variants (mean 
zone diameter, 22 ± 0.50 cm). The PUFA-evolved variants had almost a 50% reduced activity 
(mean zone diameter 12 ± 0.50 cm), and the antibiotics-evolved variants had lost even more DNase 
activity. SA3-VAN produced a mean zone diameter, 11 ± 0.55 cm and SA3-LZD produced a mean 
zone diameter, 8 ± 0.53 cm. Data are presented in Figure 6.4. 
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Figure 6.6 DNase activity in mm of S. aureus SA3 and evolved strains: DNase activity 
measured by comparing clearing zone diameters (mm) after 24 h incubation. The mean and 
standard divisions are shown from triplicate experiments. 
Reduced coagulase, haemolysin and DNase activity of evolved variants could, in part, explain their 
reduced virulence in vivo.  
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6.10 Whole genome sequencing to investigate the genetic basis for altered resistance and 
virulence phenotypes after exposure to prolonged sub-inhibitory concentrations of 
antimicrobials 
 
This study has identified differences in resistance and virulence profiles of the S. aureus 
clinical wound isolate (SA3), when it was evolved in sub-inhibitory concentrations of PUFA 
compounds and antibiotics (linezolid or vancomycin). It is likely that these changes have resulted 
from 1) genetic mutations in key genes that have been selected for by the presence of stressful 
conditions. 2) a biochemical effect (incorporation of PUFAs into bacterial membranes, affecting 
function) or 3) stress responses that lead to differential expression of key resistance and virulence 
determinants. 
To investigate the likelihood of genetic mutations as drivers of observed phenotypic 
changes, the whole genomes of parent SA3, and each evolved strain, were sequenced by Microbes 
NG University of Birmingham. Raw sequence reads were assembled, annotated and compared by 
Dr Ian Goodhead (University of Salford). Single-nucleotide polymorphisms (SNPs) in evolved 
strains compared to parent SA3, were detected using “Snippy” and “Free-bayes bioinformatics 
analysis software tools. This program identified synonymous (silent) and nonsynonymous 
(missense or nonsense) SNPs. Synonymous mutations do not change the encoded amino acid but a 
change in general the DNA sequence, while nonsynonymous SNPs do change the amino acid 
sequence, more likely resulting of differences in the encoding protein function. The 
nonsynonymous SNPs consist of two types of mutation, missense and nonsense mutation.  
This study focussed on missense and nonsense mutations, since they are more likely to confer a 
functional effect (Table 6.6). 
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Table 6.6 Non-synonymous SNPs in evolved genomes compared to parent SA3  
Shaded cells indicate SNP compared to parent. Red letters indicate non-sense mutations. Full details 
of amino acid changes are shown in a more detailed table in appendix Table S9 
nt SA3 DHA EPA PUFA LZD VAN GENE PRODUCT 
119633 C C C T C C odh Opine dehydrogenase 
406314 G G G G G A isaA putative transglycosylase IsaA 
precursor 
467840 C C C C A T clfB Clumping factor B precursor 
467843 A A A A G T clfB Clumping factor B precursor 
467948 C C C C C G clfB Clumping factor B precursor 
467984 C C C C G C clfB Clumping factor B precursor 
467987 A A A A G A clfB Clumping factor B precursor 
468531 C C C C C T clfB Clumping factor B precursor 
504148 C C C C A C SecY preprotein translocase subunit  
589448 C C C T C C walR Transcriptional regulatory protein WalR 
14541 C C C C C G yabJ Enamine/imine deaminase 
110532 C C T C C T oppC Oligopeptide transport system permease  
68847 C T C C C C treR_1 Trehalose operon transcriptional 
repressor 
68898 C C T C C T treR_1 Trehalose operon transcriptional 
repressor 
84890 G G G A G G ywqD_1 Tyrosine-protein kinase YwqD 
87768 A A A A A G pglF UDP-N-acetyl-α-D-glucosamine C6 
dehydratase 
87205 C G C C C C pglF UDP-N-acetyl-alpha-D-glucosamine C6 
dehydratase 
124672 G G T G G T rocD2_1 Ornithine aminotransferase 2 
256455 G G G G T G yezG_3 putative antitoxin YezG 
365873 G G G G T G speC_2 Exotoxin type C precursor 
146542 C C C C C G cymR HTH-type transcriptional regulator 
CymR 
151383 G G A G G A hisS Histidine--tRNA ligase 
308293 T T T T T A ribD Riboflavin biosynthesis protein RibD 
7614 G G G G A G sarA Transcriptional regulator SarA 
39605 G G A G G A feuC_1 Iron-uptake system permease protein 
FeuC 
51999 G G G G G T bceB_1 Bacitracin export permease protein 
BceB 
83534 G G G G G A chp Chemotaxis inhibitory protein precursor 
56649 C C A C C C sdrD Ser-asp repeat-containing protein D 
precursor 
56861 G G A G G G sdrD Serine-aspartate repeat-containing 
protein C precursor 
347877 T T T T A T rsmB rRNA small subunit methyltransferase 
B 
  2 7 3 9 15  Total number of non-synonymous 
SNPs 
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A total of 32 missense and 2 nonsense SNP mutations were detected in the genomes of the 
evolved strains compared to the parent SA3 (reference genome). The antibiotics-evolved variants 
had accumulated more SNPS than the PUFA-evolved variants, with most mutations detected in 
SA3-LZD (15 SNPs) followed by SA3-VAN (9 SNPS); SA3-EPA (7 SNPs); SA3-DHA+EPA (3 
SNPs). SA3-DHA carried just 2 SNPs and the other PUFA-evolved variants possessed different 
SNPS. The absence of any strong pattern in variant genomes of the PUFA-evolved strains, suggests 
that the PUFAs did not specifically select for many mutations, which are more likely to be random. 
However, SA3-DHA and SA3-EPA did both harbour a SNP in the same treR_1 gene, which 
encodes a trehalose operon transcriptional repressor. The SA3-DHA mutation occurred at position 
68847 with a C-T substitution converting the glycine to glutamic acid in the protein sequence. The 
SA3-EPA variant SNP (C-T, histidine – arginine) occurred 51 nt up-stream on the same gene (nt 
68898). This mutation was also detected in the SA3-LZD variant genome, suggesting parallel 
evolution. S. aureus are able to produce acid aerobically from trehalose, mutation in the 
transcriptional regulation of this process may affect metabolic flexibility of the pathogen in certain 
environments (Ibarra et al., 2013a).  
Other notable mutations found in the genomes of PUFA-evolved strains include a nonsense 
mutation in pglF (UDP-N-acetyl-α-D-glucosamine C6 dehydratase) of SA3-DHA (also mutated in 
SA3-VAN); the UDP-GlcNAc C6 dehydratase is involved in biosynthesis and production of 
capsular polysaccharides in S. aureus (Li et al., 2014). A missense SNP in hisS which encodes for 
Histidine-tRNA ligase which play significant role in protein biosynthesis and was found in both 
SA3-EPA and SA3-VAN genome; and a feuC_1 (iron uptake) which is siderophores ABC-
transporter and permease enzymes for acquisition of iron during infection, the siderophores 
produced by pathogenic bacteria including S. aureus are critical for their survival and often 
represent virulence factors (Hammer & Skaar, 2011). The feuC gene mutation was found in both 
SA3-EPA and SA3-LZD. Two different SNPs of sdrD were also found in SA3-EPA, the sdrD gene 
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encodea a surface component belonging to a subfamily of the Microbial Surface Components 
Recognizing Adhesive Matrix Molecules (MSCRAMM) and is involved in adhesion to human 
squamous cells (Askarian et al., 2016). Other missense mutations in oppC, rocD2_1, odh, walR, 
and ywqD_1 were only found in single variants. It would be interesting to sequence more isolates 
from these experiments and determine whether these SNPs were conserved in the populations and 
whether they would be maintained in the absence of PUFAs. Of the missense mutations detected in 
the antibiotics-evolved strains, the clfB gene was a SNP hotspot, with 4 mutations in SA3-LZD and 
4 mutations in SA3-VAN, none of which were shared by any of the variants. This gene encodes a 
clumping factor B precursor which is a staphylococcal surface adhesin for the attachment to the 
anterior nares during colonisation (Sakr et al., 2018). Furthermore, ClfB has high affinity to bind to 
cytokeratin 10 and plasma fibrinogen (Walsh et al., 2004), which is the dominant component of the 
interior of squamous cells and binds loricrin which is the most abundant protein of the cornified 
envelope of squames (Mulcahy et al., 2012). 
Exposure to linezolid produced the most SNPs, none of which were shared with SA3-VAN. 
Of note, there was a mutation in the speC_2 gene, which encodes for Exotoxin Type C which is 
likely to be involved in virulence. There was also a mutation in the sarA gene, which encodes a 
global transcriptional regulator. Evidence in chapter 5 suggests that both PUFAs and antibiotics also 
affect expression of sarA. A study by Zielinska et al (2012) demonstrate that sarA mutants of S 
aureus USA300 increased production of extracellular proteases and simultaneously promote the 
production of virulence factors, extracellular toxins such as alpha toxin and phenol-soluble 
modulins and reduced biofilm formation (Zielinska et al., 2012). This gene is well known as a 
keystone of S. aureus virulence control, therefore, long-term exposure to PUFAs may disrupt this 
system and reduce virulence. However, more replicate populations would need to be screened to 
determine whether this SNP was driven by linezolid exposure, or just a random mutation. 
.. 
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6.11 Discussion 
The prevalence of antimicrobial resistant strains could seriously limit the ability to treat 
bacterial diseases such as wound infections. In addition, with presence of polymicrobial infection 
and the escalating levels of resistance to linezolid and vancomycin, PUFAs have been reported as 
attractive potential for alternative treatments with no effect on antimicrobial resistance (Desbois and 
Smith, 2010). PUFA compounds such as DHA and EPA have exhibited a comparatively broad 
range of antimicrobial activity and anti-biofilm efficacy against different wound pathogens 
including SA3 (as shown in chapter3). This final chapter focused on the ability of SA3 to adapt to 
sub-inhibitory concentrations of PUFAs and antibiotics (LZD, VAN) and the affect that this would 
have on antibiotic susceptibility and virulence. This was tested using a range of in vitro sensitivity 
and activity assays and the in vivo G. mellonella infection model. Finally, the genetic basis of the 
observed phenotypic changes was investigated by comparing the whole genome sequence of 
evolved variants with the parent SA3. 
Resistance profiles of evolved strains were observed compared to the parent SA3 strain 
following extended exposure to PUFAs and antibiotics. However, the PUFA evolved strains 
exhibited increased sensitivity to Lincomycin and Vancomycin. Interestingly, the linezolid adapted 
strain became more sensitive to inhibition by DHA. Conversely, a marked increase in resistance to 
linezolid and vancomycin was observed for the SA3 that was evolved in the presence of antibiotics. 
In addition, from published studies suspected lack of acquired bacterial resistance mechanisms to 
PUFA has been encountered (Desbois, 2010). Although, this study has shown cross resistance when 
adapted PUFA compound are exposed to antibiotics (LZD or VAN), our serial passage that employ 
sub-inhibitory PUFA concentrations against adapted SA3 strains did not lead to the emergence or 
reduced the susceptibility of these compounds. Further study is required to determine the likelihood 
of resistance development with other clinical stains and species. 
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These observations, of altered susceptibilities after sustained exposure to PUFAs or 
antibiotics, are consistent with the suggestion that it is more difficult to select for resistance against 
PUFAs compounds that exert their antibacterial action by acting on multiple cellular targets and the 
cell membrane. Future investigations will use further adapted bacterial species and strains. 
Biofilm density by each adapted strain was significantly reduced compared to the parent (~3 
fold). Biofilms formed by the vancomycin adapted strain were denser than those formed by the 
other adapted strains, but still showed a 2-fold reduction compared to the parent SA3.MBIC and 
MBEC data suggest that all adapted strains formed weaker biofilms that were much more 
susceptible to disruption.  
The PUFA and antibiotics adapted strains clearly had reduced virulence in G. mellonella 
compared to the parent SA3. The adapted strains also showed reduced fitness, evidenced by a 
significantly reduced number of viable cells recovered from dead G. mellonella larvae. 
Furthermore, a all adapted strains were impaired in production of key virulence traits. SA3-DHA 
and SA3-VAN showed reduced coagulase activity, whilst SA3-DHA, SA3--LZD and SA3- VAN 
showed reduced haemolytic activity and all adapted strains showed reduced DNase activity 
compared to Parent SA3 strain. The present study revealed that sustained exposure to PUFA 
compounds may have important implications for virulence. However, further investigation is 
required to confirm whether these reductions in enzyme production were driven by the compounds, 
or simply by sub-culture in broth in the absence of a host. 
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Chapter 7 General Discussion and Conclusion 
 
There is a major need for novel antimicrobials and anti-inflammatory agents to treat 
complicated wound infections. This study further explores the potential of DHA and EPA; two 
major compounds of n-3 PUFAs that have been shown to have diverse beneficial effects on human 
health, including wound healing (Turk et al., 2013a). The beneficial effects are believed to be 
related to the anti-inflammatory and antimicrobial action of PUFAs (Choi et al., 2013; Dyall, 2015; 
Park et al., 2016). However, not much is known about their mechanisms of action on clinical 
bacterial isolates from wounds. Furthermore, there is little known about the long-term effects of 
PUFA treatment on bacterial populations at wound sites. 
This thesis has worked on the hypothesis that PUFAs areas key alternative antimicrobial and 
antibiofilm treatments for bacterial wound infection, but also have an effect on the virulence of S. 
aureus in vivo. Furthermore, it was important to test PUFA activity under more relevant 
conditions to wound infection and with a clinically relevant wound isolate (SA3). This was 
achieved using an established ex vivo human skin model. This study also aimed to investigate the 
mechanisms of PUFA antimicrobial activity and postulated that PUFAs interfere with global 
virulence gene regulators. Finally, considering the fact that bacteria can rapidly develop resistance, 
this study investigated the effect of long-term exposure to PUFAs vs antibiotics on resistance and 
virulence. It was hypothesised that identification of SNPs in adapted vs parent strain would provide 
clues to explain such phenotypic changes.  
Chapter 3 is an extensive study of antimicrobial and antibiofilm properties of PUFAs on 
common wound pathogens. This research found that DHA and EPA have a broad spectrum of 
bacteriostatic and bacteriocidal activity on wound pathogens. DHA and EPA activity inhibited pre-
formed biofilms and also disrupted biofilm formation. However, this activity could be further 
explored using more sophisticated biofilm models such as in flow cells that support more mature 
168 
biofilm formation. Although PUFAs compounds were less potent inhibitors compared to standard 
antibiotics (vancomycin and linezolid), some clinical S. aureus have been reported to have 
developed resistance. Wound bacteria showed reduced tolerance to PUFAs compared to antibiotics. 
In additions, although a higher concentration of PUFAs is required to inhibit wound pathogens, they 
can be considered non-toxic, and have additional immunomodulatory effects to promote wound 
healing. 
Chapter 4 involved in the study of S. aureus virulence and the antimicrobial properties of 
PUFAs in 2 different models of infection. The clinical S. aureusSA3 isolate was virulent in the G. 
mellonella model to a similar level as MRSA strain 252, killing 87.5% of the larvae within 7 days 
of infection. Furthermore, the PUFAs were found to either hinder growth or kill a proportion of 
SA3 in vivo, but much higher concentrations of PUFAs would be needed to eradicate the infection. 
This might suggest that PUFAs may have more effect on virulence, rather than a cumulative 
bacteriostatic or bacteriocidal effect. Uninfected larvae, that were treated with PUFAs remained 
100% viable, confirming the non-toxic nature of the PUFAs at these concentrations. 
The second infection model aimed to better reflect more realistic wound conditions using a 
novel ex vivo human skin model to assess the activity of DHA. This study validated the use of this 
model to assess the efficacy of novel antimicrobials. The data showed significant reduction of 
bacterial cells on wounded and non-wounded skin biopsies. These data should be compared to other 
topical antibiotics. This model also provides the possibility of exploring host-pathogen interactions, 
by measuring cytokine responses to bacteria with and without treatment. This would be a valuable 
line of research in the future. 
Chapter 5 explored the effects of different concentrations of PUFAs on the expression of 
key target genes involved in global regulation, biofilm formation and virulence. It was hypothesised 
that PUFAs may act as quorum sensing inhibitors, as a novel strategy to treat S aureus infection. 
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Target genes agr A, and sarA were chosen because they are the most common regulatory genes of 
S. aureus used to modulate behaviour in response to changing environmental conditions, including 
antimicrobial agents. Two different concentrations of PUFAs (50 and 100 µgml-1) were chosen 
because they represent sub and ultra- MICs. Each concentration delayed growth during the first 12 
h, but cultures recovered after 24 h. Differential expression of global regulators was observed at all 
concentrations and times. This suggests that PUFAs can disrupt quorum sensing. The adhesin gene 
(icaA) was also affected. Together, these findings may explain the reduced killing activity of SA3 in 
vivo in response to PUFAs. However, further work is needed to confirm the downstream effects of 
gene regulator disruption. A transcriptomics, proteomics or gene knockout approach couldshed light 
on the detailed mechanism of action. 
Disruption of bacterial regulatory networks is an attractive strategy for novel therapeutics. 
Reduction of virulence, and growth rate, would exert less selective pressure than antimicrobial 
killing activity and reduce the likelihood of resistance development. Chapter 6 explored the 
likelihood of resistance development to PUFAs by exposing SA3 to prolonged PUFA treatment 
compared to prolonged treatment with vancomycin and linezolid. The main finding from this 
research confirmed that PUFAs do not easily promote resistance development. In fact, PUFA-
adapted strains showed slightly increased susceptibility to PUFAs and antibiotics. Conversely, 
Antibiotics-adapted strains rapidly developed resistance to vancomycin and linezolid. All adapted 
strains showed reduced virulence, biofilm formation and enzyme production compared to the parent 
SA3. The final stage of this thesis was to investigate the genetic basis of these phenotypic changes. 
Whole genome sequences were compared to identify SNPs in adapted strains. Most non-
synonymous SNPs were found in the linezolid adapted strain, with multiple SNPs located in the 
clumping factor B gene, which may explain reduced virulence. However, these data do not provide 
enough evidence to suggest that PUFAs and antibiotics have driven or selected for these mutations. 
It is possible that they would have occurred randomly anyway through sequential subculture. This 
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experiment would need to be repeated with more replicates and sequencing more members of each 
population. Only when multiple versions of the same SNP are identified, would this suggest that 
PUFAs have driven the adaptation. Furthermore, this analysis only considers genetic mutation and 
does not identify any effect that antimicrobial agents may have on gene expression or biochemical 
surface structure. Further transcriptomic, proteomic and microscopic investigation would be needed 
to explore this. It would also be interesting to analyse the bacteria that were recovered from treated 
and untreated G. mellonella and skin to determine adaptation to PUFAs in the host environment. 
In conclusion this research suggests that PUFAs are an attractive alternative treatment for 
chronic wounds infected with S. aureus, that are unlikely to develop resistance. The PUFAs appear 
to interfere with global regulation and virulence, with the added benefit of non-toxicity and 
immunomodulatory properties.  
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Appendices 
Table S1 chapter 4 the virulence of Staphylococci strains in the G.mellonella model 
A number of larvae survive: 
Strains 
                    Days 
0 1 2 3 4 5 6 7 
PBS 16 16 16 16 16 16 16 15 
SA3 16 13 10 8 5 4 2 2 
#MSSA 6538 16 15 14 12 11 10 9 8 
#
MRSA 252 
16 13 10 7 5 3 2 1 
Uninfected Larvae  16 16 16 16 16 16 16 16 
 
Table S2 chapter 4 Galleria mellonellainfected with different MICs of PUFAs compound  
Larvae                         
                     Days 
0 1 2 3 4 5 6 7 
PBS 16 16 16 16 16 16 16 16 
SA3 16 13 10 8 6 4 2  2 
SA3 DHA MIC  16 15 15 15 14 13 12 11 
SA3 EPA MIC  16 14 13 12 12 10 10 9 
SA3 DHA+ EPA MIC 16 15 14 13 13 12 11 10 
SA3DHA 2 MIC 16 16 16 16 16 15 14 14 
SA3EPA2 MIC 16 16 16 16 15 14 13 12 
SA3 DHA+EPA 2MIC 16 16 16 16 15 14 13 12 
MIC DHA only 16 16 16 16 16 16 16 16 
MIC EPA only 16 16 16 16 16 16 16 16 
MIC DHA+EPA only 16 16 16 16 16 16 16 16 
2 MIC DHA only 16 16 16 16 16 16 16 16 
2 MIC EPA only 16 16 16 16 16 16 16 16 
2 MIC DHA+EPA only 16 16 16 16 16 16 16 16 
Uninfected Larvae 16 16 16 16 16 16 16 16 
 
Table S3 chapter 4 Infected G. mellonella model with MICs of LZD, VAN  
Number of larvae survive 
Strains  
                  Days 
0 1 2 3 4 5 6 7 
PBS 16 16 16 16 16 16 16 15 
SA3 16 13 10 8 6 4 2 2 
SA3 LZD MIC 16 16 16 16 16 16 15 14 
SA3 VAN MIC 16 16 16 16 16 16 15 15 
Uninfected Larvae 16 16 16 16 16 16 16 16 
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Table S4 Chapter 5 Sets of the-inhibitory DHA and EPA in two concentrations (50 μg ml-1, 
100 μgml-1) and Ethanol. 
S. N Samples sets Conc in μg ml-1 Time/hour O.D at 600 
1- DHA 50 μg ml-1 0h 0.01 
2- EPA 50 μg ml-1 0h 0.013 
3- DHA+EPA 50 μg ml-1  0h 0.04 
4- ETOH 50 μg ml  0h 0.027 
5- DHA 100 μg ml-1 0h 0.01 
6- EPA 100 μg ml-1 0h 0.016 
7- DHA+EPA 100 μg ml-1 0h 0.01 
8- ETOH 100 μg ml-1 0h 0.028 
9- DHA 50 μg ml-1 6h 0.031 
10- EPA 50 μg ml-1 6h 0.032 
11- DHA+EPA 50 μg ml-1  6h 0.028 
12- ETOH 50 μg ml  6h 0.3 
13- DHA 100 μg ml-1 6h 0.021 
14- EPA 100 μg ml-1 6h 0.026 
15- DHA+EPA 100 μg ml-1 6h 0.026 
16- ETOH 100 μg ml-1 6h 0.28 
17- DHA 50 μg ml-1 12h 0.067 
18- EPA 50 μg ml-1 12h 0.13 
19 DHA+EPA 50 μg ml-1  12h 0.097 
20 ETOH 50 μg ml  12h 0.62 
21- DHA 100 μg ml-1 12h 0.026 
22- EPA 100 μg ml-1 12h 0.073 
23- DHA+EPA 100 μg ml-1 12h 0.046 
24 ETOH 100 μg ml-1 12h 0.55 
25- DHA 50 μg ml-1 24h 0.29 
26-  EPA 50 μg ml-1 24h 0.35 
27- DHA+EPA 50 μg ml-1  24h 0.39 
28- ETOH 50 μg ml  24h 0.72 
29- DHA 100 μg ml-1 24h 0.16 
30- EPA 100 μg ml-1 24h 0.26 
31 DHA+EPA 100 μg ml-1 24h 0.21 
32-  ETOH 100 μg ml-1 24h 0.6 
 
1 
Table S 5-chapter 5 Template for calculating 2 DD CT,  
This table with CT value results from Rtq PCR was calculated in original sheet in Excel  
Average Control Ct 
Value 
Average Control Ct 
Value 
ΔCt Value 
(Experimental) 
ΔCt Value (Control) Delta Delta Ct 
Value 
Expression Fold 
Change 
TC HC ΔCTE ΔCTC ΔΔCt 2^-ΔΔCt 
- 20.27 1.80 5.27 -3.47 11.05530304 
25.53 - 
      
 
Experimental 
Well 1 
Experimental 
Well 2 
Experimental 
Well 3 
Control 
Well 1 
Control 
Well 2 
Control 
Well 3 
Average 
Experimental 
Ct Value 
Average 
Experimental 
Ct Value 
 
Raw Ct Value Raw Ct Value Raw Ct Value Raw Ct 
Value 
Raw Ct 
Value 
Raw Ct 
Value 
TE HE 
Housekeeping 
Gene 
21.00 20.50 20.60 20.00 20.50 20.30 - 20.70 
Gene being 
Tested 
24.00 23.00 20.50 26.00 24.20 26.40 22.50 - 
2 
 
Table S6 chapter 5 p value of RTq PCR for the inhibitory DHA against regulation of several genes 
at 6 and 12 hours   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DHA at 6 hours  P value  Significantly different (P < 0.05)? 
agr A DHA 50 μg ml-1 0.0014 Yes 
sarA DHA 50 μg ml-1 0.007 Yes 
icaA DHA 50 μg ml-1 0.001 Yes 
agr A DHA 100 μg ml-1 0.004 Yes 
sarA DHA 100 μg ml-1 0.0003 Yes 
ica A DHA 100 μg ml-1 0.0001 Yes 
DHA at 12 hours  
agr A DHA 50 μg ml-1 0.0009 Yes 
sarA DHA 50 μg ml-1 0.0019 Yes 
icaA DHA 50 μg ml-1 0.0002 Yes 
agr A DHA 100 μg ml-1 0.0003 Yes 
sarA DHA 100 μg ml-1 0.0005 Yes 
ica A DHA 100 μg ml-1 0.0002 Yes 
3 
Table S7 chapter 5 p value of RTq PCR for the inhibitory DHA against regulation of several genes 
at 6 and 12 hours   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S 8 chapter6 G. mellonella virulence assay with adaptions strain  
A number of larvae survive: 
Strains  
                  Days 
0 1 2 3 4 5 6 7 
PBS 16 16 16 16 16 16 16 16 
Parent SA3  16 13 10 8 6 4 2 1 
SA3 adapted DHA  16 16 16 16 16 15 14 12 
SA3 adapted EPA  16 16 16 14 13 12 11 10 
SA3 adapted DHA 
+ EPA  
16 16 16 14 12 10 9 8 
SA3 LZD adapted 16 16 16 16 16 16 15 14 
SA3 VAN adapted 16 16 16 16 16 15 15 14 
Uninfected Larvae  16 16 16 16 16 16 16 16 
DHA at 6 hours  P value  Significantly different (P < 0.05)? 
agr A EPA 50 μg ml-1 0.0026 Yes 
sarA EPA 50 μg ml-1 0.0080 Yes 
icaA EPA 50 μg ml-1 < 0.0001 Yes 
agr A EPA 100 μg ml-1 0.0009 Yes 
sarA EPA 100 μg ml-1 0.0011 Yes 
ica A EPA 100 μg ml-1 < 0.0001 Yes 
DHA at 12 hours  
agr A EPA 50 μg ml-1 0.0009 Yes 
sarA EPA 50 μg ml-1 0.0015 Yes 
icaA EPA 50 μg ml-1 0.0003 Yes 
agr A EPA 100 μg ml-1 0.0006 Yes 
sarA EPA 100 μg ml-1 0.0010 Yes 
ica A EPA 100 μg ml-1 0.0004 Yes 
4 
Table S 9 chapter 6 multiple comparisons of basic t test between different procedures and 
compounds 
 
 
 
 
 
 
 
 
 
 
 
Table S 10 chapter 6 the average of un paired t test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 h 48 h 
Strains   P value  Strains   P value  
Adapted DHA 0.0289 Adapted DHA 0.0162 
Adapted EPA 0.0328 Adapted EPA 0.0169 
Adapted DHA+EPA 0.0021 Adapted DHA+EPA 0.0165 
Adapted LZD 0.0037 Adapted LZD 0.0173 
Adapted VAN 0.0044 Adapted VAN 0.0292 
Procedure    P value  Significantly different (P < 0.05)? 
All MBICS VS All MBECS   0.3568 No 
VAN MBICs vs All other MBICs 0.0467 Yes 
VAN MBECs vs All other MBICs 0.0476 Yes 
LZD MBICs vs all PUFA MBICs 0.0091 Yes 
LZD MBECs vs all PUFA MBECs 0.0320 Yes 
DHA MBICs vs EPA MBICs 0.0020 Yes 
DHA MBECs vs EPA MBECs 0.4113 No 
5 
Table S11: Amino acid changes of SNPs of adapted strains compared to parent SA3 
PO
S 
Refer
ence 
SA3_
DHA 
SA3_
EPA 
SA3_EP
ADHA 
SA3_
LZD 
SA3_
VAN 
GEN
E 
EFFECT Amino Acid 
Change 
594
63 
G G G A G G rpoA synonymous p.Asp111Asp 
119
633 
C C C T C C odh missense p.Val201Met 
406
314 
G G G G G A isaA missense_ p.Thr169Ile 
467
819 
C C C C T C clfB synonymous p.Ser884Ser 
467
840 
C C C C A T clfB missense p.SerGlu876ArgGl
u 
467
843 
A A A A G T clfB missense p.SerGlu876ArgG
lu 
467
852 
G G G G G A clfB synonymous p.SerAsp872SerAs
p 
467
855 
C C C C T T clfB synonymous_ p.SerAsp872SerAs
p 
467
873 
C C C C T A clfB synonymous_ p.Ser866Ser 
467
927 
C C C C T T clfB synonymous_ p.Ser848Ser 
467
948 
C C C C C G clfB missense_ p.Glu841Asp 
467
963 
C C T C C C clfB synonymous_ p.Ser836Ser 
467
984 
C C C C G C clfB missense_t p.SerGlu828SerAs
p 
467
987 
A A A A G A clfB missense_ p.SerGlu828SerAs
p 
468
017 
G G T G T G clfB synonymous_ p.Ser818Ser 
468
531 
C C C C C T clfB missense_ p.Gly647Asp 
504
148 
C C C C A C 
 
missense_ p.Met174Ile 
589
448 
C C C T C C walR missense_ p.Arg119Cys 
214
74 
A A A T A A scrB synonymous_ p.Leu196Leu 
145
41 
C C C C C G yabJ missense_ p.Pro15Ala 
388
92 
T T T T C T 
 
non_coding_tra
nscript_t 
 
793 G G G G A G 
 
non_coding_tran
script_ 
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C C T C T C 
 
non_coding_tra
nscript_ 
 
125
26 
C C C C C T clfA synonymous_ p.Asp806Asp 
125
47 
C C C C C A clfA synonymous_ p.Ser813Ser 
125
65 
G G G G G A clfA synonymous_ p.Ser819Ser 
110
532 
C C T C C T opp
C 
missense_ p.Ala177Val 
6 
347
877 
T T T T A T rsmB stop_gained p.Cys264* 
409
267 
G G G G G C infB synonymous_ p.Thr283Thr 
413
094 
G G G G G A ribF synonymous_ p.Gly240Gly 
131
3 
C C T T T T 
 
non_coding_tra
nscript_ 
 
419 T C C T T T 
   
688
47 
C T C C C C treR
_1 
missense_ p.Gly65Glu 
688
98 
C C T C C T treR_
1 
missense_varian
t 
p.Arg48His 
848
90 
G G G A G G ywq
D_1 
missense_ p.Asp79Asn 
872
05 
C G C C C C pglF stop_gained p.Tyr359* 
877
68 
A A A A A G pglF missense_ p.Glu547Gly 
124
672 
G G T G G T rocD
2_1 
missense_ p.Ala153Glu 
256
455 
G G G G T G yezG
_3 
missense_ p.Asp59Tyr 
365
873 
G G G G T G speC
_2 
missense_ p.Asp188Tyr 
146
542 
C C C C C G cym
R 
missense_ p.Gly47Ala 
151
383 
G G A G G A hisS missense_ p.Arg366Cys 
308
293 
T T T T T A ribD missense_ p.Glu62Asp 
761
4 
G G G G A G sarA missense_ p.Pro65Leu 
396
05 
G G A G G A feuC
_1 
missense_varia
nt 
p.Ala261Thr 
519
99 
G G G G G T bceB
_1 
missense_ p.Ser505Ile 
835
34 
G G G G G A chp missense_ p.Glu95Lys 
512
58 
C C C A C C ywlC synonymous_ p.Ser103Ser 
520
09 
G G G G G A sdrC synonymous_va
riant 
p.Ser757Ser 
521
56 
C C C C C T sdrC synonymous_ p.Asp806Asp 
524
95 
G G G G A A sdrC synonymous_ p.Ser919Ser 
565
74 
C C T C C C sdrD synonymous_ p.Asp1128Asp 
565
86 
C C T C C C sdrD synonymous_ p.Asp1132Asp 
566
07 
G G A G A A sdrD synonymous_ p.Ser1139Ser 
566
16 
T T C T T T sdrD synonymous_ p.Asp1142Asp 
566
31 
T T C T T C sdrD synonymous_ p.Ser1147Ser 
566
43 
G G A G G A sdrD synonymous_ p.Ser1151Ser 
7 
566
49 
C C A C C C sdrD missense_ p.Ser1153Arg 
567
00 
T T T T T C sdrD synonymous_ p.Asp1170Asp 
567
18 
T T T T T C sdrD synonymous_ p.Asp1176Asp 
567
84 
C C T C C T sdrD synonymous_ p.Asp1198Asp 
568
02 
C C T C C T sdrD synonymous_ p.AspSerAsp1204
AspSerAsp 
568
05 
T T C T T C sdrD synonymous_ p.AspSerAsp1204
AspSerAsp 
568
08 
T T C T T C sdrD synonymous_ p.AspSerAsp1204
AspSerAsp 
568
11 
G G A G A G sdrD synonymous_va
riant 
p.Ser1207Ser 
568
32 
C C T C C T sdrD synonymous_ p.Asp1214Asp 
568
59 
T T C T T C sdrD synonymous_ p.Ser1223Ser 
568
61 
G G A G G G sdrD missense_varian
t 
p.SerGly1223SerA
sp 
568
68 
T T C T T C sdrD synonymous_ p.Asp1226Asp 
568
86 
C C T C C T sdrD synonymous_ p.Asp1232Asp 
568
92 
C C T C C T sdrD synonymous_ p.Asp1234Asp 
569
04 
T T T T T C sdrD synonymous_ p.Asp1238Asp 
605
92 
C C C C C T sdrE synonymous_ p.Asp989Asp 
963
16 
G G G G C G yhdN
_1 
synonymous_ p.Thr55Thr 
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Supplement 12 chapter3  
Title:An ex-vivo skin model to characterise the interplay between bacteria, host and 
antimicrobials 
Aims: 
1) Profile the dynamic interactions between bacteria and antimicrobials in the context of 
human skin 
 
2) Determine the antibacterial efficacy of antimicrobials (including bioactive lipids) in a 
wound environment 
 
3) Detect host responses to bacteria and antimicrobials (including bioactive lipids)  – 
consequences for wound healing 
 
Research Outline: 
The bacteria that live on our skin are an important part of our microbiota as they can inhibit 
invasion of pathogens and signal appropriate immune responses, but can also cause chronic disease. 
However, we do not yet know the potentially damaging effects of long-term sub-lethal exposure to 
antibiotics on this microbiota. As the human microbiota is influenced strongly by interactions with 
the host, it is essential that this research is done in the context of live human tissue. 
Furthermore, chronic wounds caused by commensal and pathogenic bacteria represent a 
significant burden to patients and current approaches to wound treatment are limited and far from 
ideal. At least 60 % of chronic wounds are infected with microbial biofilms1 that show increased 
resistance to antibiotics and play a crucial role in preventing wound healing 2, 3. This evidence, 
along with the increasing reports of multi-drug resistant bacterial wound infections4 reflect the need 
for new treatment regimens for wound care that address both host and microbial contributors. 
To research these themes, we will use ex-vivo skin as a realistic intact/wounded skin model 
(JL in prep). The model utilises full thickness ‘plugs’ of human skin tissue taken from a larger 
sheet. Skin biopsies (5 mm2) will be maintained in the correct orientation by incorporating them 
into trans-well cell culture inserts, with the basal dermal surface continually bathed in culture 
medium, whilst the upper apical epidermis will remain exposed and ‘dry’. A smaller wound will be 
created using a biopsy punch and can be of variable thickness. This model has been successfully 
developed using samples from Ethical Tissues with Catherine O’Neill at the University of 
Manchester. 
 
Objective 1: Long-term effects of exposure of the human skin microbiome to 
antimicrobials  
Bacteria are able to adapt very quickly to changes in their environment, but these 
adaptations may come with other costs5. However, we do not yet know the effects of long-term sub-
lethal exposure to antibiotics on the microbiota we rely upon to defend us against disease. 
9 
Elucidating mechanisms of adaptive resistance in these species may help prevent further 
complications in these infections. This project aims to characterise the adaptation to antibiotic 
exposure skin bacteria in the context of viable human skin. 
 
Objective 2a: Anti-bacterial Activityof bioactive lipids from marine-sourced 
polyunsaturated fatty acids (PUFA) 
The aim of this project is to assess the antibacterial and immunomodulatory activity of 
PUFAs in the context of an infected wound. An attractive aspect of potential PUFA therapies is 
their safety and lack of significant side effects. They have been found to reduce systemic levels of 
IL-1β, IL-6 and TNF-α6 but their effects in an infected wound setting have yet to be investigated. 
We will simulate wound infection; initially using single clinical isolates of Staphylococcus 
aureus obtained from infected wounds, and treat with PUFAs. Bacterial viability will be monitored 
by swabbing the skin surface to recover bacterial cells after 0 – 96 h. Later work will involve the 
incorporation of pre-formed biofilms within acollagen gel matrix with serum protein, mimicking the 
wound bed of chronic wounds7. We will establish such biofilms using key bacterial wound isolates 
and monitor bacterial viability in the presence or absence of PUFAs. 
 
Objective 2b: Immunomodulatory Activity ofPUFAs. 
PUFAs also have potent anti-inflammatory and antibacterial properties. They have been 
shown to reduce pro-inflammatory cytokines in vitro8,9  and to regulate fibrogenic activities of TGF-
β1 that can contribute significantly to wound repair processes (unpublished data). PUFAs have 
previously been incorporated into ‘solid emulsion gel’ dressings, with demonstrable stimulation of 
wound repair in an acute model10. 
Skin biopsies will be exposed to PUFAs, frozen and stored for immunological analysis. Key 
responses of the skin to the presence of bacteria or PUFAs alone and in combination will be 
assessed. Histological staining of formalin-fixed paraffin embedded sections will be performed 
using monoclonal antibodies. Re-epithelialization will be evaluated by image analysis 
measurements taken from the edge of the wound origin to the leading edge of re-epithelialization, 
according to keratinocyte staining. Cell culture supernatants will be recovered for analysis of 
markers such as matrix metalloproteinases. 
 
 
 
References: 
1. James GA et al (2008) Biofilms in chronic wounds. Wound Repair Regen.  16:37-44. 
2. Gurjala AN et al (2011) Development of a novel, highly quantitative in vivo model for the study of biofilm-impaired cutaneous wound 
healing. Wound Repair Regen. 19(3):400-10. 
3. Bjarnsholt T et al (2007), Silver against Pseudomonas aeruginosa biofilms. APMIS, 115: 921–928. 
4. Godebo G et al (2013)Multidrug-resistant bacterial isolates in infected wounds at Jimma University Specialized Hospital, Ethiopia. 
Ann Clin Microbiol Antimicrob 12: 17. 
5. Latimer J et al (2012). Attenuated virulence and biofilm formation in Staphylococcus aureus following sublethal exposure to triclosan. 
AAC. 56(6):3092-100 
6. McDaniel JC, Belury M, Ahijevych K, et al. Omega-3 fatty acids effect on wound healing. Wound Rep. Regen. (2008) 16:337-345. 
7. Werthén M, Henriksson L, Jensen PØ, Sternberg C, Givskov M, Bjarnsholt T. An in vitro model of bacterial infections in wounds and other 
soft tissues. APMIS. 2010 Feb; 118(2):156-64.  
8. Magee P, Pearson S, Allen J. (2008) The omega-3 fatty acid, eicosapentaenoic acid (EPA) prevents the damaging effects of tumour necrosis 
factor (TNF)-alpha during murine skeletal muscle cell differentiation. Lipids in Health and Disease 7:24 
9. Magee P, et al. (2012). PPAR as a molecular target of EPA anti-inflammatiry activity during TNF-impaired skeletal muscle cell 
differentiation. J. Nut. Biochem.23 (11):1440-8. 
10. Shingel KI et al. (2008) Solid emulsion gel as a vehicle for delivery of polyunsaturated fatty acids: implications for tissue repair, dermal 
angiogenesis and wound healing. J. Tissue Eng. Regen. Med. 2:383-393. 
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 EthicalTissue 
Licensed Research Tissue  
Application for Samples v5.0 
REC Ref: 07/H1306/98 
Date 05/10/2009 
ETHICAL TISSUE 
MATERIAL TRANSFER AGREEMENT 
Definitions: 
"Materials" means, respectively the human tissue supplied as outlined below including 
without limitation, tissue, tissue derivatives, cell lines, blood, blood derivatives, bio-
fluids and isolated cells. 
"Data" refers to any and all clinical or research information about the individual from 
whom the Materials were obtained, or about the Materials themselves. 
"Services" shall refer to any and all human tissue research related services as set forth in 
more detail in the applicable Part 2 Application. 
"Institution" shall refer to the academic or commercial entity that falls under the 
supervision of the Principle Investigator listed in the full Part 2 Application. 
"Recipient" shall refer to the named Principle Investigator listed in the full Part 2 
Application 
"Third Party Recipient(s)" shall refer to an academic or commercial entity or institution 
other than ETHICAL TISSUE and the named Principle Investigator/ Institution in the 
Part 2 Application 
"Principle Investigator" shall refer to the representative of an Institution in a position of 
authority to ensure suitable practices are followed to maintain compliance with 
applicable laws and this MTA. Will be expected to take responsibility for integrity and 
use of relevant material within the institution 
"Authorised Representative" shall take legal responsibility for all activities and 
agreements within the Institution, having the authority to execute this agreement on 
behalf of the Institution 
TERMS OF THE MATERIAL TRANSFER AGREEMENT 
The Recipient agrees that the Material and Data provided by ETHICAL TISSUE will be 
used only for the purposes specified in the Part 2 Application. The Recipient agrees not 
to attempt to obtain information identifying the individuals providing the Material and 
Data to ETHICAL TISSUE. The Recipient agrees that all payments made hereunder are 
for the Services provided by ETHICAL TISSUE and are not for the Material or Data 
themselves. The Recipient also agrees that they shall not transfer Material and Data (or 
any portion thereof) supplied by ETHICAL TISSUE, to Third Party Recipients without 
the prior permission of ETHICAL TISSUE. Similarly, Material must not be transferred 
11 
to Third Party Recipients without an agreement in place that the Third Party Recipient 
complies with ETHICAL TISSUE Material Transfer Agreement and all applicable laws 
and regulations relating to the use, storage, handling and disposal of the Material and 
Data including but not limited to those set down by the Human Tissue Authority or other 
foreign regulatory bodies. 
The Recipient understands that while ETHICAL TISSUE, attempts to avoid providing 
Material that is contaminated with highly infectious agents such as hepatitis and HIV, all 
Material should be handled as if potentially infectious. The individuals who have 
supplied Material to ETHICAL TISSUE, have not agreed to have clinical tests 
performed on this Material (e.g. for the presence of infective agents such as hepatitis). If 
these tests are carried out, the Recipient agrees that no results of these tests are reported 
back to ETHICAL TISSUE. The Recipient acknowledges that the Institution where the 
Material and Data will be used follows Human Tissue Authority or appropriate local 
regulations if outside England, Wales and Northern Ireland, for handling human Material 
and Data and will instruct their staff to abide by those rules. The Recipient further agrees 
to assume all responsibility for informing and training personnel in the dangers and 
procedures for safe handling and disposal of human Material. 
Material and Data are provided as a service to the research community without warranty 
of merchantability or fitness for a particular purpose or any other warranty, expressed or 
implied. ETHICAL TISSUE accepts no responsibility for any injury (including death), 
damages or loss that may arise either directly or indirectly from their use, except to the 
extent caused by the negligence or wilful misconduct of ETHICAL TISSUE. 
Specific questions about your application should be directed to Ethical Tissue, University of Bradford, 
West Yorkshire, BD7 IDP, United Kingdom. 
Tel: +44 (0)1274 235897, Fax: +44 (0)1274 233234, Email: enquiries@ethicaltissue.org 
EthicalTissue 
Licensed 
Research TSssqe 
Application for 
Samples v5.0 
REC Ref: 07/H1306/98 
Date 05/10/2009 
The Recipient agrees that the Material and Data provided by ETHICAL TISSUE: Will 
not be used in any activity that contravenes the Human Tissue Act 2004 or other 
legislative body if outside the UK; Will not be used for human application such as 
transplant use; Will not be used in research that falls under the Human Fertilisation and 
Embryo Authority (HFEA) or other foreign national equivalent bodies and involve 
activities such as reproductive cloning and cell nuclear replacement as described by 
HFEA; Will not be tested for known inherited diseases; Will onlyl be used for 
biomedical research and not for the testing of cosmetics. 
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Although desirable, it is not essential for the Recipient to acknowledge the contributions 
of ETHICAL TISSUE, in publications (including posters and presentations at 
conferences and symposia). It is also desirable, but not essential, for the Recipient to 
report back to ETHICAL TISSUE any significant research findings and publications 
resulting from the use of the Material and Data. ETHICAL TISSUE acknowledges that 
in some cases confidentiality issues may prevent this from happening. The Recipient 
agrees to return or destroy any unused Material and Data required by applicable 
legislation. ETHICAL TISSUE however accepts that, it may not be possible to remove 
Data from analyses that has already been carried out. 
The Institution acting for the Recipient agrees to assume all risks and responsibility in 
connection with the receipt, handling, storage and use of Material from ETHICAL 
TISSUE. It further agrees to indemnify and hold harmless ETHICAL TISSUE from any 
claims, costs, damages or expenses resulting from the use of the Material and Data 
provided by ETHICAL TISSUE. The indemnity in this clause will not apply where such 
claims, demands, actions, costs, expenses, losses and damages arise from the negligence 
or wilful misconduct of ETHICAL TISSUE. 
The undersigned warrant that they have authority to execute this agreement on behalf of 
the Recipient Institution. (NB Ifthe Authorised Representative and Principle Investigator 
are one, both sections should be signed off by this person). 
BY MY SIGNATURE 1 AGREE TO THE TERMS SET FORTH IN THE ABOVE 
AGREEMENT 
 Printed Name of Authorised Representative  Date 03  
Signature of Authorised 
Representative 
Name of Institution   
 Printed Name of Principal Investigator Date 04 os- 2017 
Signature of Principal Investigator 
Name of Institution 
UPON RECEIPT OF THESE SIGNED UNDERSTANDINGS AND THE 
INFORMATION REQUESTED IN THE FULL PART 2 APPLICATION, ETHICAL 
TISSUE WILL CONSIDER THIS REQUEST. 
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Specific questions about your application should be directed to Ethical Tissue, University of Bradford, 
West Yorkshire, BD7 IDP, United Kingdom. 
Tel: +44 (0)1274 235897, Fax: +44 (0)1274 233234, Email: enquiries@ethicaltissue.org 
 
 
 
Application for Samples v5.0 
 
Ethical Tissue, University of Bradford, West Yorkshire, BD7 1DPTel: 01274 235897 
 
14 
 
The Licensed Research Tissue Bank (Ethical Tissue) 
 
PART 2 APPLICATION FOR ACCESS TO  
HUMAN MATERIAL, DATA AND/OR SERVICES 
 
 
This application should be completed when Material, Data and/or Services are being requested from ETHICAL 
TISSUEand utilized by: 
• The laboratory and/or personnel at the Institution that falls under the supervision of the Principal 
Investigator listed in this application.  
 
• The third party recipient for whom the Principle Investigator from the Institution listed in this application 
is acting. In the case where human Materials and Data are to be transferred, Section 5of this Part 2 
Application must be completed. As stated on ETHICAL TISSUE Material Transfer Agreement, Material 
(or any portion thereof) must not be transferred to third party recipients without prior permission of 
ETHICAL TISSUE. Similarly, Material must not be transferred to third party recipients without an 
agreement in place that the third party recipient complies with ETHICAL TISSUE Material Transfer 
Agreement and all applicable laws and regulations relating to the use, storage, handling and disposal of the 
Material including but not limited to those set down by the Human Tissue Authority or other foreign 
regulatory bodies. 
 
ETHICAL TISSUEis authorized by the Leeds flagged REC to release samples to researchers.  
Researchers receiving samples from ETHICAL TISSUE are NOT required to have approval from NRES 
for the use of these samples, as samples will be provided anonymously with only the minimum data set. 
This application is also for the Services of ETHICAL TISSUE to obtain Ethical Approval on behalf of the 
Recipient’s Institution for the collection, use and storage of Material from the Institutions personnel and 
associated data. In both cases, researchers must be able to satisfy the Independent Scientific Advisory 
Committee (ISAC) and the Tissue Bank Management Team (TBMT) of ETHICAL TISSUE that the 
project they submit is both ethically and scientifically valid.  IF researchers are already in possession of 
NRES approval for their projects, a copy of the NRES letter should be supplied with the application.  
Researchers are advised that it is their responsibility to ensure that they comply with the Human Tissue 
Act or other appropriate laws that cover the use of human material in research.  An HTA licence is NOT 
needed to store tissue sourced from ETHICAL TISSUEfor an approved project that is subject to a signed 
Material Transfer Agreement. Where a Service Agreement is requested, the Institution is responsible for 
obtaining an HTA licence which will allow the collection, storage and use of human tissue for research 
purposes. 
 
The information requested in this form is necessary in order to document correctly your request for material and 
other services and to ensure that ETHICAL TISSUEoperates within the guidelines of the Human Tissue 
Authority.  When submitting a written request for supply of material: 
 
• Please e-mail the completed Part 2 Application form to ETHICAL TISSUE (enquiries@ethicaltissue.org) 
and send hard copies of both signed off documents (Part 2 Application and Material Transfer Agreement. 
The latter is required only when tissue is requested) by post to: 
 
  ETHICAL TISSUE,  
Application for Samples v5.0 
 
Ethical Tissue, University of Bradford, West Yorkshire, BD7 1DPTel: 01274 235897 
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  The ICT Bioincubator   
  Tumbling Hill Street 
  University of Bradford 
  West Yorkshire 
  BD7 1DP 
 
• Patient identity is confidential. Material and Data will be coded with codes supplied by Ethical Tissue with 
a minimum data set.   
 
• Details of the Service provided or processing fees for Material and Data will be sent to you following receipt 
of your full application.   
 
• Any transfer of samples from ETHICAL TISSUE to researchers will be by Courier.  Researchers 
arerequired to cover the cost of transport of their samples and supply appropriate customs declarations if 
appropriate. 
 
For additional information please contact ETHICAL TISSUE on +44 (0)1274 235897 
For Ethical Tissue Office Use Only 
Date of receipt of application  
 
Date reviewed by TBMT  
Please tick  Approved Rejected 
 
Date submitted to ISAC  
Please tick Approved Rejected 
 
Project Registration Code  
 
PLEASE COMPLETE THE FOLLOWING SECTIONS 
 
SECTION 1 – INVESTIGATOR DATA 
(Please note that the Principle Investigator named below must have the authority to sign 
the relevant section of ETHICAL TISSUE Material Transfer Agreement and will be 
required to accept the terms set forth in the agreement).  
 
Principle Investigator Dr Joe Latimer 
 Title                      First Name                       Surname 
Application for Samples v5.0 
 
Ethical Tissue, University of Bradford, West Yorkshire, BD7 1DPTel: 01274 235897 
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Qualifications BSc(Hons), MSc, PhD 
Address 
Post code 
Environment and Life Sciences, University of Salford, 
Crescent, Salford, M5 4WT 
 
Phone Number 0161 2950283 
Fax Number  
E-mail j.latimer2@salford.ac.uk 
  
  
Contact person(if different from above) 
Name  
Contact Number  
E-mail  
  
 
 
Shipping Address(if different from above) 
 
 
 
Post code 
 
 
Invoice Information 
Is a purchase order required for shipment of specimens or Services provided by Ethical Tissue? 
(Please tick box below) 
Yes 
✓ 
No 
Purchase order number 
Please supply when the project has been 
approved 
 
Currently invoices are included with the tissue shipment to the shipping address listed above.  If 
you would like the original invoice to be provided by post to another location (e.g. your finance 
department), please enter that address below.  A copy of the invoice will also be included with your 
shipment.  Where Services are provided, a Contract will be drawn up by the University of 
Application for Samples v5.0 
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Bradford Legal department, which includes a Schedule of payment for Services provided by 
Ethical Tissue. 
 
Person to whom invoice should be addressed  (if different from above) 
Name: 
 
Invoice address 
(If different from above) 
 
 
 
Post code 
 
 
 
SECTION 2 - FUNDING INFORMATION 
 
  
Please indicate the likely source(s) of funding for the proposed project and the period of support applied for.   
  
Funding Source(s) and period of support:  
 
__The Government of Libya – PhD studentship awarded to Mohamed Eshlak – 12 months remaining 
__Studentship from the Doctoral Training Alliance – 3 years_________________________________ 
        
SECTION 3 – RESEARCH OUTLINE 
 
Please provide a brief outline of the proposed research that is intended to be carried out involving the Material, 
data and/or Services requested from ETHICAL TISSUE (use separate pages). This should take the form of: 
 
▪ Title 
▪ Aims 
▪ Research Outline 
▪ References 
 
Sufficient information (approx 600 words or 2 pages of A4) should be provided to enable the Independent 
Scientific Advisory Committee to determine whether the research outputs justify the use of material and data.  
If the project has already been reviewed as part of a grant application, you may supply a copy of the scientific 
part of that grant application. 
Where Services are being requested, this will form the basis of the contract drawn up by the legal department 
of the University of Bradford. 
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Please include a CV for the principle investigator with your application. 
 
SECTION 4 - SPECIMENS REQUESTED 
 
(Please refer to ETHICAL TISSUE website (www.ethicaltissue.org) or contact ETHICAL TISSUE directly for 
an overview of the type of tissue or tissue product available).  
 
Please specify exactly what you require e.g. 20 samples of RNA extracted from superficial TCC bladder 
tumours – G1pTa (male). Please also include the time frame involved. 
 
Material Information Required: (Anatomic site of tissue, pathological diagnosis, patient age, sex will be 
provided for all samples.)Additional patient information may be available, but you must request it in this 
application and justify its necessity in the research project.  It may be possible to provide some samples 
with details of treatment and outcome – although this may not be possible for all samples. 
 
• Sections of whole skin isolated during surgery from otherwise healthy volunteers, to be 
delivered as soon as possible after excision. Approximately 2 samples per month for four 
years. 
 
SECTION 5 – UTILISATION OF MATERIAL AND DATA 
 Please delete will /willnotas appropriate in the statement below.   
The Principle Investigator must sign and date this statement. 
 
• Material and/or Data will not be transferred to third party recipient(s) 
 
Signature of Principle Investigator ____ _ 
 
Date ___26/04/2017__________________ 
 
If material and/or data are to be transferred to a third party recipient, please include a justification for 
this action here. 
 
 
___________________________________________________________________________ 
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SECTION 6 – ETHICAL TISSUE 
 
Please state how you found out about sourcing human Material and Data from ETHICAL TISSUE  
 
I have used ETHICAL TISSUE as a source of human material for a very similar project in a previous role 
 
 
